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Abstract 
Chromosomal instability (CIN) describes ongoing numerical and structural 
chromosomal aberrations in cancer cells, leading to intra-tumour heterogeneity and is 
frequently associated with polyploidy and aneuploidy. CIN is a frequent event in solid 
tumours and previous evidence has implicated CIN with acquired multidrug resistance, 
intrinsic taxane resistance and poor patient prognosis. In this thesis, I have attempted to 
explore mechanisms required for the initiation of CIN and the tolerance of this pattern 
of genome instability. 
Firstly, I have attempted to identify clinically relevant therapeutics that may have 
specific activity in CIN+ tumour cell lines. Focusing on a panel of colorectal cancer cell 
lines, classified as either CIN+ or CIN-, and treating them individually with kinase 
inhibitor and cytotoxic agent libraries, I demonstrated that CIN+ cell lines displayed 
significant intrinsic multidrug resistance. Next, I addressed if specific means to target 
CIN+ cells could be identified through pharmacological and RNA interference (RNAi) 
screens. No compounds were observed to be preferentially cytotoxic towards CIN+ 
cells in the pharmacological screen. A whole genome RNAi screen was performed to 
identify CIN+ specific survival pathways using isogenic cell line models of CIN. No 
genes were identified that conferred preferential cell death when silenced in CIN+ cells, 
despite sufficient statistical power to detect such targets. Using integrative genomics 
techniques and cell cycle data from this RNAi screen, I endeavoured to identify 
clinically relevant initiators of aneuploidy in colorectal cancer, that revealed both 
known and potential novel regulators of polyploidy. 
Finally, I endeavoured to identify a mechanistic basis for the taxane-sensitising 
phenotype associated with the silencing of the ceramide transporter, CERT, which may 
reveal means to target CIN+ cells. I demonstrated that CERT silencing sensitises 
paclitaxel-treated cells to cell death in a LAMP2-dependent manner that is associated 
with autophagy flux and may target death of multinucleated cells specifically. 
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Chapter 1. Introduction 
This thesis concerns an investigation of chromosomal instability (CIN) survival 
mechanisms in cancer. Significant intra-tumour genetic heterogeneity is associated with 
the cancer cell population in vivo (1, 2). Genomic instability mechanisms provide means 
for the acquisition of genetic variation within the cancer cell population. One such 
mechanism of genomic instability is CIN, which describes an increased rate of ongoing 
numerical and structural chromosomal changes within cells (3, 4).  
In this chapter, the CIN phenotype and its potential relationship with cancer multidrug 
resistance will be discussed. Expanding upon this, evidence suggesting that CIN may 
present a targetable phenotype in the treatment of cancer will be reviewed. Additionally, 
I will review evidence from our laboratory concerning the involvement of CERT, a 
ceramide transporter protein, in the mediation of multidrug sensitisation and introduce 
the possibility that CERT targeting may be exploitable in cancer medicine in order to 
limit drug resistance and conceivably target CIN cells.  
Sections of this chapter have been published in review form (5) and as a first author 
primary research article in (6) (See Appendix 8.1 and 8.2). 
1.1 Functional genomic approaches implicate CIN and CERT as 
pathways that may be exploited to limit drug resistance 
One of the major challenges in cancer treatment is drug resistance as it limits the 
efficacy of cytotoxics used in cancer management (7). Following the widespread 
introduction of RNA interference (RNAi) technology, several methods have been 
Chapter 1. Introduction 
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developed to enable short- or long-term target silencing in cultured cells in the 
laboratory (8), enabling the functional annotation of the human genome. RNAi allows 
for the silencing of genes in a “one by one” approach to assess the phenotypic effects of 
each gene on drug sensitivity.  
Synthetic small interfering RNA (siRNA) duplexes are commonly used in RNAi 
experiments. siRNAs are most commonly introduced into the cell using cationic lipid 
transfection agents that allow the human cell to take up the nucleic acids. The RISC 
(‘RNA-induced silencing complex’) enzyme complex recognises the siRNA and the 
antisense portion of the siRNA guides the RISC to its complementary mRNA strand. If 
it is a partial match, translation is blocked. This partial match is normally associated 
with microRNA (miRNA) processing and may explain the off-target gene silencing 
effects of siRNAs. If a complementary match with the anti-sense strand occurs, the 
siRNA is cleaved. Potential off-target effects can also occur in this pathway if the sense 
strand of the siRNA duplex is incorporated into the RISC instead of the antisense 
strand. Both partial and complementary match of the RISC with mRNA result in 
decreased levels of that mRNA and a corresponding decrease in the levels of protein 
expression. 
Several high-throughput RNAi screens have implicated hundreds of genes capable of 
inducing drug resistance in tumour cells, indicating the complexity of the problem (5) 
and suggesting that targeting individual genes to overcome drug resistance in cancer is 
unlikely to succeed due to the polygenic nature of this process. The complexity of 
multidrug resistance may provide an explanation for the lack of clinical evidence for the 
Chapter 1. Introduction 
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role of MDR transporters in acquired multidrug-resistance of cancers (9) and the failure 
of Phase III trials targeting P-glycoprotein (Pgp; an ABC transporter) (10). 
Targeting pathways that are involved in multidrug resistance or its acquisition may be a 
strategy to overcome the polygenic problem of drug resistance. Aneuploidy has been 
previously shown to be permissive for the rapid evolution of multidrug resistance (11). 
An RNAi screen for regulators of multidrug sensitivity targeting all kinases (kinome 
library 779 siRNAs) and ceramide pathway regulators (ceramidome library 50 siRNAs) 
in the HCT116 (colorectal cancer), MDA-MB-231 (breast cancer) and A549 (non-small 
cell lung cancer) cell lines was previously performed by our laboratory (12). It was 
demonstrated that a common effect of all siRNAs promoting resistance to paclitaxel (a 
taxane drug that stabilises microtubules) was a reduction in the accumulation of drug-
treated cells at the mitotic checkpoint, supporting the concept that spindle checkpoint 
disruption promotes paclitaxel antagonism (12, 13). Most siRNAs promoting resistance 
also induced the appearance of polyploid cells, multinucleation and centrosomal 
abnormalities without drug treatment, indicating the link between pathways maintaining 
chromosomal stability and drug resistance. Further examining the link between CIN and 
intrinsic taxane resistance, my laboratory demonstrated that CIN cancer cells 
overexpress a set of genes termed the microtubule-stabilising (MTS) gene signature 
(14) (see Appendix  8.3), and this enables the cells to survive the down-regulation of 
these genes resulting from MTS treatment. Given the association between CIN and 
taxane resistance and that CIN may be permissive for the acquisition of multidrug 
resistance, I reasoned that targeting CIN may be a means to limit drug resistance in the 
clinical setting. To this end, I sought to further understand CIN survival mechanisms in 
cancer and the pathways regulating the generation and maintenance of CIN. 
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The ceramide transporter CERT was identified in the same kinome and ceramidome 
screen to potentiate multidrug sensitivity to paclitaxel, doxorubicin, cisplatin and 5-FU 
(fluorouracil) when silenced by RNAi (12), indicating another pathway that could be 
targeted to limit multidrug resistance in cancer. Given the taxane sensitising affects 
mediated following CERT silencing and taxane resistance demonstrated by CIN+ cells, 
I reasoned that a clearer understanding of the process through which cells are sensitised 
following CERT silencing might identify means through which CIN+ cells might be 
more efficiently targeted.  
1.2 Regulation of chromosome segregation 
CIN reflects improper cell division, where mechanisms ensuring the fidelity of proper 
chromosome segregation are compromised during cellular division and are propagated 
in subsequent generations of cell division. The eukaryotic cell division cycle can be 
divided into four phases, Gap 1 (G1), Synthesis (S), Gap 2 (G2) and Mitosis (M) (15). 
M phase can be further divided into prophase, prometaphase, metaphase, anaphase and 
telophase. G1, S and G2 together make up the interphase period of the cell. During 
interphase, chromosomes are decondensed (16). A period of cell growth occurs during 
G1 followed by DNA replication in S phase. DNA replication in S phase results in the 
generation of paired sister chromatids consisting of two identical chromosomes, joined 
at a structure called the centromere and held together by a protein complex termed 
Cohesin (17, 18). During G2, the cell undergoes a phase of cell growth again. Finally in 
M phase, the chromosomes condense and the cell begins to divide as mitosis occurs, 
separating sister chromatids of chromosomes into two daughter nuclei. The completion 
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of cell division is achieved following cytokinesis, where daughter nuclei are separated 
into two separate daughter cells along with equally divided cytoplasm. 
1.2.1 Entry into mitosis 
Entry into mitosis is regulated by the G2/M checkpoint. CDK1 is the key regulator 
during this period of the cell cycle and is itself tightly regulated. During G2, Myt1 and 
Wee1 suppress mitotic entry via the inhibitory Thr14 and Tyr15 phosphorylation of 
CDK1 (19). This checkpoint allows for the completion of cell growth and also enables 
the repair of DNA damage errors, prior to the commencement of cell division.  
Activation of CDK1 requires both activating phosphorylation and the removal of 
inhibitory phosphorylation. The phosphorylation of the Thr161 residue (20) by CAK 
(CDK-Activating Kinase) (21) allows the formation of the Cyclin B/CDK1 complex 
(also known as Maturation Promoting Factor (MPF))(22). Formation of the Cyclin 
B/CDK1 complex leads to the activation of CDC25 phosphatase that functions to 
remove the inhibitory phosphorylation of CDK1 (23). In mammals this is accomplished 
by CDC25a and CDC25b isoforms of this protein (24). CDK1 mediates 
phosphorylation of Condensin, (25) allowing the chromosomes to condense, and also 
the phosphorylation of Lamins, leading to nuclear envelope breakdown (NEB) (26) and 
thus allowing spindle fibres access to the chromosomes to form attachments.  
Each sister chromatid has a kinetochore consisting of an inner protein plate and an outer 
protein plate that forms the site for kinetochore-microtubule attachments (27). 
Following NEB, microtubules from centrosomes at opposite poles of the cell seek out 
randomly to capture the kinetochores (28). Some microtubules that do not attach to 
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kinetochores attach instead to microtubules originating from the opposing centrosome 
to form the mitotic spindle (29). Those that fail to attach eventually depolymerise (30). 
The kinetochore-microtubule attachments coupled with polymerisation and 
depolymerisation of microtubules, provides the pulling force necessary to later separate 
the chromosome's two chromatids to the opposite ends of the cells (31). 
1.2.2 The Anaphase Promoting Complex/Cyclosome (APC/C) 
The Anaphase Promoting Complex/Cyclosome (APC/C) is an E3 ubiquitin ligase 
complex (32). It plays a role in two transitions between phases during mitosis, namely 
during the metaphase to anaphase transition and during the anaphase to telophase 
transition. The specificity of its roles is regulated by its interaction with CDC20 and 
CDH1. During the metaphase to anaphase transition, the APC/C associates with CDC20 
to target Securin, the negative regulator of Separase, for degradation (32). Separase 
functions to cleave Cohesin, and this allows for the loss of sister-chromatid cohesion 
(33). 
The APC/C is also involved in exit from mitosis. Following anaphase, exit from mitosis 
is regulated by two networks, the Cdc Fourteen Early Anaphase Release (FEAR) and 
the Mitotic Exit Network (MEN) (34). These networks act to release CDC14, which is 
normally bound to and inhibited by Cfi/Net1. An active CDC14 proceeds to 
dephosphorylate CDH1, allowing CDH1 to bind to and activate the APC/C. The 
APC/C-CDH1 complex targets Cyclin B for degradation, and thus inactivates CDK1, 
triggering an exit from mitosis (35). 
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The APC/C and CDC20 interaction is itself regulated to prevent premature chromosome 
segregation. One checkpoint regulating this is the Spindle Assembly Checkpoint (SAC). 
1.2.3 The Spindle Assembly Checkpoint (SAC) 
The SAC is a pathway that acts during mitosis and is active during metaphase to 
prevent entry into anaphase by ensuring the proper bi-orientation of sister chromatids 
and thus preventing the missegregation of chromosomes. Bi-orientation of sister 
chromatids occur when each kinetochore is attached to microtubules originating from 
opposing spindle poles (28). Sister chromatids with improper orientation fail to generate 
proper tension and this results in the removal of kinetochore-microtubule attachments 
by Aurora B Kinase (AURKB) (36). Aurora B acts to remove erroneous attachments 
recursively (37) by phosphorylating kinetochore components (38) until all sister 
chromatids are properly bi-orientated on the bipolar spindle. Examples of improper 
kinetochore-microtubule attachments include merotelic attachments, when one 
kinetochore is attached to microtubules from both spindle poles, and syntelic 
attachments, where both sister kinetochores are attached to microtubules from the same 
spindle pole (39). 
When Aurora B removes kinetochore-microtubule attachments, the unattached 
kinetochores recruit MAD1 that in turn is required for the recruitment of MAD2 (40) 
(41). MAD2, BUBR1 and BUB3 bind to CDC20 to form the mitotic checkpoint 
complex (MCC), which is the main mediator of this checkpoint and is a potent inhibitor 
of the APC/C (42). In mammalian cells, BUB1 and Aurora B appear to promote the 
binding of the MCC to the APC/C (43). Following kinetochore-microtubule 
attachments, MAD2 localisation decreases (41), and this may act to satisfy the SAC. 
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The proper generation of tension across kinetochores may also act to inactivate the SAC 
(44). This may explain why merotelic attachments, appear to be sufficient to deplete 
MAD2 and satisfy the SAC (45) as tension is still generated across the kinetochore via 
attachments to both spindle poles (Figure 1). 
Drugs such as taxanes promote mitotic arrest through the activation of the SAC, 
however, mitotic slippage describing an escape from mitosis under the continued 
presence of conditions that normally activate the SAC, may occur (27) and cells can 
then enter a multinucleated interphase (46). 
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Figure 1 Types of kinetochore-microtubule attachments and activation of the SAC 
A) Both kinetochores are attached to the microtubules from the same centrosome, 
leading to a syntelic attachment, this results in improper sister chromatid orientation and 
failure to generate tension across the kinetochore. Aurora B is recruited to detach the 
kinetochore-microtubule attachments. 
B) Unattached kinetochores result in the activation of the SAC via the recruitment of 
MCC components to the kinetochores. This inhibits the ability of the APC/C-CDC20 
complex to degrade Securin and release Separase that cleaves the cohesin complex 
holding the sister chromatids together. 
C) Merotelic attachments, where one kinetochore is attached to microtubules from both 
spindle poles fail to activate the SAC. 
D) Correct kinetochore-microtubule attachment result in bi-orientated sister chromatids. 
A 
B 
C 
D 
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1.2.4 The DNA damage checkpoint 
The DNA damage checkpoint can act to prevent progression through mitosis. In 
response to DNA damage, CHK1 and CHK2 can be activated by ATM and ATR (47). 
CHK1 negatively phosphorylates CDC25 (48) and may prevent the removal of 
inhibitory phosphorylation of CDK1 (48) and thus preventing progress into mitosis 
(49). CHK1 may also phosphorylate Securin and prevent the degradation of Securin by 
the APC/C-CDC20 complex (49). Further supporting a role for DNA damage 
checkpoints in regulating metaphase to anaphase transition, in yeast cells CHK2 acts to 
interfere with Securin and CDC20 interactions (50), thus preventing the separation of 
sister chromatids. 
1.3 Chromosomal Instability 
The number and structure of chromosomes in each cell can be perturbed in human 
cancer due to CIN, a form of genomic instability. Human cancer is associated with at 
least two distinct patterns of genomic instability, CIN or microsatellite instability 
(MIN), and most human colorectal cancers (CRC) can be classified as demonstrating 
one or the other (51). The more common form of genomic instability in CRC is CIN, 
resulting in ongoing numerical and structural chromosomal aberrations in cancer cells, 
leading to intra-tumour heterogeneity (3, 4). CIN can be classified as numerical (gains 
and losses of whole chromosomes) or structural CIN (chromosomal rearrangements 
such as translocations and deletions) and commonly both occur simultaneously (52). As 
a consequence, cancer cells demonstrating a CIN phenotype are frequently aneuploid or 
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polyploid. Aberrations in chromosome number and structure are often interlinked in 
CIN+ cancer. This has been confirmed by Roschke and colleagues who have 
demonstrated a high correlation of modal chromosome number with numerical 
chromosomal complexity (a measure of gains and losses of whole chromosomes) and a 
weak but significant correlation of modal chromosomal number with structural 
chromosomal complexity (a measure of chromosome translocations, deletions, 
duplications, insertions, inversions, or homogeneously staining regions). In addition, a 
moderate correlation between structural and numerical complexity was reported (4).  
The less common pattern of genomic instability in cancer is MIN caused by a 
deficiency in the mismatch repair apparatus. Due to the accumulation of replication 
errors, MIN results in length variation of microsatellites (or short tandem repeat 
sequences) in DNA. The majority of MIN+ CRC cell lines are near-diploid (53, 54) and 
chromosomally stable (CIN-).  
In contrast, CIN+ CRC cell lines are aneuploid and display a higher frequency of 
chromosomal missegregation errors during each mitosis relative to diploid cells (3). In 
human cancer, CIN+ is widely inferred through the measurement of tumour DNA 
ploidy using flow cytometry (55); normal diploid cells are defined by a DNA index of 
1.0 (56) and thus an increase in DNA index infers polyploidy or aneuploidy. 
Approximately 60% of human CRC are CIN+ and 15% are near-diploid MIN+. 25% of 
human CRC appears to be neither MIN+ nor CIN+, however, the insensitivity of flow 
cytometry to detect small changes in ploidy or to detect structural chromosomal 
aberrations may lead to tumours wrongly classified as CIN- (55, 57). 
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1.3.1 Polyploidy, tetraploidy, aneuploidy and CIN 
Most eukaryotic cells are diploid (2n), containing 2 sets of homologous chromosomes. 
The terms CIN and polyploidy/aneuploidy are frequently but incorrectly interchanged. 
CIN describes a dynamic state where the number or structure of chromosomes changes 
at high rate per cell division, and so gross genetic differences are frequently observed 
between different cells within the same tumour. Tetraploidy refers to the specific state 
of double the number of chromosomes present in the diploid cell (4n). Polyploidy 
describes the state of an exact multiplication of the haploid (n) chromosome and 
aneuploidy describes a non-exact multiplication of the haploid chromosome number. A 
consequence of this is that whilst CIN+ cells are aneuploid and sometimes polyploid, 
aneuploidy and polyploidy are not synonymous with CIN (Figure 2). 
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Figure 2 Ploidy and CIN 
A) An example diploid cell with 2 chromosomes (2n). 
B) Polyploidy describes the state of an exact multiplication of the haploid (n) 
chromosome. 
C) Aneuploidy describes a non-exact multiplication of the haploid chromosome number 
D) Tetraploidy is a special case of polyploidy, describing an exact duplication of the 2n 
chromosome number. 
E) CIN describes a dynamic state where the number or structure of chromosomes 
changes at high rate per cell division, resulting in a heterogeneous daughter cell 
population. 
A 
B 
C 
D 
E 
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1.3.2 Measuring Chromosomal Instability 
It is challenging to obtain true scores of CIN, especially in vivo, as it requires the 
measurement of rate of change of whole chromosome number or structure across a cell 
population. Most proxy methods of scoring CIN are static measures that take a 
“snapshot” at a certain point in time that measure the number of chromosomes, 
chromosome complexity and genetic diversity in a supposedly clonal population. 
Flow cytometry is commonly used to measure the DNA content of cancer cells and by 
extension, estimate the ploidy (55). The stemline scatter index (SSI) derived by flow 
cytometry experiments provides a clonal heterogeneity score that allows for the 
classification of tumours into diploid and aneuploid stable or unstable states (58). 
Other established methods of scoring CIN include labour intensive methods such 
Spectral Karyotyping (SKY) and centromeric Fluorescence In situ Hybridisation 
(FISH). SKY allows for scoring of modal chromosomal number, structural or numerical 
complexity and heterogeneity of chromosomal number between cells (4). The number 
of chromosomes can be counted using centromeric FISH, and a description of 
aneuploidy and chromosomal numerical heterogeneity may be obtained. 
Vast amounts of array Comparative Genomic Hybridisation (aCGH), Single Nucleotide 
Polymorphism (SNP) and gene expression microarray data are available on various 
platforms, which can be used to derive surrogate measures of aneuploidy or CIN (4, 58-
62). Recently developed algorithms for the analysis of biallelic SNP arrays allow for the 
estimation of ploidy levels, loss of heterozygosity (LOH) events and the degree of 
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chromosomal structural instability and the location of aberrant chromosomal regions 
(63) (64). 
Surrogate measures of aneuploidy based on expression microarray data include scores 
such as the CIN70 gene signature (59, 60), a gene signature reflecting total functional 
aneuploidy (tFA, a measure of the total level of chromosomal aberrations in a given 
tumour). The expression of this gene set correlates with SKY, SNP based structural 
complexity scores, and SSI derived from flow cytometry (60). A relationship of 
chromosomal instability scored by SSI with prognostic breast cancer gene expression 
signatures such as MammaPrint and Oncotype DX has been reported, suggesting that 
prognostic gene expression signatures are linked to CIN (65). 
1.3.3 Mechanisms contributing to CIN 
CIN+ cancer cells missegregate chromosomes and exhibit visible segregation errors 
during anaphase (66), such as anaphase bridges and lagging chromosomes. Various 
mechanisms have been proposed to contribute to CIN in cancer, reflecting an increase 
in chromosome missegregation events or a failure of checkpoints to detect or address 
problems in cell division. 
Aberrant regulation of pathways involved in mitosis such as the APC/C and Cyclin B 
pathways may impact upon progression through the cell cycle and proper chromosomal 
segregation (67, 68). Mutations of APC/C subunits have been shown to delay mitotic 
exit and result in aberrant Cyclin B expression (67). In yeast models, Cyclin B 
overexpression was associated with gains and losses of chromosomes leading to 
aneuploidy and the failure to activate the SAC (68). 
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It has been shown that disrupting components of the SAC may lead to the generation of 
CIN (Figure 3). Evidence for this includes loss of function experiments of SAC genes 
including BUB1, by mutation in CIN CRC cell lines (69), the induction of a CIN 
phenotype in HCT116 non-CIN CRC cells by deletion of one allele of MAD2 (70), and 
impairment of the mitotic checkpoint by a truncating mutation of MAD1L1 (71). 
Supporting this, mutations and aberrant expression of SAC genes have been found in 
some tumours in vivo (69, 72). The overexpression or depletion of SAC genes such as 
MAD2 or BUBR1 can induce chromosome segregation errors and failure to arrest cells 
in mitosis in response to mitotic arresting drugs (73-75) that lead to aberrant 
chromosome structure or number. However in vitro demonstrations have shown that 
many CIN+ cell lines have a functional SAC (66, 76, 77), suggesting that there must 
exist alternative mechanisms that generate CIN in the majority of tumours. 
Furthermore, mutations of mitotic checkpoint proteins appear to be rare in solid 
tumours (Table 1, analysis based on data from the Sanger Catalogue of Somatic 
Mutations in Cancer (COSMIC) database, (78)). Further analysis of data from the 
Sanger COSMIC database indicates that mutations in human kinetochore proteins (as 
defined in (79)) are also rare, indicating that mutations of the kinetochore-microtubule 
interface are unlikely to be the main contributor of CIN in human solid cancers (Table 
2, analysis provided by David Endesfelder). 
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Figure 3 Premature sister chromatid seperation 
Circumvention of the SAC and downstream pathways may lead to CIN due to 
premature sister chromatid separation before all kinetochores are attached to 
microtubules 
 
Chapter 1. Introduction 
 30 
 
 
B
U
B
1 
B
U
B
3 
B
U
B
R
1 
C
D
C
20
 
M
A
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Breast 0(27) 0(11) 0(27) 0(11) 0(11) 0(11) 
CNS 0(31) 0(23) 0(455) 0(23) 0(23) 0(23) 
Haematopoietic and 
lymphoid tissue 
0(27) 0(0) 0(27) 0(0) 0(0) 0(0) 
Kidney 1(116) 0(101) 1(116) 0(101) 0(101) 0(101) 
Large Intestine 0(42) 0(12) 0(42) 0(12) 0(12) 0(12) 
Lung 0(226) 0(12) 0(226) 0(12) 0(11) 0(12) 
Ovary 1(27) 1(1) 1(27) 0(0) 0(0) 0(0) 
Pancreas 0(1) 0(1) 0(1) 0(1) 0(1) 0(1) 
Pleura 0(1) 0(1) 0(1) 0(1) 0(1) 0(1) 
Skin 0(6) 0(6) 0(6) 0(6) 0(6) 0(6) 
Stomach 0(20) 0(0) 0(20) 0(0) 0(0) 0(0) 
Testis 0(13) 0(0) 0(13) 0(0) 0(0) 0(0) 
Upper Aerodigestive Tract 0(3) 0(3) 0(19) 0(3) 0(3) 0(3) 
Urinary Tract 0(2) 0(2) 0(2) 0(2) 0(2) 0(2) 
Table 1 Table of mutations in mitotic checkpoint genes 
Mutation data provided by the Sanger Institute (78) Numbers in brackets indicate the 
number of samples in which mutation data is available for. 
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CENP-A 0(11) 0(1) 0(0) 0(101) 0(12) 0(12) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
CENP-B 0(11) 0(23) 0(0) 0(101) 0(12) 0(12) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
CENP-C 0(11) 0(23) 0(0) 0(101) 0(12) 1(12) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 1(2) 0(0) 0(0) 
CENP-H 0(48) 0(22) 0(0) 0(0) 1(37) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-I 0(11) 0(23) 0(0) 0(5) 0(12) 0(11) 0(0) 0(1) 0(1) 1(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
CENP-K 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-50/ 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-O 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 1(1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-P 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 2(2) 0(0) 0(0) 0(0) 0(0) 0(0) 0(16) 0(0) 0(9) 0(0) 
CENP-Q 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 2(2) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENPR/ 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-L 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-M 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-N 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-T 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-S/APITD1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 1(1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
MIS18A 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
MIS18B/ OIP5 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
KNL2 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
MIS12 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
DSN1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 2(2) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
NSL1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
NDC80 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 1(1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
NUF2 0(11) 0(23) 0(0) 0(101) 0(12) 0(12) 3(3) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
SPC25 0(0) 1(23) 0(0) 0(101) 0(12) 0(11) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
KNL1/CASC5 0(0) 1(23) 0(0) 0(101) 0(12) 0(11) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
ZWINT 0(11) 0(23) 0(0) 0(101) 0(12) 0(12) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
ROD/KNTC1 0(11) 1(23) 0(0) 3(412) 0(12) 1(12) 5(5) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
ZW10 0(11) 1(23) 0(0) 0(101) 0(12) 0(12) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
ZWILCH 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 1(1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-F 0(32) 3(446) 0(0) 0(0) 2(35) 0(0) 6(6) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
SPINDLY/  0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 1(1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 1(1) 
DYNEIN 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
NDE1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 1(1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
NDEL1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
NUDC 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 1(1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
LIS1/ 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
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SKA1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
SKA2/ FAM33A 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CLASP1 0(11) 1(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CLIP170 1(48) 0(22) 0(0) 0(0) 0(37) 0(0) 2(2) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
EB1/MAPRE1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
TOG/CKAP5 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 1(1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
KIF2A 0(11) 0(23) 0(0) 0(101) 0(12) 0(12) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
KIF18A 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 2(2) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CENP-E 2(32) 0(23) 0(0) 0(101) 0(36) 0(12) 5(5) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
AURKB 1(27) 1(455) 0(27) 0(116) 0(42) 1(226) 0(26) 0(1) 0(1) 0(6) 0(20) 0(13) 0(19) 0(2) 0(9) 0(0) 
INCENP 0(11) 0(23) 0(0) 0(101) 0(12) 1(12) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
SURVIVIN 0(11) 0(447) 0(0) 1(101) 0(12) 0(12) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
CDCA8 0(11) 1(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
TD60/RCC2 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
SGO1/SGOL1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
SGO2/SGOL2 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 2(2) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
PPP1CC 0(11) 1(447) 0(0) 0(101) 0(12) 0(11) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
PLK1 0(27) 0(31) 0(27) 0(28) 0(42) 1(37) 0(26) 0(1) 0(1) 0(6) 0(20) 0(13) 0(3) 0(2) 0(0) 0(0) 
NUP107 0(11) 0(447) 0(0) 0(101) 0(12) 0(11) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
NUP85 0(11) 0(23) 0(0) 0(101) 0(12) 0(11) 1(1) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
NUP133 2(48) 0(23) 0(0) 0(101) 0(38) 0(11) 1(1) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
NUP160/ NUP120 0(11) 1(23) 0(0) 0(101) 0(12) 0(11) 4(4) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
NUP96/ NUP98 2(48) 1(23) 0(0) 1(101) 0(38) 0(11) 1(1) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
NUP37 0(11) 0(23) 0(0) 0(101) 0(12) 0(11) 1(1) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
NUP43 0(11) 0(23) 0(0) 0(101) 0(12) 0(11) 0(0) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
SEC13 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 1(1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
SEH1/SEH1L 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
ELYS/AHCTF1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 5(5) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
CRM1/XPO1 0(11) 1(23) 0(0) 0(101) 0(12) 0(11) 1(1) 0(1) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
RANBP2 0(11) 0(23) 0(0) 0(101) 0(12) 0(11) 0(0) 1(2) 0(1) 0(6) 0(0) 0(0) 0(3) 0(2) 0(0) 0(0) 
RANGAP1 0(11) 0(22) 0(0) 0(0) 0(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
 
Table 2 Table of mutations in kinetochore-associated genes 
Mutation data provided by the Sanger Institute (78) Numbers in brackets indicate the 
number of samples in which mutation data is available for. 
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Downstream of the SAC, defects in sister chromatid cohesion such as those resulting 
from the deletion of the PTTG1 gene (encoding Securin) (80) can also result in 
chromosomal missegregation and loss of chromosomes. However, in human cancers 
such as breast cancer, Securin appears to be overexpressed (81) and in vitro experiments 
with non-degradable Securin have shown that inhibition of chromosome segregation 
occurs, resulting in aneuploid cells (82). These experiments suggest that an optimal 
level of Securin is required to maintain proper chromosomal segregation. 
Extra centrosomes are frequently found in cancer cells (83), and are associated with 
increasing levels of CIN (84). Aurora A overexpression in cell lines has been shown to 
lead to centrosome amplification and aneuploidy (85-87). Confirming this, 
overexpression of Aurora A in mouse models demonstrated centrosome amplification, 
tetraploidy and premature chromosome segregation (88). Further supporting a role for 
Aurora A in promoting centrosome amplification and CIN, aneuploidy in gastric 
tumours has been reported to be correlated with Aurora A amplification (85). 
It has been suggested that extra centrosomes contribute to CIN by allowing the 
formation of multipolar spindles that then allow multipolar cell divisions to occur. 
However, Ganem and colleagues have shown that in experiments where extra 
centrosomes are introduced into diploid cells, the daughter cells of the multipolar 
divisions are not viable (89). Instead, they suggest that extra centrosomes generate CIN 
by promoting an increase in chromosome missegregation by generating a 'multipolar 
spindle intermediate' that promotes centrosome clustering leading to a subsequent 
increase in the incidence of merotelic attachments (Figure 4). Further evidence for the 
formation of bipolar spindles following multipolar spindle formation was provided by 
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Duncan and colleagues who reported that in polyploid hepatocytes, a high frequency of 
multipolar metaphases were observed but most cell divisions were bipolar (90). 
Additionally, hyperstable microtubules leading to spindle abnormalities (91) can 
promote an increase in merotelic attachments. Merotelic attachments may contribute to 
CIN, as too many abnormal kinetochore-microtubule attachments may be formed that 
may overwhelm the Aurora B Kinase pathway that normally functions to correct these 
misattachments. As the SAC is not activated, anaphase onset is not delayed, leading to 
an increase in the incidence of aneuploidy through increased chromosomal 
missegregation events due to an increase in lagging chromosomes (Figure 5). 
Supporting this, Thompson and Compton have shown that inducing transient monopolar 
spindle formation using a small molecular inhibitor of Eg5, a mitotic kinesin (92), 
increases the rate of chromosome missegregation in cancer cells. 
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Figure 4 Multipolar spindle formation leads to merotely 
Multipolar spindle formation resulting from extra centrosomes may lead to an increase 
in merotelic attachments following centrosome clustering and reorganisation into a 
bipolar spindle 
Centrosome 
Clustering Centrosome 
Clustering 
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Figure 5 Merotely leads to errors in chromosome segregation 
Merotelic attachments may increase the number of lagging chromosomes and anaphase 
bridges, leading to errors in chromosome segregation 
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1.3.4 Polyploidy and multinucleation as an intermediate state towards 
CIN 
Polyploidy, tetraploidy and aneuploidy may appear to be a consequence of CIN due to 
missegregation of chromosomes. However, these phenotypes may also contribute to the 
development of CIN. Yeast studies suggest that tetraploidy leads to an increase in 
merotelic attachments due to altered spatial dimensions of the volume and size of the 
cell with respect to spindle length (93). Furthermore, tetraploidy may induce the loss of 
individual chromosomes in cells at rates much higher than that of triploid or diploid 
cells (94). However, this observation could indicate an increased rate of regression to 
the diploid state rather than a sustainable elevated rate of CIN. 
Cytokinesis defects may lead to the generation of multinucleate cells with increasing 
ploidy (95-97) and these multinucleated cells demonstrate features of CIN. Shi and 
colleagues demonstrated that in human cancer cells, diploid cells can undergo a normal 
bipolar mitosis but fail to complete cytokinesis (98) leading to the generation of 
tetraploid binucleate daughter cells. These cells demonstrated an increase in 
missegregation of chromosomes 8 and 12 of between 83 and 166 fold times that of 
diploid cells. Supporting the view that multinucleation is associated with CIN, aberrant 
expression of mitotic kinases such as AURKB have been found to induce the formation 
of multinucleated cells that eventually become polyploid or aneuploid following fusion 
of the nuclei (99) (Figure 6). Fujiwara and colleagues have shown that tetraploid 
binucleate p53-null mouse mammary epithelial cells display an increase in the 
frequency of whole-chromosome aneuploidy compared to their diploid counterparts 
(increased loss of chromosomes) and higher levels of gross chromosome 
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rearrangements (as shown using SKY) (100). Failure of cytokinesis may result in 
daughter cells with extra chromosomes and the formation of multipolar spindle 
intermediates with increased merotelic attachments (89). Experiments with binucleate 
mouse hepatocytes demonstrate that the daughter cells demonstrate significant 
aneuploidy with multipolar spindle formation and defects in chromosome segregation 
(90). 
Taken together, these studies indicate that polyploidy/aneuploidy may contribute to CIN 
and that multinucleation is also associated with CIN. In this thesis, I have attempted to 
identify regulators of ploidy in human CRC as these pathways may have relevance to 
the generation or maintenance of CIN+ in vivo. 
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Figure 6 Errors in cell division may result in polyploid cell formation 
Cytokinesis failure may cause the formation of polyploid binucleate cells and 
subsequent nuclei fusion may result in an aneuploid or polyploid cell with a single 
nucleus. Mitotic slippage may also result in polyploid cells. 
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1.3.5 Adaptability of CIN/Aneuploid Cells 
Increasing evidence suggests that CIN is associated with poor prognosis in solid 
tumours (55, 59, 101). It has been suggested that adverse outcome associated with CIN 
may be related to increased tumour cell heterogeneity driving the ability of tumours to 
adapt to environmental stresses (102-104). However, while an increased level of CIN 
may be beneficial in driving adaption, more extreme levels of CIN and concomitant 
severe genetic disruption may compromise fitness, suggesting that an “optimal” level of 
CIN for carcinogenesis may exist (51, 60, 102, 105). 
In Darwinian evolution, mutations allow new variants to arise in a population and in the 
face of a selection pressure, individuals with advantageous characteristics will be 
selected for. Nowell proposed that genomic instability within cancer cells allows for the 
generation and selection of cancer cell clones with a selective advantage (106). CIN 
within cancer cells may therefore drive evolution by natural selection within the tumour 
environment due to large-scale heritable chromosomal variations resulting from intra-
tumoural genetic heterogeneity. The evolution of cancer clones is likely to occur at 
random (107), and the CIN cancer cell population may have an advantage in the face of 
selection pressure by allowing the rapid generation of new and potentially advantageous 
genotypes. An optimal level of CIN (51) leading to genetic alterations required to 
negotiate selection barriers during tumour progression might explain the selection for 
aneuploid tumours and the high frequency of karyotypic instability in solid tumours. 
The high number of tumours displaying aneuploidy and CIN (55) appears to lend 
weight to this hypothesis. 
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Consistent with this hypothesis, transient initiation of CIN, following the brief induction 
of MAD2 expression in activated-KRAS initiated mouse lung tumour models, is 
associated with a high frequency of tumour recurrence following withdrawal of the 
KRAS oncogenic stimulus (75). Weaver and colleagues demonstrated that in mouse 
models, increased chromosome missegregation caused by decreasing the levels of 
CENPE provoked an increase in levels of spontaneous tumours of the spleen and lung 
(108). In humans, patients with a rare recessive syndrome called mosaic variegated 
aneuploidy (MVA) display an increased predisposition to early onset cancer. This has 
been linked to monoallelic or biallelic mutations resulting in a decrease in levels of 
normal BUBR1 (109). 
Further supporting this view is evidence suggesting that CIN+ cells may be able to 
restore or gain phenotypes through divergent mechanisms (110). This may include 
increasing the gene expression of other proteins via copy number changes or the 
creation of fusion proteins. In experiments performed by Rancati and colleagues, yeast 
cells were depleted of a protein normally required for cytokinesis, MYO1. The deletion 
of this gene in the cells resulted in many strains of yeast that were either aneuploid or 
polyploid with a resulting change in gene expression that correlated with the change in 
number of chromosomes. Electron microscopy analysis of 10 of the MYO1 deficient 
cell lines revealed that cytokinesis was restored through 3 morphologically different 
mechanisms that were non-MYO1 dependent. Further analysis of gene expression 
changes within these cell lines revealed that 2 of the morphological changes were 
associated with changes in ribosomal biogenesis and the other was correlated with cell 
wall biogenesis. This work suggests CIN may allow for the restoration of cellular 
functions via mechanisms that bypass the original genetic defect. 
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1.3.6 CIN and drug resistance 
The development of drug resistance is a process that may be catalysed by on-going 
chromosomal re-arrangements in CIN tumours. Duesberg and colleagues demonstrated 
that aneuploid cancer cells can acquire accelerated drug resistance in vitro in the face of 
drug selection pressures (11). In their experiments, they investigated the response of 
aneuploid and diploid Chinese hamster cells to diverse drugs including puromycin, 
cytosine arabinoside, colcemid, and methotrexate. The cells were grown in the presence 
of drug, and they were able to generate drug resistant clones in the aneuploid cells but 
none from the diploid cells. Additionally, they demonstrated that cells selected to be 
resistant to one drug were cross-resistant to other drugs. 
My laboratory has proposed that CIN is associated with taxane resistance both in vitro 
and in vivo (12, 14). Taxanes hyper-stabilise microtubules by altering microtubule 
dynamics via increased polymerisation of microtubules (111), leading to the activation 
of the SAC. Cells arrest in mitosis (112) and subsequently undergo cell death, or they 
can undergo mitotic slippage, escaping the mitotic arrest. Cell death during a mitotic 
arrest or after a mitotic slippage to form a multinucleated interphase cell is termed 
mitotic catastrophe (46). 
Microtubule inhibitors are known to induce polyploidy in checkpoint-deficient or 
taxane-resistant cells (69, 113, 114), which has prompted the suggestion that polyploidy 
in response to paclitaxel may be a useful indicator of drug resistance (114). The kinome 
RNAi screen from our lab extended these observations and suggested that genes that are 
permissive for polyploidy, when targeted by RNAi, influence pathways that taxanes 
depend upon for cellular cytotoxicity, and that polyploidy or CIN prior to drug 
treatment may serve as a marker for de novo taxane resistance. Conversely, taxane 
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treatment may select for a higher frequency of CIN in residual tumour. Taxane 
treatment may result in selection of a population of cells with partial checkpoint 
dysfunction that is still sufficient to support long-term growth and survival (as 
prolonged disruption of the spindle checkpoint is not tolerated by cancer cells because 
of critical chromosome loss) (115). 
A common theme emerged from both the paclitaxel kinome screen in three cell lines 
performed by our laboratory (12) and a whole-genome paclitaxel screen performed by 
Whitehurst and colleagues (116) with respect to the relationship between mitotic arrest 
and paclitaxel efficacy. Enhancers of paclitaxel cytotoxicity (upon siRNA knockdown) 
identified in both screens – CERT (ceramide transporter protein), ACRBP (acrosin-
binding protein) and TUBGCP2 (tubulin, gamma complex associated protein 2) – were 
capable of augmenting a paclitaxel-induced mitotic arrest, growth inhibition or caspase 
activity. Intriguingly, the mitotic response to the paclitaxel-sensitisers ACRBP and 
TUBGCP2 was dependent on the cell line, indicating the uncoupling of spindle-
checkpoint-induced cell cycle arrest with downstream apoptotic pathways. In the H2126 
NSCLC cell lines, gene silencing of ACRBP and TUBGCP2 resulted in enhanced 
inhibition of proliferation with paclitaxel, whereas the depletion of these genes in 
H1155 cells enhanced caspase activation induced by paclitaxel. The authors suggest that 
tumours with a weakened spindle checkpoint may become more dependent on the 
aberrant expression of genes such as ACRBP that increase the robustness of the spindle 
assembly checkpoint, thus allowing for efficient mitotic progression. 
RNAi has also been used to validate the role of the microtubule stabilising protein TAU 
(117) as a paclitaxel-resistance factor (118). Gene expression data from tumours 
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removed from 82 patients with stage I–III breast cancer prior to paclitaxel treatment 
were analysed. TAU was one of the most significantly differentially expressed genes in 
patients with pathological complete response compared with patients with residual 
disease. Lower TAU mRNA expression was found in patients with pathological 
complete response. When ZR75.1 and MCF-7 cancer cell lines were transfected with 
siRNA targeting TAU, cell viability was decreased after treatment with paclitaxel 
compared with control-transfected cells. TAU siRNA-transfected cells also appeared to 
take up more paclitaxel. Further data suggested that TAU competes with paclitaxel for 
binding with microtubules, and therefore results in poorer efficacy of paclitaxel 
treatment. 
Carter and colleagues demonstrated the existence of gene expression signature that 
correlated with CIN, termed the CIN70 signature (59).  Expanding upon this and further 
examining the link between CIN and intrinsic taxane resistance, my laboratory proposed 
that CIN cancer cells in vivo overexpress a set of genes termed the microtubule-
stabilising (MTS) gene signature (14), that enables them to survive down-regulation of 
these genes following MTS treatment. A similar type of signature was not seen with the 
non-MTS cytotoxic, 5-FU. In cancer cell lines, MTS treatment resulted in this gene 
signature being down-regulated in CIN- CRC cell lines but not CIN+ CRC cell lines. 
Silencing these genes using siRNA resulted in an increase in paclitaxel sensitivity. 
Together, the CIN70 and MTS gene signature work are significant as they propose that 
there exists stable gene expression changes that are common across CIN+ cancers and 
that these stable gene expression changes can contribute to drug resistance. 
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Taken together, this implied 1) that pathways associated with maintaining chromosomal 
stability may contribute to sensitivity to paclitaxel and other microtubule targeting 
drugs 2) that pathways required for response to taxane treatment are de-regulated in 
CIN tumours and that CIN cancer cells may overexpress certain genes allowing them to 
better tolerate multiple cellular stresses, including cytotoxic treatment. 
1.3.7 Extreme CIN and tumour suppression 
The potential advantage conferred by genomic instability must be balanced against 
disadvantageous consequences of diversity resulting from the generation of large 
numbers of cells with deleterious variants. Muller (119) proposed that in a population 
new variants can occur at many different loci. Without genetic recombination, the 
combinations of two variants can only occur if the second one occurs in the offspring of 
the first. In the presence of a selection pressure, many new occurring variants are lost. 
Genetic material that is permanently lost cannot be regained in a population without 
recombination and this would result in a “ratchet” effect that would cause 
disadvantageous mutants to accumulate within the population and decrease the overall 
fitness of the population. The synergism where random genetic drift overwhelms the 
ability of natural selection to eradicate incoming deleterious mutations is known as 
mutational meltdown (120) and leads to eventual extinction of the population. 
One explanation as to why CIN+ tumours may not relapse by themselves in a manner 
similar to mutational meltdown may be that the tumour environment constantly exerts a 
selection pressure and deleterious variants are eliminated from the population before 
they are allowed to accumulate and remain fixed in the population. This may be similar 
to that observed in P-endosymbiont bacteria (121). As discussed previously, Rancati 
and colleagues provided evidence that CIN+ permits cells to restore lost functions by 
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altering other pathways (110). Additionally, it is conceivable that CIN cancer cells may 
duplicate genes in order to guard against potential loss of these genes, or that variants 
with these genomic duplications may be at a selective advantage in the presence of an 
external selection pressure. 
However, there is increasing support for the concept that increasing the level of 
chromosomal instability may be lethal towards cancer cells. Weaver and colleagues 
have postulated in their animal models that excessive chromosomal instability leads to 
tumour lethality (108) as the karyotype that generated the tumour is lost following 
further chromosomal missegregation and this was likened to mutational meltdown. In 
this case, CIN was acting both as a tumour initiator but excessive CIN acted as a tumour 
suppressor, supporting the idea that an optimal level of CIN is required to initiate 
cancer. Janssen and colleagues (74) proposed that reducing the protein levels of BUBR1 
and MPS1 in combination with low doses of paclitaxel increases the level of 
missegregation errors to a lethal degree. Consistent with that, Kops and colleagues 
(122) demonstrated that increasing chromosome losses by deactivating the mitotic 
checkpoint via siRNA knockdown of MAD2 and BUBR1 was lethal for cancer cells 
and that a weakened checkpoint might have negative effects on proliferation. This leads 
to the suggestion that the exacerbation of tumour genome instability may be a target for 
therapeutic intervention by overwhelming the cancer cell population with deleterious 
variants.  
Recently, our laboratory has demonstrated that there exists a non-monotonic 
relationship between CIN and clinical outcome for a variety of cancer types (60). 
According to this model, patients with tumours demonstrating an intermediate level of 
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CIN show a poorer prognosis compared to patients with extreme levels of CIN (60, 
105). This may be due to a higher degree of on-going chromosomal alterations in cells 
with extreme CIN that are not tolerated by the tumour cells analogous to bacterial 
population genetics models of mutational meltdown and animal models demonstrating a 
tumour suppressor role for CIN. 
These studies suggest that an optimal level of CIN may provide an evolutionary 
advantage but an excessive level, coupled with external stressors such as drug treatment 
may be deleterious to the CIN cancer cell population. The addition of chemotherapy as 
an additional selection pressure to cancer cells with a high level of CIN may accelerate 
cancer cell population implosion similar to Muller’s ratchet. More provocatively, it 
raises the question whether cytotoxic treatment can act as a selection pressure to drive 
tumour cells from a lower to an intermediate CIN state enhancing tumour biological 
aggressiveness and worsening patient outcome. 
1.3.8 CIN as a targetable phenotype 
Roschke and colleagues have demonstrated the existence of anticancer compounds that 
may specifically target karyotypically complex cancer cells (123), indicating that it may 
be possible to target CIN+ cancer cells specifically. Various experiments have 
suggested that there may be adaptations acquired by a CIN+ cell in order to tolerate and 
maintain the CIN state. Normal mammalian cells appear to poorly tolerate the aneuploid 
state. In humans, trisomies involving chromosomes 13, 18 and 21 are the only three that 
are tolerated in humans up to birth (124). These three chromosomes encode the smallest 
number of transcripts suggesting that normal cells poorly tolerate the increase in gene 
dosage brought about by an increase in number of chromosomes. Furthermore, studies 
in aneuploid mouse embryonic fibroblasts (125) and primary foreskin fibroblasts from 
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Down’s syndrome patients show reduced proliferation rates compared to normal 
fibroblasts (126). This suggests that CIN+ acquire additional adaptations to enable them 
to cope with the increase in genetic content. 
Experiments performed in yeast model systems have enabled us to gain insight into the 
adaptations acquired by aneuploid cells in order to tolerate aneuploidy. Polyploid yeast 
are dependent for survival upon increased expression of genes involved in pathways 
such as sister chromatid cohesion and mitotic spindle function (93). Torres and 
colleagues demonstrated that strains of aneuploid yeast show delayed cell cycle 
transition, an increase in glucose uptake, and a gene expression pattern characteristic of 
the environmental stress response (127). Despite the proliferative disadvantage that 
aneuploid cells had under general conditions, Pavelka and colleagues showed that under 
stressful conditions, such as changes in temperature or the additions of drugs to the 
media, aneuploid cell lines did not experience as large an anti-proliferative effect as the 
euploid cell lines (128).  
Following on from the experiments performed by Torres and colleagues, recently Tang 
and colleagues (129) demonstrated that CRC cancer cells lines with increased ploidy 
display increased sensitivity towards 17-AAG and AICAR compared to CRC cell lines 
with a near-diploid karyotype. This may be due to an increased demand for energy and 
dependence upon protein-folding in cells with an increase in ploidy. Additionally, non-
cancer cells with increased ploidy were more susceptible to chloroquine, an inhibitor of 
autophagy, suggesting an increased dependency on the autophagic pathway that may 
result from an increase in cellular size and protein production.  However, the findings 
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with chloroquine were not replicated when the authors compared aneuploid cancer cells 
to diploid cells. 
The discovery of the CIN70 gene signature, (59) that is overexpressed in cancer cells 
with high levels of aneuploidy, suggest that there indeed exist common pathways that 
are deregulated across CIN+ tumours of various types. Regulators of chromosome 
segregation were present in the gene signature, including AURKB, CDC20 and MAD2 
suggesting that CIN cancer cells may have a greater dependency on pathways involved 
in chromosome duplication and segregation, similar to that observed in experiments 
involving polyploid yeast (93).  
Taken together, these observations indicate there CIN+ cells certainly require 
adaptations and that there are pathways that are commonly deregulated in CIN+ tumour 
cells of differing tissue origins. Therefore, this suggests that karyotypic instability may 
be specifically targeted in human cancer. Targeting CIN survival regulators may also 
limit cytotoxicity to surrounding normal non-CIN tissue, thus limiting side effects. In 
my thesis, I have sought to identify survival pathways that CIN+ specific. 
1.4 CERT and Ceramide mediated drug sensitivity 
The ceramide pathway has been implicated in the cellular response to cytotoxic 
chemotherapy and enzymes that impair ceramide accumulation in response to drug 
exposure have been associated with multidrug resistance (130). Ceramide is a bioactive 
lipid belonging to the sphingolipid group that is pro-apoptotic (131) although the 
mechanisms have been difficult to define completely (132). The identification of small 
molecules that may potentiate the generation of ceramide in specific cellular 
compartments within cancer cells may have therapeutic potential to augment 
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chemosensitivity (133). In the previously described RNAi screen for regulators of 
multidrug sensitivity performed by our lab (12), the ceramide transporter CERT was the 
strongest hit potentiating multidrug sensitivity to paclitaxel, doxorubicin, cisplatin and 
5-FU (fluorouracil) when silenced by RNAi. CERT was relatively over-expressed in 
paclitaxel-resistant ovarian cancer and was one of six genes included in a functional 
metagene that was found by our laboratory to be predictive of combination-
chemotherapy drug sensitivity in breast cancer (134). 
CERT is a splice variant of Goodpasture antigen-binding protein that functions to 
transport ceramide from the endoplasmic reticulum (ER) to the Golgi apparatus where it 
is then converted to sphingomyelin (SM) in an ATP-dependent non-vesicular manner 
(135). The CERT protein contains a pleckstrin homology (PH) domain (136), that 
allows it to recognise PI4P and localise to the Golgi, and a (StAR)-related (START) 
domain (137) that allows the binding of long-chain ceramides (C14-C20 ceramide) 
(135). A FFAT motif exists between these two domains on CERT and this allows it to 
interact with the VAP proteins located on the ER. However, there also exists non-CERT 
mediated transport of ceramide from the ER to Golgi in the form of vesicular transport 
where ceramide is then converted to glucosylceramide instead of SM (135, 138, 139).  
Disruption of the CERT-mediated transport pathway may lead to cell death due to the 
accumulation of ceramide in the ER where it is unable to be converted into SM, 
potentially augmenting a ceramide-induced cell death response. Several cytotoxic 
agents have been shown to promote ceramide accumulation, resulting from increased de 
novo synthesis or sphingomyelinase activity. Consistent with alterations in endoplasmic 
reticulum physiology due to the accumulation of ceramide, depletion of CERT by RNAi 
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together with paclitaxel treatment leads to the synergistic induction of endoplasmic 
stress, as measured by the increase in phosphorylated PERK (protein-kinase-like 
endoplasmic reticulum kinase). Despite the association of CERT depletion with taxane 
sensitivity and ER stress activation, the molecular pathways responsible for downstream 
cell death signalling remain unclear.  
Consistent with an integral role for the ceramide pathway in influencing multidrug 
response, several enzymes in this pathway, including glucosylceramide synthase, 
dihydroceramide synthase, sphingosine kinase and acid ceramidase, have been shown to 
alter sensitivity to several common cytotoxics (140-144) 
1.4.1 CERT and Autophagy 
A clearer understanding of the molecular pathways responsible for cell death following 
CERT depletion and drug exposure may offer a broader understanding of cytotoxic 
response and offer therapeutic opportunities to delay the acquisition of drug resistance. 
Ceramide has previously been shown to induce autophagy (145). This may be the result 
of an increase in ER-stress due to the unfolded protein response (UPR) as misfolded 
proteins that accumulate in the ER can induce autophagy (146, 147). Ceramide may 
also induce starvation induced autophagy as ceramide can induce the down-regulation 
of nutrient transporter proteins (148) leading to cells not being able to efficiently use 
extracellular nutrients.  
Autophagy is a dynamic regulated pathway where cytoplasmic material (that can 
contain organelles and proteins) is delivered to lysosomes for degradation. Induction 
signals for autophagy result in the formation of the phagophore that engulfs the 
cytosolic material that is to be degraded (149) This then leads to the formation of 
Chapter 1. Introduction 
 52 
autophagosome. Many Atg proteins are involved in the formation of the 
autophagosome, a double-membraned organelle, (Atg1–10, Atg12–14, Atg16–18, 
Atg29 and Atg31). In mammalian cells, Beclin can induce autophagy and this is 
potentiated by UVRAG. LC3 is found on the inner membrane of the autophagosome 
and is a commonly used marker of autophagy induction. A step-wise maturation of the 
autophagosomes then occurs via fusion with endosomes, forming amphisomes. These 
then fuse with lysosomes to form autolysosomes (150) to degrade the contents of the 
autophagosomes (Figure 7). Autophagy can play both a protective and detrimental role 
in cell survival (151) and autophagic cell death following autophagy induction has been 
proposed (152).  
Chapter 1. Introduction 
 53 
 
Figure 7 Maturation of autophagosomes and fusion with lysosomes to form 
autolysosomes 
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1.4.2 Paclitaxel response and the lysosome  
Microtubule-stabilising agents are known to trigger activation of the protease cathepsin 
B and its release from the lysosome. Furthermore cathepsin B inhibition antagonises 
microtubule-stabilising agents (153) and lysosome-destabilising agents demonstrate 
synergistic cytotoxicity with either vincristine or paclitaxel (154). Two screens have 
identified other lysosomal regulators that influence paclitaxel response. The Gauchers 
disease gene product, GBA1, was identified by our laboratory in the screen of ceramide 
regulators as a candidate paclitaxel-resistance gene following silencing by siRNA (12). 
GBA1 protein level is induced at 12–18 h following paclitaxel treatment, coincident 
with maximal mitotic arrest of HCT-116 cells. The vacuolar ATPase subunit 
ATP6V0D2 was also identified as an enhancer of paclitaxel cytotoxicity following gene 
silencing in the genome wide screen by Whitehurst and colleagues for genes regulating 
paclitaxel sensitivity (116). In a pharmacological validation strategy, inhibition of the 
vacuolar ATPase with a synthetic lysosomal ATPase inhibitor, RTA-203, together with 
low-dose paclitaxel treatment, significantly reduced the viability of H1155 NSCLC 
cells. Targeting glucosylceramide synthase, an enzyme involved in the conversion of 
ceramide to glucosylceramide at the lysosomes, has been shown to promote sensitivity 
to doxorubicin, vinblastine and paclitaxel with a concomitant fall in expression of 
ABCB1 (144).  
Data indicating that the down-regulation of CERT may increase levels of ceramide, an 
autophagy inducer, and that cell death following paclitaxel treatment may be influenced 
by lysosomal activity together suggest that the autophagy-lysosomal pathway may play 
a role in sensitising cells to taxanes following CERT silencing. In this thesis I have 
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attempted to elucidate how CERT silencing results in the sensitisation of cancer cells to 
paclitaxel and other cancer cytotoxics using integrative functional genomics techniques 
1.5 Conclusions 
CIN is a complex multifactorial phenotype that may arise following errors in the 
machinery maintaining proper cellular division. Additional adjustments are required for 
the cell to tolerate the CIN state and chromosome missegregation and this may be 
reflected in an increased dependency on pathways regulating glucose utilisation, protein 
folding and autophagy. 
The polygenic nature of multidrug resistance as illustrated by functional genomic 
studies, combined with the ability of the tumour population to silence gene expression 
through epigenetic means (155) or activate gene expression through increased gene 
dosage triggered by chromosome reassortment in aneuploid tumours (156), may explain 
the relative ease with which tumour populations acquire resistance to non-cross-
resistant cytotoxics as treatment lines advance in solid tumours. CIN+ cells are 
intrinsically resistant to microtubule targeting drugs and functional genomic approaches 
reveal that resistance to microtubule targeting agents is mediated by the down-
regulation of genes maintaining chromosomal stability. Attempts to limit cytotoxic 
resistance and improve patient survival with ‘non-cross-resistant’ agents are likely to 
produce only modest benefits unless strategies can be identified to target the underlying 
genetic propensity of the cancer cell to rapidly disrupt the expression of large numbers 
of genes potentially involved in multidrug resistance pathways. 
In this thesis, I have addressed four questions that attempt to explore the underlying 
basis for the initiation and the tolerance of CIN: 
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1. Is CIN associated with intrinsic resistance to other clinically relevant drugs? 
2. Can specific means to target CIN+ cells be identified through pharmacological 
and whole genome RNA interference screens? 
3. Can clinically relevant initiators of aneuploidy be identified through integrative 
functional genomics techniques? 
4. Can a molecular basis for CERT-mediated paclitaxel sensitisation be defined 
that might support the targeting of CIN+ cells? 
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Chapter 2. Materials and Methods 
2.1 Kinase inhibitor and cytotoxic agent screens to identify 
CIN survival mechanisms 
2.1.1 Cell lines 
All cells were incubated at 37 ºC with 10% CO2 in Dulbecco's Modified Eagle Medium 
(D-MEM) (1X), liquid (High Glucose) with L-Glutamine from Gibco (Invitrogen) and 
supplemented with 1:10000 of Penicillin-Streptomycin (catalogue no. P4333, 10000 
units penicillin, 10 mg Streptomycin) from Sigma. 
27 CRC cell lines previously characterised for numerical/structural CIN, MIN status (3, 
157-159) were used (Table 3).  
Publicly available somatic mutation data from the Sanger Institute Cancer Cell Line 
Project (CLP) and COSMIC database (78) was used. 15 CIN+ and 6 CIN- cell lines 
used in my analysis were present within the CLP database. A total of 20 out of the 61 
genes resequenced in the project were found to have somatic mutations in at least 1 of 
those 21 cell lines. Additional information regarding the somatic mutation status of 
APC, CTNNB1, KRAS, MLH1, PIK3CA and TP53 were obtained from both published 
(160-163) and internal laboratory data.  
Isogenic HCT116 MAD2+/- cell lines (164) and HCT116 PTTG1-/- cell lines (80) were 
donated courtesy of Drs Benezra and Vogelstein respectively. 
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To generate tetraploid HCT116 cells, naturally occurring tetraploid cells were isolated 
from the parental cell line and single cell sorted using flow cytometry. Clonal FISH was 
performed with Centromere Enumeration Probes (CEP) against Centromere 2 and 15. 
Chapter 2. Materials and Methods 
 59 
 
Cell Line 
C32 
COLO205 
COLO678 
DLD1 
GP2D 
HCA7 
HCI-H508 
HCI-H747 
HCT116 
HCT15 
HDC57 
HT55 
LS1034 
LS174T 
RKO 
SKCO1 
SW1116 
SW1222 
SW1417 
SW1463 
SW403 
SW48 
SW620 
SW837 
SW948 
T84 
VACO5 
Table 3 Table of colorectal cancer cell lines used 
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2.1.2 Calbiochem kinase inhibitor library and 5-FU screen 
Calbiochem Kinase Inhibitor Libraries I and II (EMD Biosciences) containing 160 
inhibitors were used. Comprehensive data for these inhibitors including references 
documenting target inhibition or downstream signalling cascade inactivation can be 
found on the manufacturer’s website (165). 
 Cells were plated into 96-well tissue culture microplates at an initial seeding density of 
4000 cells/well. After 24 hours, cells were treated with the inhibitors at a final 
concentration of 10µM/well. This concentration was selected following drug titration 
test analysis to give an optimal range of mean relative surviving cells following 
inhibitor treatment across all cell lines. After 72 hours of treatment, cell viability was 
assayed using the Celltiter-Blue Cell Viability Assay (Promega). The assay reagent was 
added at a 1:5 dilution and cells were incubated at 37 ºC for 1 hour before recording 
fluorescence (560(20)Ex/590(10)Em) using an Envision plate reader. The readout for 
each inhibitor treated well was normalised to vehicle control wells. For the HCT116 
MAD2 isogenic cell lines, a final inhibitor concentration of 1µM/well was used to allow 
for a larger range of number of surviving cells across all inhibitors. 
5-FU (Sigma) was used at both 1µM and 10µM for a treatment length of 72 hours. The 
27 CRC cell lines were plated and assayed using the same conditions and methods as 
above. 
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2.1.3 Anti-Cancer agent screen 
Biolog Anti-Cancer Agent Microplates M11-M14 consisting of 92 anti-cancer agents at 
4 increasing concentrations between 0.1 µM and 25µM per agent were used. Cells were 
plated at an initial seeding density of 5000 cells/well. After 72 hours, Biolog Redox Dye 
Mix MA was added at a 1:6 dilution and cells incubated for 6 hours at 37 ºC. The 
number of surviving cells per well was assayed using an Envision plate reader to detect 
absorbance at 590nm and normalised to the negative control wells. 
2.1.4 Cell proliferation assay 
The proliferation rate of all 9 CIN- and 18 CIN+ CRC cell lines was measured using the 
IncuCyte Long-term Cell Imaging System. Cell lines were plated in 96-well plates at an 
initial plating density of 4000 cells/well and phase contrast images were obtained 2-
hourly over 70 hours allowing measurements of cell monolayer confluence. Outliers 
were removed manually and growth curves were fitted by splines with the R package 
grofit (166) with smoothing parameter smooth.gc = 0.7.  
2.1.5 Meta-Analysis of CIN outcome  
Axel Walther performed the analysis presented in this section. 
Survival data were summarised using a log hazard ratio for comparison between CIN+ 
and CIN- groups. Data from individual studies were extracted using the methods 
described by (167) and pooled to generate the summary statistic and confidence 
intervals using a fixed-effects model with inverse variance weighting. All meta-analyses 
were performed using Stata 10.1 (Stata Corp, College Station, TX). 
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2.1.6 Statistical methods 
In this section, I was assisted by David Endesfelder. 
All tests were performed as two-sided unless otherwise mentioned. To remove outliers, 
drugs resulting in relative number of cells >1.4 compared to vehicle control were 
eliminated from analysis. A Kolmogorov-Smirnov test was performed to test for overall 
differences in the distribution of relative cell numbers following inhibitor treatment 
between CIN+ and CIN- cell lines. Inhibitors that showed a fraction of surviving cells > 
0.8 in > 75 % of the cell lines were excluded from the analysis. For comparisons of 2 
cell lines, drugs resulting in relative number of cells >0.8 in both cell lines were 
removed from analysis. A Wilcoxon signed-rank test was used to test for differences 
between CIN+ and CIN- cells (for each concentration of drug in Biolog microplates). 
For the Biolog microplates, each concentration of drug was used in duplicate; therefore 
the replicates which showed the least difference in cell number between the 2 cell lines 
was used for further analysis. 
The maximal slope of the growth curve (mu) for each cell line was used to test if the 
difference in drug sensitivity between CIN+ and CIN- colorectal cancer cell lines were 
not solely due to different proliferation rates. CIN+ and CIN- cell lines with mu < 1 
were tested with a one-sided Wilcoxon-Mann-Whitney test. Next, the influence of the 
proliferation rates of each cell line was corrected. A linear regression model for all cell 
lines with mu < 1 was estimated, where mu was used as the independent variable and 
the mean fraction of surviving cells over all inhibitors as the dependent variable. The 
residuals of this analysis were tested for significant differences between CIN+ and CIN- 
with a one-sided Wilcoxon-Mann-Whitney-Test (168). An analysis of covariance model 
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with interactions was applied, where the mean fraction of surviving cells over all 
inhibitors was used as the dependent variable, mu as the linear independent and CIN 
status as the factor variable. The interaction term was utilised to test for significant 
differences in slopes between CIN+ and CIN- cell lines. 
To test for significant differences in sensitivity to thymidylate synthase inhibitors 
comparing HCT116 diploid parental to PTTG1-/- or MAD2+/- cells, the influence of 
different concentrations was corrected by estimating a linear regression model for near 
linear correlations between concentration and sensitivity or a one-way ANOVA 
otherwise. In each case the concentration was used as the independent variable and the 
resulting residuals were tested for differences between CIN+ and CIN- cells with a 
Wilcoxon-Mann-Whitney test.  
2.2 Whole genome RNAi screens for regulators of CIN survival 
and ploidy 
2.2.1 Cell culture and siRNA transfection protocol 
The same conditions were used to transfect the HCT116 diploid parental and MAD2+/- 
cells. All cells were incubated at 37 ºC with 10% CO2 in Dulbecco's Modified Eagle 
Medium (D-MEM) (1X), liquid (High Glucose) with L-Glutamine from Gibco 
(Invitrogen) and supplemented with 1:10000 of Penicillin-Streptomycin (catalogue no. 
P4333, 10000 units penicillin, 10 mg Streptomycin) from Sigma.  The cell lines were 
used coutesy of Dr Benezra (164). 
The Dharmacon whole genome siRNA library targeting 21222 genes in triplicate was 
used. The screen was performed using 96-well tissue microplates with a final 
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concentration of siRNA of 37.5nM and 0.3µl/well of Lipofectamine RNAiMAX 
(Invitrogen). The microplates were plated with 0.1% Poly-L-Lysine (Sigma) diluted 1:8 
in PBS prior to cell culture. 
The whole genome siRNA library was resuspended in 10µl of HBSS (Invitrogen) and 
pre-aliquoted into 96-well microplates. On the day of the screen, 0.3µl of Lipofectamine 
RNAiMAX diluted in 10µl of Optimem-I (Invitrogen) was added to each well. The 
mixture was allowed to incubate at room temperature for 15 minutes. 4000 cells in 80µl 
media were added to each well. The plates were incubated for 72 hours at 37ºC and 
10% CO2. Following this, the medium was aspirated from each well and 150µl of a -
20ºC 80% Ethanol solution was added as a fixative. All plates were stored at -20ºC prior 
to analysis. DAPI (Roche) was used to label the DNA. DAPI staining was performed as 
follows: Each well was washed three times using 35µl of PBS each time. 35µl of a 
DAPI in PBS solution (1µg/ml) was added to each well. Plates were incubated for 30 
minutes at room temperature. The DAPI solution was then aspirated and 35µl of PBS 
was added to each well prior to sealing the plates. The plates were scanned on an 
Acumen ex3 laser scanning cytometer to measure cell number and cell cycle profile.  
2.2.2 Statistical normalisation of screening data 
Becky Saunders performed the analysis described in this section. 
For analysis of cell number data from the whole genome RNAi screens, cell number 
was normalised as follows: Normalised value = log (well value / plate median value) to 
provide a normal distribution. A z-score for each well was calculated by dividing the 
normalised well plate value by the plate median absolute deviation (MAD). The median 
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z-score across triplicate wells was then calculated to provide the final z-score for each 
candidate gene. 
For the analysis of cell cycle profile data from the whole genome RNAi screens, to 
allow comparison of z-scores obtained from the HCT116 diploid parental screen with 
other whole genome screens in fibrosarcoma (HT1080), lung cancer (PC9) and renal 
cancer (RCC4) cell lines, the >4n data for the HCT116 diploid parental cell line was 
renormalised as follows: Normalised well  = (well value - plate median value) / screen 
MAD.  
2.2.3 Statistical analysis of screen variance 
This section was performed by Stuart Horswell. 
Raw (absolute) count data were normalized for plate and possible edge effects by fitting 
a linear model with row/column interaction terms and an independent "plate" factor. 
Initially a Poisson model was used, but as this provided evidence of over-dispersion, the 
dispersion parameter was estimated and a negative binomial model was applied instead. 
Model fitting was performed using the "glm" function in base R, with dispersion 
parameter estimated using glm.nb and the negative binomial family implemented using 
the negative.binomial family, both from the MASS package. 
Residuals were extracted from these models and are subsequently referred to as 
"normalised" data. The fitting of mixture models was performed using the lme function 
from package nlme, with siRNA nested within MAD2 status for the random effects, and 
siRNA, MAD2 status and siRNA * MAD2 status interaction as the fixed terms. A 
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retrospective power analysis was performed using the critical values obtained from a z-
score analysis of the data from the mixture models. 
All analyses were performed using R. 
2.2.4 Defining significant and consistent regions of copy number 
alteration in cell lines 
The following analysis steps was performed by David Endesfelder 
The analysis was performed using R. First, minimum consistent regions of genomic 
alteration were identified across all cell lines. Next, each of these regions was assessed 
for gain in DNA copy number. Since many CIN cell lines are near triploid or tetraploid, 
using a diploid baseline (copy number = 2) would result in most of the genome being 
computed as gained. Therefore to select for genomic regions altered specifically relative 
to the background ploidy of the cell line, ploidy status was estimated for each cell line 
using the median copy number over all SNP probes. Each region in each cell line was 
then defined as either gained (copy number > ploidy baseline) and normalised to the 
ploidy baseline of the cell line or not gained and set to 0. Then each region was assessed 
for loss in the same manner.  
To test for statistical significance between CIN+ and CIN- cell lines a d-score for each 
lost and gained region was computed by calculating the mean normalised copy number 
across CIN+ and CIN- cell lines, thereby accounting for both amplitude and frequency 
of genomic aberrations. A Significance Analysis of Microarrays was then performed 
with a modified two-sample t-statistic. In comparison to a standard two-sample t-
statistic, SAM includes an additional parameter which decreases the influence of high 
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sample variance. This was empirically set to 0.5 which results in a balanced weighting 
of frequency and amplitude.   
To detect significant regions, 10000 random class label permutations were performed 
and all regions with a q-value < 0.05 were defined as significantly gained or lost. To 
ensure the selection of genes consistently altered across aneuploid tumours, any 
genomic change not seen across >50% of the tumours was excluded from further 
analysis. Regions were then mapped to genes using BioMart. 
2.2.5 Live cell imaging  
For live cell imaging H2B-mRFP HCT-116 cells were monitored at 37ºC and 5% CO2 
in LabTech II (LabTech) chambers. Cells were plated into chamber slides for reverse 
transfection. Images were acquired every 3 min for 8 h using a 40x oil NA 1.3 objective 
on an Olympus Deltavision Personal microscope (API) equipped with a DAPI-FITC-
Rhod/TR-CY5 (Chroma) filter set and environmental chamber. 
2.3 CERT multidrug sensitisation pathway 
2.3.1 Cell culture and siRNA transfection protocol 
All cells were incubated at 37 ºC with 10% CO2 in Dulbecco's Modified Eagle Medium 
(D-MEM) (1X), liquid (High Glucose) with L-Glutamine from Gibco (Invitrogen) and 
supplemented with 1:10000 of Penicillin-Streptomycin (catalogue no. P4333, 10000 
units penicillin, 10 mg Streptomycin) from Sigma. Where siRNA transfection was 
performed, the media was not supplemented with Penicillin-Streptomycin. 
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Cell lines used include HCT116 and the HER2+ breast cancer cell lines BT474, 
HCC1954 and SKBR3. The GFP-LC3 HEK293 cell line was used courtesy of Dr 
Sharon Tooze. 
All siRNAs were obtained from Dharmacon and siRNA transfections were performed 
using reverse transfection methods with Lipofectamine RNAiMax reagent (Invitrogen) 
at 0.3µl per well of a 96-well plate or 2µl per well of a 6-well plate and with a final 
concentration of siRNA of 37.5nM. For siRNA transfections in 96-well plates, a final 
volume of 100µl with 4000 cells per well was used. Both siRNA and transfection 
reagent were made up to 10µl each in Optimem-I from Gibco (Invitrogen). After 5 
minutes incubation at room temperature, both mixtures were added together and 
vortexed. The mixed solution was allowed to incubate for at least 20 minutes at room 
temperature. Cells were trypsinised and resuspended in tissue culture medium. The 
Optimem-I mix and medium containing cells were added to the each well to make up 
the final volume for 100µl. For siRNA transfections in 6-well plates, a similar protocol 
to that of the 96-well plates was used, but scaled up proportionally to a final volume of 
1.5ml with 300000 cells per well. Both siRNA and transfection reagent were made up to 
200µl each in Optimem-I when using 6-well plates. 
2.3.2 Fluorescent ceramide transport analysis 
Dr Charles Swanton performed the analysis described in this section. 
HCT116 cells were seeded the day before the experiment on 25-mm diameter coverslips 
at a density of 2 × 105 cells. On the day of the experiment the coverslip was placed into 
a chamber and the cells were washed in modified Krebs-Ringer buffer and incubated on 
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ice for 20 min with 0.05 µm BODIPY® FL C5-ceramide and excess dye was removed 
by washing with modified Krebs-Ringer buffer. The coverslip was then mounted on a 
heated stage after replacing the medium with fresh medium at 37 °C. The distribution of 
ceramide was analyzed after 20 minutes using an inverted Zeiss LSM-510 scanning 
laser confocal microscope (Thornwood, NY). 
2.3.3 Lipid extraction, liquid chromatography / mass spectrometry 
(LC/MS) analyses of ceramide 
Liquid Chromatography / Mass Spectrometry were performed by Stefka Spassieva and 
Lina Obeid. 
Briefly, cell pellets were fortified with internal standard (C13/C16 ceramide, C17/C16 
ceramide, and C17/C24:1) and lipids were extracted with 2 ml ethyl 
acetate/isopropanol/water (60/30/10 v/v) solvent, dried under a stream of nitrogen, and 
re-suspended into 150 μl 1 mM NH4COOH in 0.2% HCOOH in methanol. The MS 
analyses of endogenous ceramide species were performed on a Thermo Finnigan TSQ 
Quantum triple quadrupole mass spectrometer, operating in a Multiple Reaction 
Monitoring positive ionization mode. Lipid extracts were gradient eluted from the BDS 
Hypersil C8, 150 x 3.2 mm, 3-μm particle size column, with a 1.0 mM methanolic 
ammonium formate/2 mM aqueous ammonium formate mobile phase system. Peaks 
corresponding to the target analytes and internal standards were collected and processed 
with Xcalibur software. Quantitative analyses were based on the calibration curves 
generated by spiking an artificial matrix with known amounts of the target analyte 
synthetic standards and an equal amount of the internal standard. The target 
analyte/internal standard peak areas ratios were plotted against analyte concentration. 
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The target analyte/internal standard peak area ratios from the samples were similarly 
normalized to the internal standard and compared to the calibration curves, using a 
linear regression model. The phosphate contents of the lipid extracts were used to 
normalize the MS measurements of ceramides. The phosphate contents of the lipid 
extracts were measured with a standard curve analysis and a colorimetric assay of ashed 
phosphate. 
2.3.4 CERT microarray expression profiling 
Philip East performed the analysis described in this section 
HCT116 cells were transfected with either siCON or siCERT and treated in triplicate 
with paclitaxel, C6-ceramide, or vehicle control for 8h for use on HuEx-1_0-st-v2 exon 
arrays (Affymetrix). 
The HuEx-1_0-st-v2 exon arrays were processed using RMA (169) to generate gene 
level signal estimates for core level probesets. The arrays were normalised using 
quantile normalisation and antigenomic probes used to model the background. 
Quantification was run using apt-1.10.0 from Affymetrix. Prior to statistical analysis 
genes showing low variance across all samples were removed (coefficient of variance < 
0.05) along with those with a consistently low signal in all samples (< 10th percentile in 
all but 1 or less samples). All Affymetrix control probe sets were excluded from further 
analysis. Condition dependent gene changes were selected using a linear model where 
the standard errors were corrected using empirical Bayes shrinkage. Statistically 
significant genes were selected using a nestedF procedure run across applied contrasts 
(fdr < 0.05 ). Analysis was carried out in Bioconductor using Limma (170).  
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2.3.4.1 Enriched functional signatures 
Metacore from GeneGo Inc. was used to identify any enriched biological signatures 
within the CERT depleted dependent gene changes in the presence of Ceramide. 
Differential genes (fdr < 0.05, no prior filtering) were tested against Metacore’s process 
networks using the HuEx-1_0-st-v2 array as background. To refine this analysis a more 
comprehensive autophagy gene set was constructed from Metacore’s process network 
set and its autophagy Map. This autophagy gene set was mapped back to the array data 
and tested for enrichment in CERT dependent gene changes (p-value < 0.05). The 
autophagy gene set was also tested using GSEA running 10000 permutations on the 
gene names and using a modified t-statistic to rank the genes (171, 172). 
2.3.5 qPCR validation of microarray data 
cDNA from the same samples used in the exon array analysis were used in Taqman 
Arrays (Applied Biosystems). 30 to 1000ng of cDNA was made up to 50µl using 
RNAase free water. The sample was then added to 50µl TaqMan® Universal PCR 
Master Mix (2✕) (Applied Biosystems) in a 1.5ml microcentrifuge tube and vortexed. 
100µl of the vortexed mix was added to each Taqman Array fill reservoir and 
centrifuged according to manufacturer’s instructions to distribute cDNA samples within 
the Taqman Array card. Cards were then sealed using the provided card sealer and the 
qPCR reaction was run on an Applied Biosystems 7900HT instrument according to the 
Taqman Array protocol. The Taqman probes that were used are listed in Table 4. 
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18S-Hs99999901_s1 GBA-Hs00164683_m1 
AADACL1-Hs00736941_m1 HPS5-Hs00200565_m1 
ACADM-Hs00163494_m1 JUN-Hs00277190_s1 
ATF1-Hs00270896_m1 KIF20A-Hs00194882_m1 
ATF2-Hs00153179_m1 KLF6-Hs00154550_m1 
AURKA-Hs01597773_mH LAMP2-Hs00174474_m1 
BDNF-Hs00538277_m1 MARVELD2-Hs00376394_m1 
BNIP3L-Hs00188949_m1 MDK-Hs00171064_m1 
BUB3-Hs00190920_m1 MRS2L-Hs00252895_m1 
CASP4-Hs01031947_m1 MT1A-Hs00831826_s1 
CCNE2-Hs00180319_m1 MTO1-Hs00201667_m1 
CDC20-Hs00415851_g1 NEFL-Hs00196245_m1 
CENPH-Hs00224722_m1 NR4A2-Hs00428691_m1 
COL4A3BP-Hs00178615_m1 PBX1-Hs00231228_m1 
COL4A3BP-Hs00178621_m1 PDIA6-Hs00194922_m1 
CPA4-Hs00275311_m1 PTTG1IP-Hs00188967_m1 
CREB3L2-Hs00811200_m1 SCML1-Hs00232467_m1 
CYP24A1-Hs00167999_m1 SCML2-Hs00232330_m1 
DDIT3-Hs00358796_g1 SPRR2D-Hs00863465_m1 
EIF2AK3-Hs00178128_m1 TGFBR3-Hs00234257_m1 
ENAH-Hs00430216_m1 TRIB3-Hs00221754_m1 
FOXL2-Hs00846401_s1 TRIB3-Hs01082394_m1 
FYCO1-Hs00225888_m1 WDFY1-Hs00604732_m1 
GAPDH-Hs00266705_g1 WIPI1-Hs00215872_m1 
 
Table 4 List of Taqman probes used 
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2.3.6 Drug response assays 
Cells were plated into 96-well tissue culture microplates at an initial seeding density of 
4000 cells/well for siRNA reverse transfection. After 48 hours of paclitaxel (Sigma) or 
vehicle control (DMSO, Sigma) treatment, cell viability was assayed using the Celltiter-
Blue Cell Viability Assay (Promega). The assay reagent was added at a 1:5 dilution and 
cells were incubated at 37 ºC for 1 hour before recording fluorescence 
(560(20)Ex/590(10)Em) using an Envision plate reader. 
2.3.7 LC3 immunoblotting 
Cells were plated into 6-well tissue culture microplates at an initial seeding density of 
300000 cells/well for siRNA reverse transfection. Cells were then harvested at 24h after 
paclitaxel or vehicle control treatment or at other specified timepoints. Where relevant, 
the protease inhibitor leupeptin (Sigma Aldrich) was used at a final concentration of 
1µg/ml. As a positive control for the induction of autophagy, 1.5ml of Earle’s Balanced 
Salt Solution (EBSS) was added to each well, following the aspiration of media and 
three 5-minute washes with PBS. Cells were harvested 2 hours following the addition of 
EBSS. 
2.3.7.1 Lysate harvesting 
6-well microplates were placed on ice and cell culture medium was aspirated followed 
by 3 washes with PBS. Final aspiration was performed and TNTE buffer (20mM Tris-
HCl; 150mM NaCl; 0.3% Triton X-100; 5mM EDTA; pH 7.5) was added at 150µl per 
well and cells were harvested using a cell scraper. 150µl of lysate were added to a 1.5ml 
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tube and centrifuged for 5 minutes at >10000rpm. 130µl of the supernatant was 
aliquoted to a fresh tube. The supernatant was used immediately for immunoblotting. 
2.3.7.2 Immunoblotting protocol 
All reagents used were from Invitrogen unless otherwise stated. 30µl of lysate was 
aliquoted into a fresh 1.5ml tube containing 10µl of NuPAGE LDS Sample Buffer (4X) 
and 4% beta-mercaptoethanol (Sigma). Samples were heated on a heating block at 65ºC 
for 2 minutes. 35µl of the heated sample was loaded per well in a 1.5 mm, 10 well 
NuPAGE Novex 4-12% Bis-Tris Gel. 1x MES running buffer was used for gel 
electrophoresis at a voltage of 200V for 45 minutes. Upon completion of gel 
electrophoresis, the gel was washed for 5 minutes in 2x Transfer Buffer (with 10% 
methanol) prior to sandwiching in between chromatography paper (pre-soaked for 10 
minutes with 2x Transfer Buffer with methanol) and a PVDF membrane (GE 
Healthcare) (presoaked in methanol for 10 seconds) for transfer of proteins. A semi-dry 
transfer was performed for 30 minutes at a constant 15V. 
Upon completion of the semi-dry transfer, the PVDF membrane was washed for 5 
minutes with TBS, followed by blocking of non-specific binding by incubating the 
membrane for 1 hour in a 5% non-fat Milk in TBS solution at room temperature. This 
was followed by three 5-minute washes in TBS prior to incubating with primary anti-
LC3 mouse antibodies (Nanotools) at a dilution of 1:250 in the milk in TBS solution 
overnight at 4ºC. 
The membrane was washed three times in TBS for 10 minutes each prior to incubating 
with HRP-conjugated secondary antibodies (GE Healthcare) at dilution of 1:10000 in 
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the milk solution at room temperature. The membrane was washed three times in TBS 
for 10 minutes each, prior to adding ECL reagents (GE Healthcare) for detection of the 
HRP-conjugated antibody. 
2.3.8 Immunofluorescence microscopy 
Cells were transfected in 6-well plates containing glass cover slips. The 6-well plate 
siRNA transfection protocol was used. Cells were fixed using PTEMF (20 mM PIPES 
(pH 6.8), 10 mM EGTA, 1 mM MgCl2, 0.2% Triton X-100 and 4% formaldehyde) at 
room temperature for 10 minutes. Primary antibodies were diluted as follows in PBS + 
3% BSA; anti-LAMP2 (Abcam) 1/1000 and cover slips were incubated for one hour in 
the antibody solution. Following three 5-minute washes with PBS, cross-adsorbed 
secondary antibodies were used (Molecular probes) in PBS + 3% BSA. Cover slips 
were incubated for one hour at room temperature in the secondary antibody solution 
followed by three 5-minute washes with PBS. To visualise the cell nuclei, cover slips 
were then incubated in a 1µg/ml DAPI (Rosche) in PBS solution for 30 minutes at room 
temperature. Three 5-minute washes with PBS were then performed. The cover slip was 
dried before being mounted on a glass slide. 
3D image stacks were acquired in 0.2 µm steps using a 100x oil NA 1.4 objective on an 
Olympus Deltavision Personal microscope (API) equipped with a DAPI-FITC-
Rhod/TR-CY5 filter set (Chroma) and a Coolsnap HQ camera. The 3D image stacks 
were deconvolved with SoftWorx (API). 
For quantification of LAMP2 spot intensity, cells were plated into 96-well tissue culture 
microplates at an initial seeding density of 4000 cells/well for siRNA reverse 
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transfection. After 48 hours of paclitaxel treatment, cells were fixed using 80% ethanol 
at -20ºC for 1 hour. Primary and secondary antibodies were used following the same 
protocol as in the previous section. Cytoplasmic spot intensity was measured using a 
Cellomics Arrayscan high-throughput imaging system. 
2.3.9 Live cell imaging  
For live cell imaging H2B-mRFP HCT-116 cells were monitored at 37ºC and 5% CO2 
in LabTech II (LabTech) chambers. Cells were plated into chamber slides for reverse 
transfection using the same protocol as transfection for 6-well plates but scaled down 
proportionally by 4 times. Cells were then treated with paclitaxel or vehicle control. 
Images were acquired every 10 minutes for 48h using a 40x oil NA 1.3 objective on an 
Olympus Deltavision Personal microscope (API) equipped with a DAPI-FITC-
Rhod/TR-CY5 (Chroma) filter set and environmental chamber. 
2.3.10 Tissue Microarray cohort 
Patricia Gorman and Rebecca Roylance performed the analysis described in this 
section. 
Archival paraffin-embedded breast cancer tissue was obtained from 356 patients 
diagnosed at Leeds Teaching Hospitals NHS Trust between 1983-1997. Tissue 
microarrays (TMAs) were constructed containing cores, 0.6mm in diameter and 4μm in 
thickness, selected from representative tumour areas as determined by a consultant 
breast histopathologist (AMH) from H&E stained sections. Full clinico-pathological 
data was available. The majority of chemotherapy treated patients were given CMF 
(cyclophosphamide, methotrexate and Fluorouracil 5-FU) or FEC (Fluorouracil 5-FU, 
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epirubicin and cyclophosphamide) treatment. Ethical approval was obtained (Leeds East 
06/Q1206/180).  
Briefly, following deparaffinisation an antigen retrieval step was performed. This was 
done using the automated Ventana system and Tris buffer (Ventana Medical Systems, 
Inc). Tissue sections were incubated with CERT rabbit polyclonal antibody (Bethyl 
laboratories. Inc) dilution 1:3500 for 1 hour. Appropriate biotinylated secondary 
antibodies were used followed by streptavidin–biotin–peroxidase complex. Peroxidase 
was localised using diaminobenzidine, with counterstaining with Mayers haematoxyin. 
Negative controls were the omission of primary antibody. A known positive control was 
used with each batch of staining. Slides were viewed by two independent scorers 
blinded to each others findings.  
CERT localised to the cytoplasm. Scoring was performed of both the percentage and 
intensity of staining using a scale of 0-3, with 0 = tumours with no staining whatsoever; 
1 = tumours with rare scattered positive staining; 2 = tumours with moderate to strong 
staining but with some cells showing no readily detected staining; and 3 = tumours with 
strong staining, uniformly visualized over the whole section. A quickscore (percentage 
of cells staining positive x intensity) was quantified (173).  
Survival analysis was performed by David Endesfelder and Jil Sander. 
Survival analysis was performed with a univariate cox-proportional hazard regression 
model and a log-rank statistic was used for significance testing. A maximally selected 
rank statistic (174) was used on all 356 patients to detect a CERT expression quickscore 
threshold for separating good from poor prognosis. The R-package maxstat (175) was 
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used to derive the reported threshold of 175. To test for differences of CERT 
expression. A maximally selected rank statistic (174) was used on all 356 patients to 
detect a CERT expression quickscore threshold separating good from poor prognosis. A 
significant result of the maximally selected rank statistic suggests that a threshold 
separating good from poor prognosis exists. Based on this threshold (quickscore = 175), 
CERT expression was grouped into high and low expression for the whole dataset. 
Survival analysis was performed with a univariate cox-proportional hazard regression 
and a log-rank statistic was used for significance testing between the CERT high and 
CERT low groups. To test for differences of CERT expression levels between HER2+ 
and double-negative breast cancers (ER-/HER2-) a two-sided t-test was used. 
2.3.11 Electron microscopy 
Cells were grown on 13mm glass coverslips in 6-well tissue culture microplates. HCT-
116 cells were transfected with siCERT or siCON using the standard protocol for 6-well 
tissue microplates. Following 48h of siRNA transfection, cells were treated with 25nM 
paclitaxel or vehicle control for 24h. Cells were fixed with 2.5% glutaraldehyde/ 4% 
paraformaldehyde in 0.1M Phosphate Buffer (PB) for one hour. The samples were 
passed on to the Electron Microscopy Facility where samples were post-fixed in 
reduced osmium tetroxide, stained with tannic acid, dehydrated step-wise to 100% 
ethanol and embedded in epon. Sections (~70nm) were cut using a Leica Ultracut UCT 
ultramicrotome and post-stained with lead citrate before viewing in a Tecnai G2 Spirit 
120kV transmission electron microscope (FEI Company) using Ultrascan and Orius 
CCD cameras (Gatan UK). 
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2.3.12 CERT gene expression in breast cancer datasets 
Nicolai Juul Birkbak performed the analysis of microarray datasets. 
Raw microarray expression data for 12 publicly available breast cancer cohorts were 
used ((176-187) and GSE2109). Kruskal Wallis tests were performed to test for 
expression differences. 
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Chapter 3. Chromosomal instability confers intrinsic 
multidrug resistance 
 
3.1 Introduction 
In the Introduction, I discussed the association of CIN with acquired drug resistance 
(11) and intrinsic taxane resistance in vitro and in vivo (14). Furthermore, in patients 
with solid tumours, CIN is associated with poor prognosis (55, 59, 101). In this chapter, 
I discuss my attempts to 1) test the hypothesis that CIN cancer cells are intrinsically 
multidrug resistant, and 2) identify pathways that are essential for the survival of CIN+ 
cancer cells compared to CIN- cancer cells. 
Kinase inhibitor and cytotoxic libraries were used in an attempt to identify agents that 
might be preferentially lethal towards CIN+ cells. The majority of this work has been 
published as a joint first author paper (6) (see Appendix 8.2) and was done mainly in 
collaboration with David Endesfelder who assisted in copy number analysis and 
statistical analysis. Section 3.2.7, examining the link of the CIN+ phenotype with 
patient outcome in clinical datasets was done in collaboration with Dr Axel Walther. 
3.2 Results 
3.2.1 Classification of CIN+ cell lines and relationship with ploidy status 
and Structural Chromosomal Complexity 
9 CIN- and 18 CIN+ CRC cell lines (Table 5) were selected for use in the study. The 
CIN status for these cell lines had been previously described in terms of numerical and 
structural chromosomal aberrations (3, 157-159).  
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In order to confirm the utility of published approaches for defining the CIN status of the 
cell lines and to confirm the CIN+ or CIN- status of these cell lines, where SNP Array 
data was available, ploidy status of the cell lines were estimated using weighted mean 
integer copy numbers derived from the PICNIC (Predicting Integral Copy Numbers In 
Cancer) algorithm (63) (Figure 1A). Ploidy estimates classified cells as CIN+ if they 
surpassed a threshold of ploidy >2.2 (corresponding to an estimated DNA index of 1.1). 
Modal chromosomal number as determined previously using high quality metaphase 
spreads (157, 158) correlated well with ploidy estimates derived from weighted mean 
PICNIC copy number analysis using the SNP Array data (Pearson’s CC=0.94, 
Pearson’s correlation test p<0.0001) (Figure 1B). These data support the utility of SNP 
Array data for estimating cell line ploidy status and are consistent with ploidy estimates 
by traditional measures, confirming the CIN status of cell lines used in this analysis. 
Next the relationship between CIN status and structural chromosomal complexity was 
addressed using a summary Structural Chromosomal Complexity Score (SCCS) derived 
from the SNP Array datasets. This SCCS was determined by summarising (i) the 
number of breakpoints, (ii) loss of heterozygosity (LOH) events as predicted using 
PICNIC (63) and (iii) the Genome Integrity Index (GII) (61), into a single value for 
each cell line (Figure 1C). There was a highly significant correlation between ploidy 
status and the SCCS (Pearson’s CC =0.746, p=0.0002). Taken together, these analyses 
confirm that cells classified as CIN+ have significantly greater ploidy and structural 
chromosomal complexity compared to CIN- cells. 
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Table 5 Cell lines used in this study 
CIN, MIN, ploidy and mutation status of the cell lines used in this study. Black 
indicates presence of a mutation, white indicates absence and grey indicates that the 
mutation status is unknown. 
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Figure 8 Ploidy and structural chromosomal complexity analysis of cell lines  
A) Barplot of the ploidy status of 20 CRC cell lines determined using mean copy 
number PICNIC analysis of SNP Array data. Red line indicates ploidy value threshold 
of 2.2. CIN+ cell lines in black text and CIN- cell lines in red text throughout. 
B) Correlation of modal chromosomal numbers and weighted mean copy numbers of 
the cell lines as determined by PICNIC. Pearson’s CC=0.94, p<0.0001. 
C) Correlation of Structural Chromosomal Complexity Score with ploidy as determined 
by weighted mean copy number PICNIC analysis of SNP Array data. Pearson’s 
CC=0.746, p=0.0002. 
 
C A 
B 
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3.2.2 CIN+ status is associated with intrinsic multidrug resistance 
Next, I wanted to determine whether a specific kinase inhibitor could be identified to 
selectively target CIN+ cell lines. A small molecule library (Calbiochem Kinase 
Inhibitor Library I and II) that included 160 inhibitors was used to treat the 18 CIN+ 
and 9 CIN- cell lines. Preliminary drug titration experiments revealed that the majority 
of the CIN+ cell lines were resistant to concentrations up to 1μM (Figure 9) and 
therefore 10μM was selected as the optimal drug concentration for cell growth 
inhibition across the majority of cell lines in order to attempt to identify drugs that were 
specifically active in CIN+ cells. No specific inhibitor or inhibitor family was found to 
be preferentially active in CIN+ cell lines compared to CIN- cell lines. In contrast, 
CIN+ cancer cell lines were significantly more resistant to the inhibitors (Kolmogorov-
Smirnov test, p<0.0001) (Figure 10, Figure 11). Following correction for multiple 
testing hypotheses, 45 inhibitors were identified which demonstrated significantly 
greater activity in CIN- cell lines compared to CIN+ cell lines (Table 6) and 15 out of 
this 45 kinase inhibitors primarily target the CDK family. The relative resistance of 
CIN+ cell lines to these CDK inhibitors may be due to overexpression of cell cycle 
regulatory genes such as CDK1 in CIN+ cancer cells (59). 
To address whether the variation in drug sensitivity between the CIN+ and CIN- cell 
lines was attributable to differences in proliferation rate, the maximum growth rate 
(maximal slope (mu) of growth curve) was calculated for each cell line. The CIN+ and 
CIN- cell lines displayed significantly different slopes in regression lines (t-test, p = 
0.007) with the CIN- cell lines demonstrating a higher proliferation rate compared to the 
CIN+ cell lines (Wilcoxon-Mann-Whitney test, p = 0.003). These data are consistent 
with previous studies suggesting that aneuploidy (125) (126) or chromosomal 
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segregation defects (188) (66) have a negative impact on cellular proliferation rate. A 
significant correlation was observed between increased sensitivity to the inhibitors at 
higher proliferation rates for CIN+ cell lines (Pearson’s CC = 0.61, p = 0.007). In 
contrast, no such correlation was observed between proliferation rate and drug 
sensitivity in CIN- cell lines (Pearson’s CC = 0.24, p = 0.55) (Figure 12A). Neither 
ploidy index nor the SCCS showed a significant correlation with proliferation rate.  
I next wanted to ask whether CIN+ and CIN- cell lines with similar proliferation rates 
displayed differential drug sensitivity. Cell lines with mu of the growth curve < 1, 
indicating a lower proliferative rate, were examined (22 out of 27 cell lines). CIN+ cell 
lines remained multidrug resistant compared to CIN- cell lines within this group (one-
sided Wilcoxon-Mann-Whitney test p = 0.013). Next, a more conservative statistical 
approach was used to normalise the proliferation rate of each individual cell line within 
this group. CIN+ cell lines remained significantly more drug resistant compared to CIN- 
cell lines (one-sided Wilcoxon-Mann-Whitney test, p = 0.049) after this correction 
(Figure 12B). These data suggest that at similar growth rates, CIN+ cell lines remain 
more drug resistant compared to CIN- cell lines, indicating that proliferation rate is 
unlikely to be the main determinant of drug sensitivity. 
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Figure 9 10 CIN+ CRC cell lines were treated with 160 kinase inhibitors at 10µM and 
1μM for 72 hours.  
Barplot shows mean cell number across all cell lines following each inhibitor treatment. 
The CIN+ cell lines appear to be largely resistant to inhibitor treatment at 1µM. 
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Figure 10 18 CIN+ and 9 CIN- CRC cell lines were treated with 160 kinase inhibitors at 
10μM for 72 hours 
A) A higher fraction of cells survive inhibitor treatment in CIN+ cell lines compared to 
CIN- cell lines. (p<0.0001). 
B) Boxplot of median cell number following inhibitor treatment across all inhibitors for 
all cell lines. The length of the whiskers was limited by maximal=1.5 times the IQR in 
this boxplot and throughout. 
A 
B 
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Figure 11 Heatmap of 18 CIN+ and 9 CIN- CRC cell lines were treated with 160 kinase 
inhibitors at 10μM for 72 hours 
Heatmap shows the relative numbers of surviving cells following inhibitor treatment 
across the cell lines (Inhibitors that have minimal impact on cell growth defined as a 
surviving cell fraction of >0.8 in >75% of the cell lines tested have been excluded).  
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Inhibitor Name 
Median 
fraction of 
surviving 
cells CIN+ 
Median 
fraction of 
surviving 
cells CIN- 
Adjusted P-
Value 
(Bonferroni-
Holm) 
Akt Inhibitor IV  0.33 0.11 0.0205 
Alsterpaullone  0.55 0.18 0.0163 
Alsterpaullone,2-Cyanoethyl  0.50 0.20 0.0128 
Aminopurvalanol A  0.48 0.13 0.0033 
AMPK Inhibitor,Compound C  0.64 0.21 0.0011 
ATM/ATR Kinase Inhibitor  0.54 0.27 0.0128 
Aurora Kinase Inhibitor III  0.56 0.23 0.0304 
Aurora Kinase Inhibitor III  0.56 0.21 0.0304 
Aurora Kinase/Cdk Inhibitor  0.53 0.17 0.0043 
Bisindolylmaleimide I  0.69 0.21 0.0043 
Cdk/Crk Inhibitor  0.42 0.14 0.0057 
Cdk1 Inhibitor  0.58 0.20 0.0033 
Cdk1 Inhibitor, CGP74514A  0.40 0.12 0.0043 
Cdk1/2 Inhibitor III  0.44 0.14 0.0033 
Cdk2 Inhibitor III  0.60 0.27 0.0057 
Cdk4 Inhibitor  0.51 0.18 0.0033 
Cdk4 Inhibitor III  0.37 0.14 0.0366 
Compound 52  0.86 0.55 0.0366 
EGFR Inhibitor  0.47 0.16 0.0074 
EGFR/ErbB-2/ErbB-4 Inhibitor   0.51 0.16 0.0205 
Fascaplysin, Synthetic  0.34 0.13 0.0247 
Flt-3 Inhibitor II  0.76 0.41 0.0033 
Flt-3 Inhibitor III  0.55 0.15 0.0366 
Go 6983  0.75 0.31 0.0304 
GSK-3 Inhibitor IX  0.37 0.12 0.0043 
GSK-3 Inhibitor X  0.52 0.16 0.0128 
GSK3b Inhibitor XII, TWS119   0.66 0.25 0.0057 
IC261  0.66 0.20 0.0016 
Indirubin Derivative E804  0.42 0.16 0.0247 
JAK3 Inhibitor VI  0.61 0.25 0.0205 
JNK Inhibitor IX  0.57 0.16 0.0011 
K-252a, Nocardiopsis sp.   0.38 0.14 0.0043 
PDGF Receptor Tyrosine Kinase Inhibitor III  0.53 0.30 0.0205 
PDGF Receptor Tyrosine Kinase Inhibitor IV  0.48 0.16 0.0033 
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PDK1/Akt/Flt Dual Pathway Inhibitor  0.34 0.12 0.0205 
PI 3-Kg Inhibitor   0.96 0.50 0.0247 
PKR Inhibitor  0.44 0.15 0.0074 
PP1 Analog II 1NM-PP1  1.00 0.73 0.0033 
Purvalanol A  0.58 0.30 0.0163 
Staurosporine N-benzoyl-  0.59 0.32 0.0304 
Staurosporine Streptomyces sp.  0.37 0.11 0.0163 
Staurosporine, Streptomyces sp.  0.34 0.13 0.0057 
SU11652  0.33 0.11 0.0205 
SU9516  0.66 0.29 0.0033 
Syk Inhibitor III  0.62 0.19 0.0443 
Table 6 Table of inhibitors that preferentially target CIN- cell lines over CIN+ cell lines 
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Figure 12 Analysis of impact of proliferation rate on response to kinase inhibitors. 
A) Mean relative surviving cell number following kinase inhibitor treatment was plotted 
against mu for each cell line. CIN+ cell lines in black and CIN- cell lines in red. Shaded 
area indicates cell lines with mu <1. 
B) At similar low proliferation rates (mu<1), CIN+ cell lines were more resistant to 
kinase inhibitor treatment compared to the CIN- cell lines when corrected for the 
influence of proliferation rate (p = 0.049). 
A 
B 
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3.2.3 Somatic mutation status and drug sensitivity 
Next I asked whether distinct tumour cell line somatic mutations might be the 
underlying determinant of drug resistance rather than genomic instability status. 
Publicly available somatic mutation data from the Sanger Institute Cancer Cell Line 
Project (CLP) and COSMIC database (78) was used. 15 CIN+ and 6 CIN- cell lines 
used in my analysis were present within the CLP database and a total of 20 out of the 61 
genes resequenced in the project were found to have somatic mutations in at least 1 of 
those 21 cell lines. I investigated whether the somatic mutation status of the 20 genes 
(as listed in Table 5) was associated with either altered sensitivity to inhibitors grouped 
according to target kinase family (Aurora kinases, AKT, CDK, EGFR, FLT-3, GSK-3, 
JAK3, JNK, MEK, PDGFR, PI3K and SYK) or to all inhibitors combined. Comparison 
of drug sensitivity response in mutated and wild-type cell lines was not performed for 7 
out of the 20 genes due to insufficient numbers of cell lines with mutations in either the 
wild-type or mutated group leading to insufficient statistical power. 
PIK3CA mutation was the only somatic mutation significantly associated with altered 
sensitivity to inhibitors grouped according to target kinase families (PIK3CA mutation 
associated with increased sensitivity to inhibitors targeting AKT, Aurora kinases, 
EGFR, PDGFR and PI3K, Wilcoxon-Mann-Whitney-Test, corrected p = 0.003, p = 
0.038, p = 0.016, p = 0.038 and p = 0.004 respectively) (Figure 13A). No evidence for a 
specific association with either PIK3CA exon 9 or exon 20 mutation status and drug 
sensitivity was found. Notably, PIK3CA mutations were more likely to occur in CIN- 
than CIN+ cell lines (p=0.0066, Fisher’s exact test). 
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No single somatic mutation was associated with altered sensitivity to all inhibitors. 
Next, data for somatic mutation status and CIN status were pooled. When corrected for 
multiple testing with Benjamini-Hochberg under the assumption that the tests are either 
positively correlated or independent (189), CIN+ status was the only parameter 
significantly associated with multidrug resistance (corrected p = 0.01) (Figure 13B). 
Taken together, these data suggest that the association of PIK3CA mutation with CIN- 
status may confound the interpretation of the association of PIK3CA mutation status 
with sensitivity to specific inhibitors and may simply reflect the intrinsic drug 
sensitivity of CIN- cells.  
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Figure 13 Analysis of somatic mutation status and response to kinase inhibitors 
A) PIK3CA mutation was the only somatic mutation significantly associated with 
increased sensitivity to inhibitors grouped according to the target kinase families: AKT, 
Aurora kinase, EGFR, PDGFR and PI3K (Wilcoxon-Mann-Whitney-Test). 
B) CIN+ status appeared to be associated significantly (corrected p=0.01) with altered 
drug sensitivity across all kinase inhibitors when tested together with mutation status of 
13 other genes and corrected for multiple testing. Only genes where mutation status was 
associated with an alteration in drug sensitivity with p-value<0.6 have been shown. 
A 
B 
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3.2.4 Isogenic CIN+ CRC cell lines display intrinsic multidrug resistance 
In order to support a direct role for the contribution of CIN to the multidrug resistant 
phenotype, drug sensitivity was assessed in isogenic CRC models of CIN. The HCT116 
MAD2+/- cell line has one allele of the SAC gene, MAD2, deleted by homologous 
recombination, resulting in numerical CIN relative to its diploid parental cell line (164). 
The isogenic HCT116 MAD2+/- cell line and its parental diploid cell line were treated 
with the kinase inhibitors. The MAD2+/- cell line was found to be more resistant overall 
compared to the parental diploid cell line (one-sided Wilcoxon signed-rank test, 
p=0.001) (Figure 14A, B) and this was consistent with the non-isogenic cell line drug 
sensitivity data. No single inhibitor appeared to specifically target the HCT116 MAD2 
+/- cell line. 
In order to further test the association of CIN with intrinsic drug resistance to drugs 
other than kinase inhibitors, the HCT116 MAD2+/- and another CIN+ isogenic cell line, 
HCT116 PTTG1-/- (encoding for Securin), were challenged together with their isogenic 
parental diploid HCT116 cell lines with the Biolog cytotoxic library containing 92 anti-
cancer cytotoxic agents. Consistent with the data from the kinase inhibitors, both the 
CIN+ MAD2+/- and PTTG1-/- cells were significantly more resistant (one-sided 
Wilcoxon signed-rank test, p<0.001, except p=0.035 at the lowest concentration of drug 
for PTTG1 -/-) to a diverse range of anti-cancer agents compared to the parental diploid 
cell lines (Figure 15, Figure 16). However, the magnitude of difference in relative cell 
number between the PTTG1-/- and diploid parental cells was small despite being 
statistically significant. 
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Importantly both the HCT116 MAD2+/- and parental diploid cell lines continue to 
display MIN+ (Figure 17), indicating that MIN status is unlikely to sufficiently explain 
the altered drug sensitivity in the CIN+ isogenic models. These data suggest that CIN+ 
status, initiated by ongoing chromosome missegregation events driven by loss of two 
distinct proteins controlling mitotic fidelity, is the dominant phenotype associated with 
altered drug sensitivity.  
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Figure 14 Isogenic CIN+ and CIN- cell lines were treated with kinase inhibitors  
A) Boxplot showing that following treatment with kinase inhibitors, there appeared to 
be a higher surviving fraction of cells in the HCT116 MAD2+/- cell line compared to its 
parental diploid cell line (p<0.001) following treatment with each equivalent inhibitor. 
B) Heatmap showing the relative numbers of surviving cells following the inhibitor 
treatments compared to vehicle control across the HCT116 MAD2+/- and parental 
diploid cell lines (Inhibitors that show a surviving cell fraction of >0.8 in both cell lines 
have been excluded). 
A 
B 
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Figure 15 Isogenic CIN+ and CIN- cell lines were treated with cytotoxic agent panel 
Biolog M11-M14 drug microplates were used at 4 increasing concentrations per drug 
(0.1µM to 25µM) to treat HCT116 MAD2+/- and PTTG1 -/- and their parental diploid 
cell lines for 72 hours. The boxplot shows difference in relative surviving cell number 
across all drugs at each of the four concentrations, comparing MAD2+/- and PTTG1 -/- 
cells to their specific isogenic parental cells. Significant p-values suggest higher 
resistance in MAD2+/- or PTTG1-/- cells compared to their parental diploid cells. 
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Figure 16 Heatmap of isogenic CIN+ and CIN- cell lines were treated with cytotoxic 
agent panel 
Heatmap of surviving fraction of cells compared to negative control in HCT116 
MAD2+/-, PTTG1 -/- and their parental diploid cell lines treated with Biolog drug 
microplates. Drugs resulting in a surviving cellular fraction of >0.8 compared to 
negative control in both isogenic cell lines were excluded. 
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Figure 17 Microsatellite PCR fragment analysis (marker 15_XVII) 
A similar profile for HCT116 Mad2+/- and diploid parental HCT116 was observed. 
SW1116 is a representative MIN- cell line for comparison. 
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3.2.5 CIN+ not tetraploidy is associated with multidrug resistance 
CIN+ CRC cell lines missegregate chromosomes at a high rate, in contrast to CIN- CRC 
cells that have a lower frequency of mitotic errors (3, 51). In addition, CIN- cells fail to 
tolerate the propagation of CIN when chromosome segregation errors are artificially 
induced by drug treatment (66), suggesting that sustaining CIN in a cell population may 
require a specialised survival phenotype. The majority of CIN+ CRC cell lines used in 
this study are triploid or tetraploid. I therefore considered whether altered ploidy status 
rather than ongoing CIN might be associated with enhanced drug resistance. Clonal 
tetraploid and diploid HCT116 cells were treated with the kinase inhibitors. There was 
no significant difference in the relative number of surviving cells following drug 
treatment between HCT116 Tetraploid Clone 4 (TC4) cell line and Diploid Clone 8 
(DC8) cell line. However, Tetraploid Clone 9 (TC9) was significantly more resistant 
compared to the DC8 cell line (Wilcoxon signed-rank test, p<0.001) (Figure 18A). 
Further investigation by clonal FISH (Figure 18B) revealed that TC9 had a more 
heterogeneous karyotype compared to TC4 cell lines with a significantly higher 
proportion of cells that deviated from the mode of four copies of both Chromosomes 2 
and 15 (Fisher’s exact test, p=0.05) (Figure 19). This implies that karyotypic 
heterogeneity rather than increased ploidy might be responsible for increased drug 
resistance compared to karyotypically stable diploid cells. I cannot formally exclude the 
possibility that acquired mutations present in the drug resistant tetraploid clone that may 
have permitted the spontaneous tetraploid phenotype may primarily be responsible for 
increased drug resistance. 
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Taken together with the isogenic cell line data presented here, where CIN is artificially 
induced through loss of one allele of MAD2 or both copies of PTTG1, these results 
support the contribution of CIN rather than increased ploidy status or MIN in conferring 
altered drug sensitivity. 
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Tetraploid Clone 4   Tetraploid Clone 9 
Figure 18 Isogenic tetraploid and diploid HCT116 cell lines were treated with kinase 
inhibitors 
A) Boxplot of relative surviving cell numbers comparing HCT116 Tetraploid Clone 4 
(TC4) and Diploid Clone 8 (DC8) cell lines, and Tetraploid Clone 9 (TC9) with DC8 
cell lines. The TC9 cell line was significantly more resistant compared to DC8 
(p<0.001). The difference in drug sensitivity between TC4 and DC8 was not significant 
(p=0.078). 
B) Representative FISH images for TC4 and TC9. Probes against Chromosome 15 in 
green. 
A 
B 
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Figure 19 Histograms showing distribution of number of markers per cell corresponding 
to Chromosome 2 and 15 in TC4 and TC9 
TC9 had a statistically significant higher proportion of cells that deviated from having 4 
copies of both Chromosome 2 and 15 (p=0.05) compared to TC4. 
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3.2.6 CIN+ CRC cell lines do not demonstrate increased sensitivity 
towards AICAR and 17-AAG 
It has been reported that AICAR (5-aminoimidazole-4-carboxamide riboside), a cell-
permeable precursor of ZMP (an AMP analogue), which allosterically activates AMP-
activated protein kinase (AMPK), thereby mimicking energy stress, and 17-AAG (17-
allylamino-17-demethoxy-geldanamycin), that inhibits the chaperone Hsp90, may 
selectively target aneuploid cells over diploid ones for death, due to an induction of 
energy and proteotoxic stress (129). In their study, Tang and colleagues then went on to 
observe preferential death in five (CACO2, HT29, SW403, SW480, SW620) aneuploid 
(CIN+) cancer cell lines compared to five (HCT116, HCT15, DLD1, SW48, LOVO) 
diploid or near-diploid MIN+ (CIN-) CRC cell lines when treated with these 
compounds. 
I next wanted to investigate if I could replicate their observations in a larger panel of 
CRC cell lines. 14 CIN+ cell lines (C32, COLO205, COLO678, HDC57, HT55, 
LS1034, SKCO1, SW403, SW480, SW620, SW837, SW1222 AND T84) and 8 CIN- 
cell lines (DLD1, GP2D, HCA7, HCT15, LS174T, RKO, SW48 and VACO5) were 
treated with 5 concentrations of 17-AAG ranging from 5-1000nM and 5 concentrations 
of AICAR ranging from 100-1000µM (Figure 20). At the 2 highest concentrations of 
17-AAG used and at all concentrations of AICAR used apart from 100 and 750µM, the 
CIN+ cell lines showed a statistically significant increase in mean relative surviving cell 
number compared to the CIN- cell lines (p<0.05, Mann-Whitney U test). 
The HCT116 diploid parental and MAD2+/- cell lines were also treated with 17-AAG 
(5 concentrations ranging from 5-1000nM) and AICAR (5 concentrations ranging from 
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1-100µM) (Figure 21). I was not able to observe a significant difference in sensitivity at 
each concentration of drug for both cell lines. 
Finally, DC8, TC4 and TC9 cell lines were treated with 5 concentrations of 17-AAG 
ranging from 5-1000nM, 5 concentrations of AICAR ranging from 100-1000µM, and a 
combination of 200µM AICAR with 0, 50, 100, or 200nM 17-AAG (Figure 22). I was 
not able to observe a significant difference in mean relative surviving cell number 
between these cell lines, despite the increase in ploidy of the tetraploid clones. 
Restricting analysis to cell lines that overlapped between the study by Tang and 
colleagues and my experiments (CIN+ : SW403, SW480, SW620 and CIN- : HCT116, 
HCT15, DLD1, SW48), I was unable to observe a significant difference in cell viability 
between the CIN+ and CIN- cell lines following treatment with either 17-AAG or 
AICAR (Figure 23) 
Therefore, in the panel of CIN+ and CIN- CRC cell lines, and in the isogenic MAD2 
and tetraploid/diploid cell lines, I was unable to observe preferential death in CIN+ or 
cell lines with increased ploidy. 
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Figure 20 Boxplots of CIN+ and CIN- CRC cell lines individually treated with 5 
concentrations of 17-AAG or AICAR 
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Figure 21 Graphs of mean relative cell numbers in HCT116 diploid parental and 
MAD2+/- cell lines after treatment with 17-AAG or AICAR 
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Figure 22 Graphs of mean relative cell number in DC8, TC4 and TC9 cell lines after 
treatment with 17-AAG, AICAR or a combination of both 
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Figure 23 Graphs of mean relative cell number in CRC cell lines that overlapped 
between two studies 
CIN+ cell lines (SW403, SW480, SW620) and CIN- cell lines (HCT116, HCT15, 
DLD1, SW48) were individually treated with 17-AAG or AICAR. 
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3.2.7 Relationship between CIN status and benefit from cytotoxic therapy 
Meta-analysis of clinical datasets in this section has been contributed by Dr Axel 
Walther. 
Published clinical data support the view that CIN+ CRC is associated with a worse 
prognosis compared to CIN- tumours (55) and data presented here suggest that CIN+ 
cell lines display intrinsic multidrug resistance. Conceivably the poorer prognosis of 
CIN+ disease may relate in part to intrinsic thymidylate synthase inhibitor drug 
resistance, cytotoxics commonly used in the adjuvant treatment of CRC. Using the 
panel of CIN+ and CIN- CRC cell lines, I next wanted to investigate if the CIN+ CRC 
cell lines displayed intrinsic resistance to clinically relevant drugs. Consistent with this 
hypothesis, isogenic CIN+ cells are significantly more resistant to the majority of 
thymidylate synthase inhibitors tested, including 5-FU, and methotrexate, a 
dihydrofolate reductase inhibitor. Non-isogenic CIN+ cells also appeared to be more 
resistant to 5-FU compared to CIN- cell lines, at physiological concentrations (as 
measured by peak plasma concentration, approximately between 200nM and 5µM)(190, 
191) (Figure 24).  
Next, using clinical datasets, I wanted to know if CIN+ status might be associated with 
poorer outcome following adjuvant therapy with 5-FU-based regimens. A meta-analysis 
of studies examining the relationship between CIN and prognosis in locoregional (non-
metastatic) CRC revealed that CIN+ disease (defined as aneuploidy/polyploidy 
measured by flow cytometry) confers a worse overall survival (30 studies) (Figure 25) 
and progression-free survival (15 studies) (Figure 26) compared to patients with diploid 
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CRC. Similarly, if only patients who received chemotherapy were included (2 studies) 
(192) (193), CIN+ status is associated with a worse overall survival (Figure 27). 
Two studies explored the predictive value of CIN (192, 194) in patients with 
locoregional CRC who received either adjuvant chemotherapy or no chemotherapy 
following surgery (Figure 28). Patients with diploid CRC appear to benefit from 5-FU 
based therapy (N=262, HR=0.61; 95% CI 0.40-0.94, p=0.024; I2=0%, p=0.467) 
compared with untreated diploid controls, whereas there was no significant difference 
between treated and untreated CIN+ CRC (N=303, HR=0.81; 95% CI 0.57-1.16, 
p=0.250; I2=0%, p= 0.932) despite the similar number of patients involved in the study. 
The combined analysis of all patients suggests a benefit following 5-FU treatment 
comparable to that reported in the literature for genetically unselected patients (195). 
Whilst these studies are limited, they are consistent with the view that patients with 
CIN+ CRC derive less benefit from 5-FU based adjuvant cytotoxic chemotherapy than 
patients with diploid CRC. 
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Figure 24 Analysis of drug sensitivity of isogenic CIN+ cell lines to clinically relevant 
cytotoxics 
A) HCT116 MAD2+/- and PTTG1 -/-  cell lines appeared to be more resistant compared 
to their parental diploid cell lines when treated for 72h with clinically relevant 
cytotoxics at a range of concentrations from 0.1µM to 25µM present on the Biolog 
Microplates. Boxplot shows mean cell number relative to negative control at each 
concentration of drug used. Significant p-values suggest higher resistance in MAD2+/- 
or PTTG1-/- cells compared to their parental diploid cells. 
B) 18 CIN+ and 9 CIN- cells were treated with 1µM and 10µM of 5-FU for 72 hours. 
CIN+ cell lines appeared to be significantly more resistant compared to CIN- cell lines 
(p=0.035, Wilcoxon-Mann-Whitney-Test) at 10µM of 5-FU. 
A 
B 
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Figure 25 Fixed effects meta-analysis of studies reporting the relationship between CIN 
and overall survival 
Fixed effects meta-analysis of studies reporting the relationship between CIN and 
overall survival: p= 2.22E-16, I2=0%. Only studies reporting data on stage 1 - 3 are 
included (192-194, 196-222). 
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Figure 26 Fixed effects meta-analysis of studies reporting the relationship between CIN 
and progression-free survival 
Fixed effects meta-analysis of studies reporting the relationship between CIN and 
progression-free survival: p= 3.29E-08, I2= %. Only studies reporting data on stage 1 - 3 
are included (193, 198, 208, 209, 214, 223-232). 
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Figure 27 Analysis on impact of CIN on patient survival 
Impact of CIN on disease free survival, overall survival, and those receiving adjuvant 
chemotherapy in locoregional CRC. Overall CIN+ appears to confer a worse prognosis 
compared to diploid. 
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Figure 28 Analysis on impact of CIN on benefit from adjuvant chemotherapy 
Benefit derived from adjuvant 5-FU in patients with (near) diploid (top) and CIN+ 
(middle) CRC. Patients with diploid CRC appear to benefit more from chemotherapy 
compared to patients with CIN+ tumours. Combined analysis of CIN+ and diploid 
patients shows similar magnitude of benefit as would be expected from literature 
(bottom) (195). 
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3.3 Discussion 
In this analysis I have provided evidence that CIN+ CRC cell lines display intrinsic 
multidrug resistance compared to CIN- cell lines. No specific kinase inhibitor was 
identified that resulted in preferential lethality of the CIN+ cell lines. I cannot exclude 
the potential for off-target effects at the concentrations of kinase inhibitors used in this 
analysis, however the same conditions were applied to the CIN- cells and therefore off-
target phenomena are unlikely to change the conclusions of this work. Furthermore, in 
the isogenic systems, I observed significant drug resistance in the CIN+ cell lines 
relative to their isogenic parental CIN- pairs at almost all concentrations of cytotoxics 
tested (ranging from 0.1µM to 25µM). Intriguingly, work with the isogenic CIN+ and 
tetraploid cell lines suggest that the primary association is between multidrug resistance 
and CIN+ rather than polyploidy. 
I was unable to produce results that agreed with the observation by Amon and 
colleagues (129) that CRC cancer cells lines with increased ploidy demonstrate 
increased sensitivity towards 17-AAG and AICAR compared to CRC cell lines with a 
near-diploid karyotype. I speculate that one explanation for this may be the limited 
genetic diversity of the panel of CRC cell lines used in their study (5 CIN+ and 5 CIN-) 
compared to my analysis using 14 CIN+ and 8 CIN- cell lines. Furthermore, 2 of the 
CIN- cell lines that they used, HCT15 and DLD1, are likely to have originated from the 
same patient (based on DNA fingerprinting analysis) (233, 234). Similarly, 2 of the 
CIN+ cell lines they used, SW480 and SW620, originated from the same patient (235), 
further limiting the genetic diversity of their cell line panel. Moreover, I failed to 
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observe a difference in sensitivity in the isogenic models of CIN and tetraploidy 
compared to the parental diploid cells, further disagreeing with their observations. 
It has been previously demonstrated that aneuploid cell lines can acquire multidrug 
resistance at an accelerated rate (156) that may be driven by cancer cell heterogeneity 
resulting from multiple chromosomal reassortments in aneuploid cells. The short time 
course of my experiments in comparison to this study suggests that multidrug resistance 
that I observed is likely to be an intrinsic property of CIN+ cells rather than a process 
that is acquired in the cell lines over multiple generations. I speculate that either basal 
population heterogeneity in CIN+ cell lines is sufficiently diverse to confer a cell 
viability advantage following drug exposure or there is a specific CIN+ survival 
phenotype that initiates a tolerance of ongoing chromosomal rearrangements that is also 
associated with multidrug resistance. 
There is increasing evidence in support of a CIN+ survival phenotype and putative 
molecular coordinators of this property. Cell death after mitotic arrest may result from 
transcriptional inhibition due to condensed chromatin, precipitating the degradation of 
short-lived mRNA encoding pro-survival proteins (46). CIN+ cells may overexpress 
these pro-survival genes compared to diploid cells (14) that may drive the resistance of 
CIN+ cells to a mitotic arrest triggered by taxanes. Jeganathan and colleagues have 
demonstrated that tolerance of chromosome missegregation events can be conferred by 
a hypomorphic BUB1 allele in mouse embryonic fibroblasts (236). Recently, Thompson 
and Compton have demonstrated that chromosome missegregation in diploid human 
cells triggers an increase in nuclear p53 and that p53 null cells are able to tolerate 
chromosome missegregation events enabling the propagation of aneuploid genomes 
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(237). A higher proportion of the CIN+ cell lines used in my study have mutant p53 in 
comparison to the CIN- cell lines (where p53 mutation status is known, 3 out of 8 CIN- 
cell lines and 14 out of 17 CIN+ cell lines). However when data for somatic mutation 
status and CIN status was pooled, CIN+ status was the only parameter significantly 
associated with resistance to these inhibitors. 
Therefore, evidence exists for the coordination of apoptotic/cell death pathways 
following chromosome missegregation events. Conceivably, common molecular 
pathways regulating cell death following a chromosome missegregation event may 
become disrupted in CIN+ cells, simultaneously triggering tolerance of chromosome re-
assortments and, as an indirect consequence, resistance to drug exposure. 
3.4 Conclusion 
The observations that CIN+ cancer cell lines appear to be less sensitive to a range of 
anti-cancer agents compared to diploid cells and that poorer patient outcome follows 
cytotoxic treatment of CIN+ tumours compared to diploid counterparts, strongly 
suggest the need to consider tumour stratification according to CIN status in the design 
of clinical trials testing novel anti-cancer agents in CRC. This is particularly relevant to 
the advanced CRC setting where the incidence of CIN+ is greater than in early stage 
disease. Stratifying drug response according to CIN status may limit the risk of early 
drug attrition and heighten the chance of identifying responder populations in patients 
with diploid tumours. Importantly, these data indicate that specifically targeting cancer 
cells with CIN+ status using currently available kinase inhibitors appears challenging. 
An improved understanding of the mechanisms associated with the generation and 
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survival of CIN+ CRC will be important to drive the development of new therapeutic 
approaches in order to improve patient outcome in this high risk disease subtype. 
With this in mind, I next used whole genome RNAi functional genomics approaches in 
an effort to identify CIN+ survival pathways and mechanisms responsible for the 
initiation or maintenance of this CIN+ phenotype. 
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Chapter 4. Unbiased whole-genome RNAi screens to 
identify survival mechanism in CIN+ cancer 
4.1 Introduction 
One common application of RNAi technology in cancer research is in genome wide 
RNAi screens to identify genes whose loss of function results in synthetic lethality, 
where the combination of loss of function of the gene with the particular genotype of 
interest results in a decrease in cell viability compared to an isogenic cancer cell without 
that genotype of interest (238-240). 
In the previous chapter, I have shown that CIN+ cancer cell lines appear to be less 
sensitive to a range of anti-cancer agents including kinase inhibitors and cancer 
cytotoxics compared to diploid cells. There may be two potential explanations for this 
observation 1) basal population heterogeneity in CIN+ cell lines is sufficiently diverse 
to confer a Darwinian-like cell viability adaptive advantage following drug exposure or 
2) a specific CIN+ survival phenotype is associated with a tolerance of ongoing 
chromosomal rearrangements (66, 236) that indirectly impacts upon drug sensitivity, 
initiating multi-drug resistance. 
As discussed in section 1.3.8, experiments conducted using yeast model systems have 
shown that polyploid yeast are dependent for survival upon increased expression of 
genes involved in pathways such as sister chromatid cohesion and mitotic spindle 
function (93). Furthermore, Torres and colleagues have shown that strains of aneuploid 
yeast show delayed cell cycle transition, an increase in glucose uptake, and a gene 
expression pattern characteristic of the environmental stress response (127). In the 
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previous section, I observed that CIN+ colorectal cancer (CRC) cell lines on average 
display a lower proliferative rate compared to CIN- CRC cell lines. These experiments 
suggest that there are specialised adaptations and possible compromises required to 
sustain aneuploidy or polyploidy. Additionally, as discussed in the previous chapter, 
Tang and colleagues demonstrated that CIN+ CRC cell lines might be more susceptible 
to inhibitors of protein folding (17-AAG) and activators of AMPK (AICAR). However, 
I was unable to obtain similar results using our panel of non-isogenic CIN+ and CIN- 
CRC cell lines, and our isogenic models of CIN and tetraploidy. 
I reasoned that mammalian CIN+ cancer cells have acquired adaptations to tolerate a 
polyploid or aneuploid state similar to that observed in yeast cells and that these 
adaptations may be exploitable to limit the survival of CIN+ cells specifically. Specific 
therapeutic targeting of CIN+ tumour cells may also reduce side effects associated with 
treatment by limiting cytotoxicity towards normal diploid cells. To this end, I used a 
functional genomics approach to identify regulators of CIN+ survival in human cancer, 
by performing unbiased whole genome RNAi screens in the HCT116 (diploid) cell line 
and its isogenic HCT116 MAD2+/- cell line. MAD2 heterozygosity is sufficient to 
induce CIN in (164). The high-throughput RNAi study presented in this chapter has 
been performed with extensive support from the High-Throughput Screening Facility 
(Michael Howell, Ming Jiang, Rachael Instrell and Becky Saunders) in this Institute. 
Section 4.2.6, analysing the variance within the whole genome RNAi screen and 
subsequent validation experiments has been completed in collaboration with Stuart D. 
Horswell who performed the statistical analysis.  
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4.2 Results 
The CRC cell line HCT116 and its isogenic CIN+ cell line were chosen for the screen. 
The HCT116 cell line is a non-CIN cell line with microsatellite instability (MIN) and a 
near diploid modal chromosomal number (6). An isogenic clone of HCT116 with one 
allele of MAD2 (a component of the spindle assembly checkpoint (SAC)) deleted by 
homologous recombination (164) was the CIN+ counterpart of the HCT116 cell line 
used for the screen. This cell line displays some of the phenotypes proposed to be 
associated with CIN, such as premature sister chromatid separation (80), failure to arrest 
appropriately in the presence of mitotic inhibitors (73-75), an increase in aneuploidy (3, 
52) as scored by clonal FISH, and an increased rate of chromosomal loss compared to 
the parental diploid cell line.  
4.2.1 Optimisation of screening parameters 
Various parameters were assessed prior to the whole genome RNAi screen to optimise 
the dynamic range and reproducibility of our results in measuring cell number and cell 
cycle profile parameters (subG1, G1, S, 4n and >4n) following 72h of siRNA 
transfection. The Acumen eX3 laser scanning cytometer instrument was used. This 
instrument is equipped with scanning lasers with excitation and emission wavelengths 
compatible with fluorescent probes. Images are then acquired through a wide field 
objective across the bottom of a microplate, with a resolution equivalent to a 20x 
microscope objective (241). DAPI was used to stain cellular DNA content fluorescently 
for use with the instrument. 
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Positive control siRNAs resulting in distinct cell cycle phenotypes were used in the 
optimisation of the conditions for the screen. The controls included TOP2A siRNA, 
which results in an increase in the >4n population of cells, and PLK1 siRNA, which 
reduces cell viability. Various parameters for the plating of the cells were tested in order 
to optimise the balance between initial seeding cell density (so as to minimise errors due 
to low numbers of cells) and the dynamic range of both the cell cycle profile and 
numbers of surviving cells. The parameters that were analysed were poly-L-lysine 
concentration (to promote cell adhesion and prevent loss of cells during washing and 
fixing of cells prior to DAPI staining) and initial cell plating density. Twenty-three 
transfection reagents were also assessed at various concentrations and a range of siRNA 
concentrations to identify the optimal transfection with minimal cytotoxicity associated 
with non-targeting control and transfection reagent only and maximal dynamic range of 
phenotype following silencing of positive control genes (eg >4n induction by siTOP2A 
and decrease in cell viability following siPLK1). Various fixative agents were assessed 
in an effort to identify one that would give the best quality in terms of the cell cycle 
profile readout. Cell cycle profile identification was tested with propidium iodide (PI) 
and DAPI at various concentrations. The conditions were optimised for both 96-well 
and 384-well plate formats. The 96-well format was chosen for the final screen was due 
to its better reproducibility of results. Figure 29 demonstrates the good dynamic range 
and small variance between replicates following transfection with control siRNAs in the 
HCT116 diploid parental cell line. 
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Figure 29 Pre-screen optimisation 
Percentage of cells with >4n DNA content (top) and cell number (bottom) 72h after 
siRNA knockdown using positive control siRNAs under optimal transfection 
conditions. Error bars represent standard deviations across replicate wells. 
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I wanted to identify a positive control that selectively killed CIN+ cells in advance of 
the screens. From the previous chapter, I have shown that the MAD2+/- cells are 
resistant to multiple drugs with no single agent being able to selectively target this cell 
line over its diploid parental counterpart. This excluded the use of any of the kinase 
inhibitors or cytotoxic agents that we used in the previous chapter.  However, I was 
concerned that the resistance of MAD2+/- cells to multiple drugs with differing 
mechanisms of action may have resulted from a cloning artefact subsequent to the 
homologous recombination step required to generate these cells. In order to exclude this 
possibility, I silenced the BUB1B gene, a component of the SAC, in the HCT116 wild 
type cells in order to investigate whether this observation was specific to SAC 
disruption.  In this investigation, I used 5 drugs with different mechanisms of action at 
concentrations ranging from 0.1µM to 20µM. The drugs were Dactinomycin, 
Ancitabine, Podophyllotoxin, Doxorubicin and Flavopiridol. The BUB1B silenced cells 
were more resistant to these drugs compared to the control silenced cells (Figure 30) 
reinforcing the observation that deficiency in SAC components can promote multidrug 
resistance. Possible explanations for why BUB1B silencing confers drug resistance may 
include: 1) The silencing of BUB1B selects for a sub-population of cells that are able to 
tolerate a compromised SAC, and thus are able to better tolerate other stresses such as 
drug treatment. 2) BUB1B silencing results in CIN and the generation of a 
heterogeneous population of cells. However, this is unlikely to fully explain the drug 
resistance phenotype observed due to the short time duration of the experiments. 3) a 
functioning SAC triggers cell death pathways following drug treatment and BUB1B 
silencing overcomes this. 
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Figure 30 Drug response following BUB1B silencing in HCT116 cells 
Graph of relative corrected Caspase 3/7 activity in HCT116 cells after transfection with 
siCON or siBUB1B for 48h followed by 48h of exposure to Ancitabine, Dactinomycin, 
Doxorubicin, Flavopiridol or PodoPhyllotoxin at 4 concentrations ranging from 0.1µM 
to 20µM. 
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The drug screens did not reveal a positive control that was selectively lethal in CIN+ 
cells. Since silencing of kinetochore components has been shown to result in an increase 
in mitotic catastrophe in SAC-compromised cells (242) I reasoned that a small-scale 
cell viability screen with siRNAs against 27 different kinetochore components in the 
HCT116 MAD2+/- and diploid parental HCT116 cells might reveal a positive control. I 
was unable to identify any siRNA that resulted in preferential lethality within the CIN+ 
cell lines at a magnitude that could confidently be replicated in a whole genome RNAi 
screen (Figure 31). Therefore I was unable to selectively identify genes that induce 
preferential lethality of CIN+ isogenic cells in advance of the screen. 
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Figure 31 Silencing kinetochore components in HCT116 diploid parental and MAD2+/- 
cell lines 
Relative cell number after 72h of knockdown with siRNAs targeting kinetochore 
components in HCT116 diploid parental and MAD2+/- cell lines. 
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4.2.2 The screen 
The HCT116 parental diploid cell line and MAD2+/- isogenic cell line were transfected 
with the Dharmacon whole genome siRNA library targeting 21222 genes in triplicate 
(267 96-well plates in triplicate) (Figure 32A). This high throughput screen allowed me 
to address whether loss of function of any of these genes caused a greater reduction in 
cell viability in the MAD2+/- cell line compared to its diploid parental cell line. Both 
cell lines were transfected in 96-well plates and were fixed 72 hours after transfection. 
Plates were then stained with DAPI, to allow us to quantify the number of surviving 
cells following siRNA transfection. Data was normalised and analysed as described in 
material and methods. 10 plates from the screen in the HCT116 MAD2+/- cell line were 
excluded from analysis due to errors in the readouts of the DAPI staining on these 
plates. 
Z-scores (a score measuring standard deviations from the mean for normalised data) for 
cell number were obtained from this normalised data for cell number following siRNA 
transfection. Z-scores for non-targeting control siRNA (siCON) and non-targeting non-
RISC-processed control siRNA (RISC-FREE) transfected cells tended to lie slightly 
right of the median z-score value for cell number in both MAD2+/- and diploid parental 
cell lines (Figure 32B). The shifting of negative controls to the right of the normalised 
cell number curve does not contradict previous observations in other whole genome 
siRNA screens (243) and may indicate that the majority of siRNAs have negative cell 
viability effects when transfected into these cell lines. 
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To select candidate genes whose loss of function results in a preferential decrease in the 
viability of the MAD2 deficient cell line, I overlapped siRNAs that resulted in a 
maximal cell number z-score of -2 in the MAD2 deficient cell line and whose z-score 
was at least 2 less compared to thee corresponding HCT116 diploid parental screen 
(Figure 32C). I was able to identify 69 candidate genes for follow up whose loss of 
function may be preferentially lethal to CIN+ cancer cells. 
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Figure 32 Screen overview, and candidate gene selection  
A) Workflow diagram of screen. 
B) Distribution of cell number z-scores in HCT116 MAD2+/- cell line (left) and diploid 
parental cell line (right). siCON values are highlighted in red and RISC-FREE in blue. 
C) Diagram of criteria for selection of candidate genes for follow-up. 
A 
B 
C 
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4.2.3 Validation of candidate genes for on-target effects 
siRNAs may not only silence a target gene but may also suppress the expression of 
other genes through off-target effects. I wanted to assess these candidate genes for off-
target effects prior to validating preferential lethality in CIN+ cancer cell lines. To 
address this, I first repeated the high throughput screen assay in the HCT116 MAD2+/- 
cell line using the four individual siRNAs that make up the Dharmacon SmartPool 
siRNAs for each gene of interest. 69 candidate genes were reassayed (Figure 33). The 
number of surviving cells for each siRNA was normalised to non-targeting control 
siRNAs and expressed as a percentage of control value (POC). I was unable to 
standardise cell number values to derive z-scores for these candidate genes as I was 
reassaying a smaller number of candidate genes compared to the genome-wide screen 
and this was a biased list in terms of impact on cellular viability. The results enabled me 
to select 17 candidate genes that resulted in a reduction of cell number in HCT116 
MAD2+/- to ≤66% of control siRNA as both an average of the 4 individual siRNAs that 
make up the pool and also in at least 2 out of 4 individual siRNAs for follow-up 
experiments. 
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Figure 33 Heatmap of candidate gene validation  
Performed in HCT116 MAD2+/- single cell line to exclude off-target effects for cell 
viability. Genes highlighted in red were selected for further validation. 
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4.2.4 Validation of candidate genes for differential lethality effects 
I next wanted to determine whether these candidate CIN+ synthetic lethal genes would 
induce a greater decrease in viability in CIN+ cell lines compared to CIN- cell lines. 
The 17 candidate genes selected in the previous section were rescreened 3 times in the 
HCT116 MAD2+/- and diploid parental cell line. Unfortunately, I was unable to 
validate any of these genes as consistently being able to preferentially decrease cell 
viability in the HCT116 MAD2+/- cell line compared to its parental diploid cell line 
(Figure 34A).  
In an attempt to try to capture cell death at different time points following gene 
silencing, the experiment was repeated at three different endpoint times (Figure 34B) 
but similar results were obtained. 
Finally, most of the 17 candidate genes that we reassayed caused a reduction of cell 
viability of at least 50% in both cell lines when silenced. Such a magnitude of cell death 
in both cell lines may have been masking a differential lethality effect. The initial whole 
genome RNAi screen was performed using siRNA at a final concentration of 37.5nM. I 
therefore repeated the assay with 18.75nM of siRNA, to attempt to establish if a 
reduction in magnitude of gene knockdown and toxicity of siRNA transfection may 
reveal a difference in magnitude of cell death between the two cell lines (Figure 34C). 
Although there was a reduction in magnitude of cell death, we were still unable to 
observe consistent preferential lethality effects in the MAD2+/- cell line. 
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Figure 34 Assessment of differential lethality in HCT116 MAD2+/- cell line and diploid 
parental cell line 
A 
B 
C 
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Error bars represent standard deviations across replicate wells. 
A) Graph of relative cell number 72h after siRNA transfection. Experiment was 
repeated three times in both cell lines. Bars are arranged for each siRNA as three pairs 
of corresponding experiments in HCT116 diploid parental and MAD2+/- cell lines 
(labelled in graph as repeat 1, 2 or 3). 
B) Graph of relative cell number 30h, 48 and 96h after siRNA transfection. Experiment 
was repeated three times in both cell lines. Bars are arranged for each siRNA as three 
pairs of corresponding time point experiments in HCT116 diploid parental and 
MAD2+/- cell lines (labelled in graph as 30h, 48h or 96h). 
C) Graph of relative cell number 72h after siRNA transfection at a reduced final 
concentration of 18.75nM. Experiment was repeated twice in both cell lines. Bars are 
arranged for each siRNA as two pairs of corresponding experiments in HCT116 diploid 
parental and MAD2+/- cell lines (labelled in graph as repeat 1 or 2). 
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These 17 candidate genes were also rescreened in a non-isogenic panel of 7 CIN+ and 6 
CIN- cell lines. The CIN+ cell lines used were C70, COLO205, HRA19, HT29, HT55, 
SKCO1 and SW620. The CIN- cell lines were DLD1, GP2D, HCA7, RKO, SW48 and 
VACO5. However, in agreement with results in the isogenic cell lines, depletion of 
these candidate genes did not appear to result in a significant difference in cell death in 
the CIN+ cells compared to CIN- cells (Figure 35A and B). 
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Figure 35 Assessment of differential lethality of the 17 candidate genes in non-isogenic 
CIN+ and CIN- cell lines 
Error bars represent standard deviations across replicate wells. 
A) Graph of relative cell number 72h after siRNA transfection. Each bar represents a 
single individual cell line. 
B) Boxplot of relative cell number 72h after siRNA transfection in CIN+ and CIN- cell 
lines. Whiskers limted by 1.5x interquartile range. 
A 
B 
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4.2.5 Reselection of candidate genes and validation 
I was concerned that the inability to consistently validate candidate genes as being 
preferentially lethal towards CIN+ cells was due to a flaw in the selection process of our 
candidate genes. An alternate method for selecting candidate genes that are required for 
the survival of HCT116 MAD2+/- cells was used. Instead of comparing the cell number 
z-scores with the HCT116 diploid parental cell line, z-scores from the HCT116 
MAD2+/- screen was compared with three other whole genome RNAi screens assayed 
in the Institute using the same methods as this HCT116 screen These other screens were 
performed using cell lines of a different tissue origin; fibrosarcoma (HT1080), non-
small cell lung cancer (PC9) and renal cancer (RCC4). The rationale for this selection 
method was 1) As candidate genes were selected using a differential z-score approach, 
there was potential to not select a candidate gene if there was an error in the readout for 
the parental diploid cell line. An error in a single replicate may affect the mean 
surviving cell number, and thus affect the z-score. 2) Comparing across 4 screens 
performed in different cell lines may result in more specific candidate gene selection 
and this reduces the number of false positives and will hopefully reveal candidate genes 
that are specifically lethal towards HCT116 MAD2+/- cells when silenced. However, I 
acknowledge that these genes may not be specifically lethal towards CIN+ cell lines but 
may be a result of other specific lethalities such as colon-specific or MIN+ specific 
lethality. 
Candidate genes were selected on a criteria of z-score <-2.5 in the MAD2+/- screen and 
non-significant z-scores (>-2 and <2) in the three other whole genome RNAi screens 
(Figure 36A). I obtained a list of 75 additional candidate genes having excluded 
candidate genes that had already been selected using the previous method.  
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These 75 candidate genes were next screened in the HCT116 diploid parental and 
MAD2+/- cell lines to validate their effects on cell viability and to assess for differential 
lethality effects (Figure 36B). I performed this screen of the 75 genes twice in each cell 
line. On both occasions, just under a fifth of the 75 candidate genes resulted in a 
reduction of cell number to ≤66% of control siRNA when silenced in both cell lines. 
This was a slightly lower validation rate compared to the 69 candidate genes selected on 
the basis of z-score comparison with the HCT116 diploid parental cell line, where 17 
genes resulted in a reduction of cell number to ≤66% of control siRNA when silenced in 
the HCT116 MAD2+/- cell line (24.6% validation). The magnitude of cell death 
resulting from silencing of these 75 genes appeared to vary between experiments, 
however the positive control siRNA, KIF11, reliably resulted in at least an 80% 
reduction of cell viability in both cell lines for each repeat of the experiment. This 
suggested that the effects of siRNAs causing a strong reduction in cell viability are 
unlikely to be masked by variation arising from performing the experiment on separate 
occasions. 
However, only some of the 75 candidate genes caused a similar magnitude of decrease 
in cell viability on the two different occasions the two cell lines were screened. 
Furthermore, only silencing of three genes, AAAS, CD37 and PPHLN1 resulted in an 
greater decrease of cell viability of at least 20% in the HCT116 MAD2+/- cell line 
compared to the diploid parental cell line on both occasions. These genes were selected 
for further validation experiments. OCIA was not selected as it appeared to cause an 
increase in cell proliferation rate in the diploid parental cell line compared to control 
siRNA transfected cells. I next attempted to validate these candidate genes on a further 
three occasions as being preferentially lethal in the HCT116 MAD2+/- cell line 
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compared to its diploid parental cell line. Again, I was unable to confidently validate 
candidate genes as being consistently selectively lethal towards CIN+ cells (Figure 37). 
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Figure 36 Reselection of candidate genes and assessment for differential viability 
effects. Error bars represent standard deviations across replicate wells 
A) Diagram of candidate gene selection criteria. 
B) Heatmap of relative cell number 72h after siRNA transfection in HCT116 diploid 
parental and MAD2+/- cell line. Experiment was repeated 2 times. KIF11 (positive 
control) highlighted in green. Candidate genes selected for follow up highlighted in red. 
A 
B 
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Figure 37 Further assessment of candidate genes for differential viability effects 
Graph of relative cell number 72h after siRNA transfection in HCT116 diploid parental 
and MAD2+/- cell lines. Experiment was repeated three times in both cell lines. Bars 
are arranged for each siRNA as pairs of the three experiments. 
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4.2.6 Statistical analysis of noise within the system and reproducibility of 
results 
The statistical analysis presented in this section has been performed by Stuart D. 
Horswell. 
I was unable to validate any candidate gene as being consistently able to induce 
preferential cell death in the MAD2+/- cell line despite selecting candidate genes using 
two different methods. I was concerned that the level of variance within our system was 
affecting the reproducibility of our results and hoped that statistical models could be 
used to estimate the levels of variance within the screen in order to better understand the 
reasons why the screen may have failed and to estimate the power of the screen to 
detect synthetic lethal candidate genes. 
To this end, mixed effects models were used to estimate the levels of variance 
contributed by various component within the system. The mixed effects model 
decomposes the overall variation observed in the data by estimating the contribution of 
each variable to the total variation. Any residual or "unaccounted for" variation is 
inferred to be noise that may be systemic. For our system, this involved defining the 
variables within our system, fitting separate models for each of these predictor variables 
and finally using well-defined algorithms to estimate the “noise” term associated with 
each predictor (244, 245).  
The variables within this system were defined as MAD2 status, siRNA and replicates for 
each siRNA (triplicate per siRNA). The ‘unknown’ noise component within the system 
was defined as θ. Cell count data was fitted into the model and was analysed in 
groupings of 5 and 15 plates (Figure 38A and B). The θ-noise component in all 
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groupings contributed approximately 30 to 50% of the variance within the system. This 
noise component was extremely similar in magnitude (but not identical) to the variance 
contributed by the siRNA component and therefore may have resulted in the ‘masking’ 
of the effects on cell viability of the various siRNAs. 
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Figure 38 Usage of mixture models to assess noise factors 
A) Graph of estimation of variance components in whole genome screen when 
analysing plates in groups of five. Plate groups where the mixture models failed to 
converge were excluded. 
B) Graph of estimation of variance components in whole genome screen when 
analysing plates in groups of fifteen. Plate groups where the mixture models failed to 
converge were excluded. To speed up analysis, estimation of noise due to replicates was 
excluded as noise due to this term was much smaller compared to other terms. 
A 
B 
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Fitting the cell count data into the model, and applying a z-test at the level of p=0.05 
across all plates, it was found that the minimal critical cell count difference in order to 
confidently identify a difference between the two cell lines was approximately 4707 
cells.  
The screen workflow was analysed to identify if any possible sources of variability such 
as “batch effects” may have contributed to this variance but no such artefacts were 
identified within our model, suggesting that the unknown noise was not contributed by 
any obvious breaks or pauses in the manner in which the screen was performed. 
4.2.7 Retrospective power analysis of whole genome RNAi screen 
A retrospective power analysis was performed. Observed power values were modelled 
(Figure 39A) using an idealised surviving cell number of 10000 (Figure 39B, based on 
the average cell number of control transfected cells in validation experiments) in the 
HCT116 diploid parental cell line and a critical cell number difference of 4707. The 
statistical power was 50% to detect an approximate 50% difference in cell number 
between the two screens. The screen appeared to be modestly powered to detect a large 
difference in cell number between the two cell lines (Power= 75% to detect ≈60% 
difference in cell number). 
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Figure 39 Retrospective power analysis of whole genome RNAi Screen and average cell 
number in control transfected cells 
A) Graph of retrospective power analysis of whole genome RNAi Screen. 
B) Scatter plot of cell number following 72h of siCON transfection in HCT116 diploid 
parental and MAD2+/- cell lines. Horizontal lines represent median and interquartile 
range. 
 
A 
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4.3 Discussion 
4.3.1 Summary of screen results 
In this study I have attempted to use a synthetic lethal high throughput siRNA screen to 
identify pathways that are necessary for the survival of CIN+ cells. The screen did not 
identify candidate genes that are able to consistently display selective lethality in CIN+ 
cell lines compared to CIN- cell lines. 69 candidate genes were selected based on the 
criteria that these genes induced preferential cell death in HCT116 MAD2+/- cell line 
but not its diploid parental cell line. I was able to validate 17 of these genes as having 
on-target effects on cell viability in the MAD2+/- cell line but was unable to validate 
these genes as being selectively lethal towards CIN+ cell lines specifically compared to 
diploid isogenic and non-isogenic cells. A further 75 candidate genes were selected on 
the basis of being selectively lethal towards the HCT116 MAD2+/- cell line but not in 
three other cancer types. Again I was unable to validate these candidate genes as being 
preferentially lethal towards CIN+ cancer cells. Figure 40 summarises the candidate 
gene selection and validation process. 
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Figure 40 Workflow of candidate gene selection and validation 
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4.3.2 Estimation of noise component in genome wide siRNA screen and 
validation experiments 
An attempt has been made to assign variance within our system to various components. 
Here, using mixed effects models; it is shown that there exists a component of variance 
unaccounted for that contributes approximately 30 to 50% of the total variance within 
the system within the parameters of the whole genome screen. I was unable to attribute 
this component to technical reasons such as “batch” effects.  
Moreover, the critical cell count for the whole genome screen in order to confidently 
detect a difference between the two cell lines was approximately 5000 cells. On the 
basis that the cell number in control transfected cells range from about 7500 to 10000 
cells (Figure 39B), this implies that in order to reliably observe a difference in cell 
lethality at the p=0.05 level, an approximate 50% reduction in MAD2+/- cell line 
viability and none in the diploid parental cell line needs to be observed. 
4.3.3 Suitability of siRNA screening approach for synthetic lethality 
I speculate that there may have been a variety of factors contributing to our inability to 
identify pathways required for survival of CIN+ cells. Firstly, the siRNA screening 
approach may not have been a suitable approach to identify synthetic lethal genes in an 
isogenic model of CIN+. Many RNAi screens for synthetic lethality in human cancer 
cell lines have been published. However, the majority of these published screens in 
human cell lines have either used shRNA (238, 246-251), (shRNA results in a longer 
duration of knockdown of target gene compared to siRNA (252)). Additionally, it has 
been reported candidate genes identified using shRNA screening may not be picked up 
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in similar siRNA screens (253), suggesting that the two techniques may produce 
different results, possibly due to factors such as technique of RNAi delivery into the 
cells or duration or magnitude of knockdown. There have been recent published siRNA 
synthetic lethal screens using isogenic cell lines, where the investigators have been able 
to identify and validate candidate genes, however they used endpoints of a longer 
duration post siRNA transfection such as 7 days (254) or 5 days (255). This suggests 
that following siRNA transfection; subtle differences in cell viability between isogenic 
cell lines may only become more apparent following a longer duration of gene 
silencing. There exists a published siRNA synthetic lethal screen with a 72-hour gene 
silencing endpoint, targeting cancer cells with activated K-ras (256), however the 
validated genes identified from that screen caused a two to three fold increase in cell 
death (measured using an assay for apoptosis) in the activated K-ras cell line compared 
to that without activated K-ras; a much greater difference in cell viability between the 
two cell lines compared to the cell viability effects of candidate gene knockdown 
observed in our screen. Unfortunately the authors did not report the cell number 
difference between the two isogenic cell lines following silencing of their validated 
candidate gene. The lack of published work using the siRNA synthetic lethal screening 
techniques combined with our datasets in isogenic cell line models suggest that pathway 
dependencies for survival in isogenic cell lines may be too subtle to be reliably 
detected.  
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4.3.4 Suitability of HCT116 MAD2+/- cell line as a model of CIN+ synthetic 
lethality 
I cannot exclude the possibility that the model system that we used for our screens may 
have been flawed. Firstly, there is a small difference in proliferation rate between the 
HCT116 diploid parental and MAD2+/- cell line, where the MAD2+/- has a slower 
growth rate, resulting in a 10% difference in cell number at the end of the 72-hour time 
point when starting with the same initial cell number. The proportion of cells 
undergoing events such as DNA synthesis, cell septation, cell constriction, and 
enzymatic activity peaks is increased with an increased proliferation rate within a given 
time-frame (257). Therefore an increased proliferation rate may result in an increased 
susceptibility to the effects of a particular gene knockdown as a higher proportion of 
cells may require the use of that gene within the time frame of the experiment. 
Furthermore, HCT116 MAD2+/- cells may not faithfully re-capitulate CIN in human 
cancer. MAD2 is a SAC gene, however there may be limited evidence for checkpoint 
dysfunction in CIN tumours as in vivo mutations appear rare (Table 1) and in vitro 
demonstrations show that many CIN+ cell lines have a functional SAC (66, 76, 77). 
This suggests that SAC aberrations may not be the cause of CIN in the majority of 
tumours and the MAD2 deficient cell line may not recapitulate CIN as it exists in 
naturally occurring CIN+ tumours. 
The variation analysis as presented in Figure 38 suggests that relative to the noise, the 
contribution of MAD2 status is far bigger than that of the contribution of siRNA whose 
effects appear to be obscured by the noise factor. The close ratio of siRNA variance to 
noise within our system could either mean 1) The noise within our system is too great, 
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leading to differences in cell number due to siRNA to be obscured by this noise. 2) The 
similarity of both cell lines results in cell number differences between the two cell lines 
post siRNA transfection to be subtle, and this is not able to overcome the noise inherent 
within the system. 
4.3.5 The CIN model system and the technical challenges of siRNA 
screening may lead to yield poor validation rate 
The CIN phenotype in the MAD2+/- cell line may have compounded other difficulties 
associated with siRNA transfection. siRNA transfection has been shown to induce 
broad gene expression changes and that is not likely to be attributable to off-target 
effects (258, 259). The CIN phenotype results in alterations in gene copy number and 
structure and these may affect gene dosage across the genome, that may differentially 
influence siRNA-induced gene expression changes between the CIN and non-CIN cell 
lines. Cell to cell variability within a cell population may result in low phenotypic 
penetrance (260) and this is likely to be compounded by the increased heterogeneity in a 
CIN cancer cell population. Such heterogeneity may result in difficulties reproducing 
phenotypes observed in the primary screen or resistance to cell death following gene 
silencing due to underlying genomic heterogeneity in the CIN cell line. 
Finally, non CIN-specific technical challenges associated with the use of siRNA may 
have contributed to our problems in candidate gene validation. siRNA transfection 
reagents may display significant batch to batch effects (261) and this may have affected 
out ability to reproduce the differential phenotype observed in  our primary screen in 
our validation experiments.  
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4.3.6 Comparison with screens performed in yeast to identify polyploidy 
and aneuploidy survival regulators 
The screen was unable to confirm the findings of genome-wide screens performed in 
yeast to identify survival regulators of polyploid and aneuploid yeast cells (93, 127). 
We speculate that this may be due to a number of reasons. Firstly, our screen was set up 
to discover CIN specific survival pathways and not aneuploidy/polyploidy survival 
pathways. CIN reflects a dynamic state of changes of chromosome number and 
structure and this leads to a higher level of inter-cell heterogeneity. This may lead to 
inter-cell variation in dependency on certain pathways for survival. Why were 
polyploid/aneuploid survival pathways not identified in my screens? Although the 
MAD2+/- cells display an increase in aneuploidy compared to their diploid parental cell 
line, this only results in an increase in proportion of aneuploid cells in the total cell 
population from about 15% in the diploid parental cell line to approximately 25% in the 
MAD2+/- cells (164). Therefore there may be an insufficient proportion of aneuploid 
cells within the population for us to observe a significant difference in cell viability due 
to lack of phenotype penetrance in our siRNA screen. 
Furthermore, the experiments conducted in the yeast model systems involved the stable 
overexpression of whole copies of chromosomes where else we performed a loss of 
function screen. Not only were the yeast experiments gain of function experiments, but 
the magnitude and stability of gene expression changes are likely to be lower in our 
RNAi screen due to the short time span of siRNA knockdown. 
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4.4 Conclusion 
In conclusion, I was unable to identify any synthetic lethal survival regulators of CIN+ 
cancer cells. A noise component within the screen was identified that may contribute to 
about a third of the variance within the system. However, despite the noise within our 
system, the reproducibility of the phenotype observed with positive control siRNAs and 
good dynamic range of our output measurements imply that the screen was not flawed. 
Statistical estimations suggest that the screen was sufficiently powered (power=75%) to 
detect candidate genes resulting in approximately 60% more death within HCT116 
MAD2+/- cell line compared to its diploid parental cell line. 
In agreement with the previous chapter where it was shown that CIN+ cells are 
intrinsically multidrug resistant, I speculate that the adaptations acquired by these CIN+ 
cells in order to maintain or initiate CIN may lead to adaptations and compensations 
that render them less sensitive to perturbations of genetic pathways crucial for cell 
survival. Additionally, CIN may allow for redundancy in survival pathways to be 
generated within the cells via CIN-mediated increase in copies of beneficial genes. 
Therefore it is likely that identifying candidate genes resulting in at least 50% greater 
cell death in CIN+ cells will be challenging to identify. A more attractive way of 
targeting CIN may be to identify pathways involved in initiating or maintaining a CIN+ 
phenotype to in order to limit adaptation and phenotypic heterogeneity. 
 
Chapter 5. Results 
 159 
Chapter 5. Identification of novel ploidy regulators 
with relevance to CIN+ Colorectal Cancer 
5.1 Introduction 
In Chapter 3, I proposed that CIN+ cancer cells are intrinsically multidrug resistant. In 
the previous chapter, it has been discussed that the identification of CIN-specific 
lethality pathways may be challenging in the context of mammalian cancer cell 
synthetic lethality screens. Carrying on from this, I reasoned that improved 
understanding of mechanisms involved in the generation or maintenance of polyploidy 
that are tumour relevant may provide further insight into understanding CIN and may be 
exploited to limit CIN in cancer. 
As discussed in section 1.3.4, polyploidy, tetraploidy and aneuploidy may appear to be 
a consequence of CIN due to missegregation of whole chromosomes but these 
phenotypes may also contribute to CIN. In order to identify putative tumour-relevant 
regulators of ploidy, cell cycle data from the whole genome siRNA screen performed in 
HCT116 cancer cell lines (as described in the Chapter 4) was combined with cell cycle 
data from other whole genome RNAi screens performed in this Institute. Using SNP 
array data from CRC cell lines provided by the Wellcome Trust Sanger Institute, the list 
of ploidy regulators obtained from the screens was filtered to regions of DNA copy 
number loss as these regions may contain genes that are lost in CIN+ tumours in order 
to maintain or initiate an increase in ploidy. The overlapping genes may allow the 
identification of novel ploidy regulators. 
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Data from the high-throughput RNAi screens presented in this chapter were made 
available from the High-Throughput Screening Facility (Michael Howell, Ming Jiang, 
Rachael Instrell and Becky Saunders) at the Cancer Research UK London Research 
Institute. The DNA copy number analysis was performed by David Endesfelder. 
5.2 Results 
5.2.1 Whole Genome RNAi screen identifies potential tumour relevant 
genes that are involved in the generation or maintenance of 
polyploidy 
As described in Chapter 4, a high throughput loss of function screen using synthetic 
siRNA oligonucleotide pools from Dharmacon targeting 21122 genes was performed in 
the HCT116 cell line. Cells were stained with DAPI to enable the measurement of cell 
number and cell cycle profile data. The cell cycle profile data was used in this chapter to 
address whether loss of function of any of these genes resulted in an increase in the 
fraction of polyploid cells within the colorectal cancer (CRC) HCT116 cell line, a CIN-, 
near-diploid cancer cell line. 
The HCT116 CRC cell line was transfected with 21122 siRNA pools in triplicate, each 
siRNA pool containing 4 different siRNA sequences. Cells were transfected in 96-well 
plates and were fixed 72 hours after transfection. Plates were then stained with DAPI, to 
allow a quantitative assessment of cellular DNA content and cell cycle profile following 
gene silencing. 
The population of cells with DNA content greater than 4n (>4n -corresponding to 
aneuploid or polyploid cells and possibly tetraploid cells in S-phase) was determined for 
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each siRNA pool and the data were normalised and analysed as described in material 
and methods. Z-scores (scores measuring the standard deviations from the mean in 
normalised data) for the >4n data for each siRNA were obtained from this normalised 
data. A threshold of Z-scores of 2.5 or greater was used to define candidate siRNAs that 
induced polyploidy, yielding a total of 301 candidate genes whose gene silencing 
resulted in an increase in the >4n fraction of cells (Figure 41A). 
Of the list of 301 candidate genes, I next wanted to investigate whether any of these 
genes are preferentially lost in CIN+ cancer cells. To address this, we used a dataset of 
single-nucleotide polymorphism comparative hybridisation data (SNP 6.0 Affymetrix) 
from the Wellcome Trust Sanger Institute for 20 CIN+ and 9 CIN- CRC cell lines 
(CIN+ status of cell lines defined by an increase in DNA index as in section 3.2.1) to 
identify genomic regions that were commonly altered in CIN+ colorectal cancer cells. 
Genomic regions that are consistently and stably lost at the DNA copy number level in 
CIN+ cancers compared to non-CIN cancers may reflect adaptations necessary for 
maintaining or initiating polyploidy, and these regions may contain dosage sensitive 
genes whose loss of function may contribute to polyploidy. Minimum consistent regions 
of genomic alteration between all cell lines were defined and assigned a score of 
significance based on both frequency and amplitude of aberration, adjusting for tumour 
baseline ploidy (see materials and methods for details). After controlling for multiple 
testing using a false discovery rate of 0.05, 2377 genes were identified that were 
contained within genomic regions that were lost in CIN+ cells relative to the median 
copy number (which approximates the ploidy) of the cell line compared to non-CIN cell 
lines (Figure 41B). 
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The list of 301 candidate genes whose silencing induces polyploidy were overlapped 
with the 2377 genes that are lost in CIN+ cell lines relative to median ploidy (Figure 
41C). A total of 28 genes were in common between these two lists. This list of 28 genes 
did not represent a significant enrichment in either list. This may be due to two reasons: 
1) Many genes may induce polyploidy when silenced but this loss may not be 
sustainable in cancer due to negative survival effects, and therefore are not stably lost in 
CIN+ CRC cell lines. 2) Not all genes that are lost at the copy number level in CIN+ 
CRC cell lines may be regulators of ploidy. 
It was next investigated if there were any genes whose loss of function was able to 
induce polyploidy not only in CRC but also in cancer cells of different tissues of origin, 
but that were still preferentially lost in CIN+ cancer cell lines. To address this, we 
obtained >4n cell cycle data from three other whole genome RNAi screens assayed 
using the same methods as the HCT116 screen. These other screens were performed 
using cell lines originating from fibrosarcoma (HT1080), lung cancer (PC9) and renal 
cancer (RCC4). The >4n data from the HCT116 screen were re-normalised (as in 
materials and methods) and new Z-scores calculated so as to enable comparison with 
the Z-scores from the other 3 screens. Z-scores in the re-normalised HCT116 data 
displayed an increased value compared to Z-scores obtained using the original 
normalisation method. To identify candidate genes that were able to induce polyploidy 
in cancer cells of different tissue types, a threshold of at least 2.5 Z-scores (reflecting a 
lowered threshold in the case of the HCT116 screen, due to the increase in value of 
HCT116 z-scores upon renormalisation) in 3 or more different cancer cell lines was 
used. This was compared to the list of genes lost in CIN+ colorectal cancer cell lines to 
give 9 further candidate genes (Figure 41D). Of these 9 genes, 4 of them, KIF17, 
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KNTC2, MAD2L1, and RBX1 have known or putative roles in cell division (242, 262) 
(27, 263). This gave me the confidence that these methods enabled us to identify 
potential regulators of polyploidy in colorectal cancer. 
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Figure 41 Cell cycle profile data from whole genome siRNA screens and overlapped 
with DNA copy number data in CIN+ CRC cell lines 
C 
A B 
D 
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A) Cumulative frequency plot of Z-scores for >4n data in HCT116 screen. A threshold 
of 2.5 Z-scores was chosen to select candidate genes for follow-up. 
B) Q –Plot of SNP-CGH data indicating regions of loss or gain in copy number relative 
to median ploidy in CIN+ CRC cancer cell lines. 
C) Heatmap of Z-scores of candidate genes selected from HCT116 screen that 
overlapped with list of genes that are lost relative to median ploidy in CIN+ cells  
D) Heatmap of Z-scores of candidate genes selected from HCT116, HT1080, PC9 and 
RCC4 screens that overlapped with list of genes that are lost relative to median ploidy 
in CIN+ cells and appeared in at least 3 of those screens. 
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5.2.2 Validation of candidate genes for on-target effects 
Candidate genes from the previous section, encoded in regions of copy number loss in 
CIN+ cells, and which had no previously described cell division function, were assessed 
for off-target effects. To address this, the high throughput screen assay was repeated in 
the HCT116 cell line using the four individual siRNAs that make up the Dharmacon 
SmartPool siRNAs for each gene of interest.. 
29 unique candidate genes (Figure 42A) were re-assayed. The percentage of >4n cells 
for each siRNA was normalised to non-targeting siRNA controls (siCON). A threshold 
of at least a two-fold increase in the percentage of >4n cells relative to siCON in at least 
2 or more individual siRNAs for each gene of interest was considered an on-target 
effect. 13 siRNAs (Figure 42B) met this threshold. 
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Figure 42 Validation of candidate genes for off-target effects 
A) Heatmap of fold change compared to siCON of >4n population of cells for single 
siRNAs for each candidate genes. 
B) Table listing the candidate genes that caused at least a 2-fold increase relative to 
siCON in % of >4n cells in at least 2 out of 4 single siRNAs. 
A 
B 
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5.2.3 Live cell microscopy analysis reveals potential mechanisms for the 
generation of polyploid cells 
Each of the 13 validated candidate genes were then analysed using live cell microscopy 
to identify potential mechanisms for the generation of polyploidy. siRNAs were 
transfected into a HCT116 cell line which stably expresses Histone 2B tagged with RFP 
(H2B-RFP) enabling visualisation of DNA, in order  to allow the tracking of cells for 
mitotic defects using both phase contrast images of the cell and fluorescent images of 
the cellular chromatin. Cells were transfected for 48h with the siRNA of interest and 
then imaged every 3 minutes using the Deltavision imaging system for a total of 8 
hours. 
CD52 silencing induced a change in nuclear and cellular morphology to that which was 
spindle-like (Figure 43) with no obvious errors in mitosis or cytokinesis and was 
regarded as a false positive in my screen for the induction of polyploidy. 
Chapter 5. Results 
 169 
 
 
Figure 43 Representative time-lapse phase-contrast images following CD52 silencing in 
HCT116 cells 
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The percentage of cells entering mitosis was scored for each candidate gene (Figure 
44A). Cells that increase ploidy without entering mitosis may reflect an increase in 
DNA content without cell division. None of the siRNAs appeared to induce a 
statistically significant increase in percentage of cells entering mitosis compared to 
siCON (Fisher’s exact test). ANKFY1, IER3IPI, PTPRU and TAS1R2 all reduced the 
percentage of cells entering mitosis to less than 10% each over the duration of the 
movie. However only IER3IPI and PTPRU resulted in a significant decrease in 
percentage of cells entering mitosis (p=0.018 and 0.01 respectively, Fisher’s exact test). 
Candidate genes whose depletion did not result in a reduction of cells entering mitosis 
to less than 10% were further investigated. Cumulative frequency plots of the time each 
cell spends in mitosis post transfection were plotted for the remaining candidate genes. 
An extended time spent in mitosis may reflect mitotic errors and subsequent arrest. The 
lines for BBS7, FRG2, HTR6, PUM1 and TAX1BP3 both appeared to be shifted to the 
right compared to siCON transfected cells, indicating an increase in time each cell 
spends in mitosis (Figure 44B). 
Next, numbers of mitotic slippages resulting in giant nuclei reformation or 
multinucleated cells were scored (Figure 45A), representing the numbers of polyploid 
cells being generated. BBS7, KREMEN1 and PCDH18 silencing led to an increase in 
giant nuclei interphase cells following mitotic slippage when compared to control 
transfected cells. FRG2, PUM1 and TAX1BP3 appeared to increase the proportion of 
multinucleated cells generated following mitotic slippage. 
Lagging chromosomes and anaphase bridges are errors that can arise following 
merotelic kinetochore-microtubule attachments, in which one sister chromatid is 
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attached to microtubules originating from both centrosomes (45, 76). This can then lead 
to whole chromosome non-disjunction and/or structural chromosome damage, 
promoting the generation of CIN. Anaphase bridges, lagging chromosomes and 
multipolar divisions were scored following gene silencing (Figure 45B). BBS7, FRG2, 
PUM1 and TAX1BP3 appeared to induce higher rates of these errors compared to 
control transfected cells. Approximately 80% of cells that were silenced for PCDH18 
underwent mitotic slippage and this may account for the decrease in lagging 
chromosomes/anaphase bridges and multipolar divisions being measured following 
silencing of this gene. 
Representative images for the phenotypes scored are presented in Figure 46. 
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Figure 44 Graphs of percentage cells entering mitosis and time spent in mitosis 
A) Barplot of percentage of cells entering mitosis. 
B) Cumulative frequency graph of time each cell spends in mitosis. 
A 
B 
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Figure 45 Percentage of mitotic errors in cells following candidate gene silencing 
A) Barplot of percentage of mitotic cells slipping out of mitosis and forming giant 
nuclei or multinucleated interphase cells. 
B) Barplot of percentage of mitotic cells demonstrating lagging chromosomes and 
anaphase bridges or multipolar divisions. 
B 
A 
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Figure 46 Representative images of mitotic errors 
A) Representative images of lagging chromosomes and anaphase bridge formation 
followed by exit from mitotis to form a single polyploid nuclei following BBS7 
silencing. 
B) Representative images of anaphase bridge formation followed by exit from mitosis 
to form a multinucleated cell following TAX1BP3 silencing. 
A 
B 
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5.3 Discussion 
In this study, 13 genes with no previously described function in cell division have been 
identified that may be relevant to the generation or maintenance of polyploidy in CIN 
cancer cell lines. A genome wide siRNA screen was used to identify genes that induce 
polyploidy in the near-diploid CRC cell line, HCT116 and cancer cell lines from other 
tissue types (HT1080, PC9, RCC4). I then focused on candidate genes that were in 
common with genes that are lost at the DNA copy number level in CIN relative to 
diploid colorectal cancer cell lines. This method allowed the identification of 28 
candidate genes that are lost in CIN cancer cells and that result in polyploidy when 
silenced in HCT116 cancer cell lines and 9 genes that result in the same phenotype 
when silenced in cancer cell lines originating from other tissue types. This gave a total 
of 35 unique genes identified through the screen, of which 4 have described functions in 
cell division. 13 of these genes were deemed less likely to have off-target effects 
(Figure 47) as the phenotype was reproducible in at least 2 out of the 4 individual 
siRNA sequences making up the pooled siRNAs. 
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Figure 47 Workflow of candidate genes selection and validation 
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There appeared to be no common pathway to link these 13 candidate genes together in 
generating polyploidy. Further investigation by live cell microscopy and FACS 
suggested that polyploidy was induced by loss of function of these genes through 
various mechanisms. For 6 of these genes (BBS7, CSN1S1, KREMEN1, PCDH18, 
PUM1, TAX1BP3) loss of function appeared to cause an increase in mitotic slippage 
followed by giant nuclei formation or multinucleation compared to control transfected 
cells. PCDH18 in particular induced very high levels of mitotic slippage to form a 
mononucleate polyploid cell. Depletion of HTR6 appeared to result in multipolar 
divisions. FRG2 silencing appeared to induce a very modest increase in rates of mitotic 
errors compared to siCON transfected cells but we were not able to measure an increase 
in observable mechanisms of generation of polyploidy during the short time course of 
the live cell microscopy experiments. For four of these genes, there was a decrease in 
the number of cells entering mitosis following silencing of ANKFY1, IER3IPI PTPRU 
or TAS1R2. This may be a mechanism of polyploidy induction for these genes. CD52 
appeared to be a false positive as it induced spindle-like morphological changes without 
any erros in mitosis or cytokinesis being observed. 
Two of these genes (TAX1BP3 and KREMEN1) may induce polyploidy through 
deregulation of the Wnt/Beta-catenin signalling pathway. In the Wnt signalling 
pathway, Beta-catenin is constantly targeting for degradation by the Beta-catenin 
destruction complex via GSK3beta-mediated phosphorylation (264). Wnt signalling 
inhibits the destruction of Beta-catenin by interfering with GSK3beta-mediated 
phosphorylation and thus allows an increase in levels of Beta-catenin (265). With 
relevance to cell division, WNT/beta-catenin signalling has been shown to peak at 
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G2/M and Beta-catenin has been reported to localise to both interphase and mitotic 
centrosomes (266). Depletion of Beta-catenin has been reported to cause an increase in 
monopolar spindle formation and the failure of centrosomes to separate (267). 
Stabilisation of Beta-catenin (via mutations of GSK3beta phosphorylation sites, thus 
preventing degradaton of Beta-catenin) on the other hand, induces centrosome 
separation (266). TAX1BP3 (also known as TIP-1) has been shown to bind to Beta-
catenin with high affinity and inhibit its transcriptional activity (268). Depletion of 
TAX1BP3 may therefore increase the levels of active Beta-catenin. KREMEN1 is a 
transmembrane coreceptor for Dickkopf-1, a negative regulator of Wnt signalling. 
KREMEN1 double knockout mice have been shown to have an increase in Wnt 
signalling (269). KREMEN1 down-regulation could therefore also result in an increase 
in active Beta-catenin via increased levels of Wnt that prevent degradation of Beta-
catenin. I speculate that down-regulation of either TAX1BP3 or KREMEN1 may result 
in an increase in levels of active Beta-catenin and therefore cause disruptions in 
centrosome cohesion. 
PUM1 encodes a PUF family RNA-binding protein, a regulator of posttranscriptional 
gene expression. Morris and colleagues (270) have previously shown that knockdown 
of PUM1 results in a decreased rate of mRNA decay of genes involved in the mitotic 
cell cycle such as Cyclin B1 and CKS2. In their study they did not observe a function 
for PUM1 in cell cycle progression (data not shown in study). In my data, I did not 
observe alterations in the amount of time that cells spend in mitosis, however, there 
appeared to be an increase in proportion of cells slipping through mitosis leading to 
giant nuclei and multinucleated interphases following knockdown of PUM1. However, 
it has been also shown that elevated levels of Cyclin B1 prevent cells from undergoing 
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mitotic slippage (271) and that CKS2 depletion concurrent with CKS1 depletion leads 
to mitotic slippage and polyploidy (272). Therefore elevated half-lives of Cyclin B1 and 
CKS2 mRNA following PUM1 knockdown may not be the explanation for the increase 
in mitotic slippage and mitotic errors that we observed. 
Loss of function of BBS7 has been shown to cause defects in the structure and functions 
of cilia (273) and mutations in this gene have been shown to affect the localisation and 
motility of IFT88/Polaris. In other studies, depletion of IFT88 has been shown to induce 
mitotic defects such as an increase in mitotic defects and delayed mitotic progression. 
This may be due to disruption of the spindle poles, an increase in chromosome 
misalignment and spindle misorientation (274). I speculate that depletion of BBS7 may 
lead to defects in proper localisation or function of IFT88. IFT88 and other IFT proteins 
localise to the spindle poles during mitosis and their disruption may cause defects in 
mitosis such as the ones we observed with an increase in mitotic errors. Interestingly, 
HTR6 has been reported to localise to cilia but the function or significance of its 
localisation is as yet unknown (275). 
5.4 Conclusion 
The identification of genes with known cell division functions and also novel genes that 
may be implicated in pathways that ensure proper mitotic segregation by overlapping 
our HTS screen data with data obtained from an analysis of SNP-CGH data in CIN and 
non-CIN CRC cell lines suggests the utility of our approach. Further work investigating 
the function of these genes and also genes that have no known mitotic function or are 
not implicated in any pathways maintaining mitotic fidelity may allow us to better 
understand the generation and maintenance of polyploidy in CIN cancer cells. 
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Chapter 6. CERT predicts chemotherapy benefit and 
mediates cytotoxic and polyploid-specific cancer 
cell death through autophagy induction 
6.1 Introduction 
The ceramide transporter CERT was identified through a multidrug sensitivity RNAi 
screen to enhance sensitivity to paclitaxel, cisplatin, 5-FU and doxorubicin when 
silenced from multiple cancer cell lines (12). Given that 1) CIN+ cells are intrinsically 
resistant to taxanes but the silencing of CERT results in taxane sensitisation, and 2) 
identifying pathways that are required for the specific survival of CIN+ cancer cells is 
challenging (Chapter 3 and Chapter 4), I reasoned that a clearer understanding of the 
molecular pathways responsible for cell death following CERT depletion and paclitaxel 
exposure may offer a broader insight into mechanisms regulating mitotic catastrophe 
and suggest therapeutic opportunities to specifically limit the development of 
chromosomally unstable cells.  
Through parallel integrative genomics approaches combining transcriptomic analyses 
with RNAi-based functional genomics and live cell microscopy studies, I identified that 
CERT silencing resulted in multidrug sensitisation through the augmentation of 
LAMP2-dependent autophagic flux. This process results in the specific death of 
multinucleated cells following paclitaxel exposure and thus CERT targeting may serve 
as a rational approach to attempt to eliminate precursors of intra-tumour heterogeneity 
in cancer. 
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The work presented in this section has been published as a first author article (276) (see 
Appendix 8.4). Part of section 6.2.2 has been published as a first author article in (277) 
(see Appendix 8.5). Philip East performed the microarray analysis. In section 6.2.10 and 
section 6.2.12, analysis of CERT expression in cancer cell lines has been performed by 
Neil P. Jones, analysis of CERT expression data in breast cancer microarray datasets 
has been performed by Nicolai Juul Birkbak and analysis of CERT TMA data has been 
performed by David Endesfelder and Jil Sander with IHC staining and quantification 
performed by Patricia Gorman and Rebecca Roylance on samples (and corresponding 
patient data) provided by Valerie Speirs and Andrew Hanby. 
6.2 Results 
6.2.1 CERT depletion results in ceramide accumulation 
CERT, identified in a paclitaxel-sensitisation RNAi screen (12), encodes a lipid 
transporter that transports long-chain ceramides (C14-20) as well as short chain 
fluorescent ceramide analogues from the endoplasmic reticulum to the Golgi apparatus 
(135). I hypothesised that CERT silencing in the presence of paclitaxel might mimic the 
effect of ceramide exposure through the attenuation of ceramide transport from the ER 
to the Golgi and its subsequent conversion into sphingomyelin. Depletion of CERT by 
RNAi (siCERT) in HCT116 cells was confirmed to result in attenuation of ceramide 
transport with ceramide confined to membranous and diffuse cytoplasmic structures, in 
contrast to control transfected cells (siCON), in which ceramide is localised to Golgi-
like punctate perinuclear regions (Figure 48A) (278). 
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To establish whether CERT depletion might induce alterations in ceramide levels that 
could be exacerbated by paclitaxel exposure, lipid extracts were analysed for their 
ceramide content by mass spectrometry from siCERT-transfected cells treated with 
vehicle or paclitaxel (25nM for 48 hours) compared to siCON transfected cells under 
identical conditions. Paclitaxel treatment of siCON transfected cells did not 
significantly increase total ceramide levels (Figure 48B). CERT depletion resulted in an 
increase in total ceramide levels relative to siCON transfected cells (p=0.008) and the 
combination of siCERT with paclitaxel treatment resulted in a greater increase in total 
cellular ceramide levels (p=0.0001) relative to siCON transfected cells. An increase in 
total ceramide accumulation occurs within the same timeframe as the marker of 
endoplasmic reticulum stress, CHOP, is detected in HCT116 cells under identical 
conditions (12). 
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Figure 48 Validation of siRNA transfection and measurements of ceramide content of 
cells 
A) Fluorescent C5-Ceramide was added to cells transfected with either siCON or 
siCERT and imaged 20 mins following exposure to drug. 
B) Relative ceramide levels were measured using mass spectrometry. Graph shows  
ratio of total ceramide normalised to total phosphate within each condition in 
siCON/vehicle control, siCON/paclitaxel, siCERT/vehicle control and 
siCERT/paclitaxel. Error bars represent standard deviations across triplicate 
experiments for each condition. 
B 
A 
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6.2.2 Transcriptomic analysis reveals a CERT-specific response 
I hypothesised that the CERT-specific paclitaxel sensitisation phenotype may be 
attributable to two mechanisms; the first readies the cell for paclitaxel-induced cell 
death following CERT silencing, the second mechanism might be attributable to a 
response derived from ceramide sequestration within the ER that acts synergistically to 
enhance cell death. I reasoned that through the identification of a CERT-specific and a 
possible ER-localised ceramide transcriptional response, mediators of this process 
might be identifiable. 
First I addressed whether CERT depletion is associated with a specific transcriptional 
response that might inform upon the mechanism through which CERT silencing primes 
cells for paclitaxel induced death. Microarray expression analysis of HCT116 cells was 
used to identify genes differentially regulated following CERT depletion in the presence 
of ceramide, paclitaxel or DMSO vehicle control compared to the same treatments in 
siCON transfected cells. A common CERT-specific transcriptional response was 
identified (Figure 49). Variation in expression pattern between the triplicates may 
reflect the analysis of biological triplicates for each condition. 
24 genes, including CERT, were selected for qPCR validation of gene expression 
changes following CERT silencing and vehicle control treatment (Figure 50A). I found 
that microarray profiles correlated closely with gene expression changes validated by 
qPCR (R=0.97) (published in (277), see Appendix 8.5) indicating the reliability of gene 
expression changes quantified by Affymetrix HuEx-1_0-st-v2 (Human Exon) array 
profiling (Figure 50B). Moreover, it has been previously reported that gene expression 
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fold changes <1.5 as determined using traditional microarray profiling, correlate poorly 
with qPCR assessments of gene expression (279, 280). Analysis of the correlation of 
exon array expression and qPCR data used in my study for gene expression fold 
changes <1.5 revealed a correlation coefficient of 0.84.  
Reasons for the improved estimates of gene expression using the Affymetrix exon array 
analysis may include the use of multiple probes per exon allowing data to be collected 
from the whole gene and not just the 3' end, and the use of labelled cDNA, in contrast to 
other microarray platforms which use labelled cRNA. Labelled cDNA produces less 
cross hybridisation compared to labelled cRNA and may contribute to the high 
performance of the exon array platform (281). The high concordance of the exon array 
gene expression data with qPCR assessments of gene expression even at low fold 
changes gave me the confidence to further investigate these genes. 
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Figure 49 CERT gene expression signature  
Heatmap of differentially expressed genes in HCT116 cells 8h after paclitaxel, C6-
ceramide or vehicle control treatment, 48h following siCERT transfection. siCON 
transfected samples treated with paclitaxel or ceramide provided for comparison. 
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Figure 50 qPCR validation of microarray data 
A) Graph of qPCR validation of 24 genes that are differentially expressed following 
CERT depletion. Error bars represent standard deviations across triplicate experiments. 
B) Linear regression model of relative gene expression changes quantified by exon 
array and TLDA gene profiling. Correlation coefficient = 0.97. 
B 
A 
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6.2.3 CERT depletion induces LAMP2 which is required for paclitaxel cell 
death 
Gene expression changes following CERT depletion might prime cells for subsequent 
cell death initiated by paclitaxel. I reasoned that silencing the expression of these genes 
through RNAi might antagonise paclitaxel response and siCERT-specific paclitaxel 
sensitisation. To explore this possibility, seven genes (CPA4, FYCO1, KLF6, LAMP2, 
MDK, WDFY1, WIPI1), whose expression were induced following CERT depletion 
(and validated by qPCR), were silenced by siRNA in HCT116 cells and paclitaxel 
sensitivity was assessed. Two of the seven genes promoted paclitaxel resistance when 
silenced in HCT116 cells, LAMP2 (encoding a lysosomal membrane protein) (282) and 
CPA4 (a carboxypeptidase with unknown specific substrate) (Figure 51A). Induction of 
LAMP2 protein following CERT silencing and efficient knockdown of LAMP2 protein 
by RNAi were confirmed (Figure 51B). Real-time qPCR quantification using primers 
specific to the LAMP2a and to all LAMP2 splice variants revealed an increase in 
expression of LAMP2 and LAMP2A specifically (Figure 51C). To assess whether 
siCERT-mediated paclitaxel sensitisation was dependent upon LAMP2 expression, both 
CERT and LAMP2 were co-depleted and paclitaxel sensitivity was assessed. siLAMP2 
abrogated the ability of siCERT to sensitise cells to paclitaxel exposure (Figure 51A). 
Co-silencing of both CERT and LAMP2 was confirmed by qPCR (Figure 51D) and 
antagonism of paclitaxel was confirmed for two separate siLAMP2 siRNA 
oligonucleotide sequences (Figure 51E).  
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Figure 51 Investigation of pathways mediating paclitaxel-induced cell death following 
CERT silencing 
A) Graph of relative cell number following transfection of siCON, siCERT, siCPA4, 
siLAMP2 or siCERT+siLAMP2 and vehicle control or paclitaxel treatment. Data were 
normalised to cell number in siCON/vehicle control or siCON/paclitaxel for paclitaxel 
treated experiments. Error bars represent standard deviations across 6 replicates. 
B) Western blot analysis showing LAMP2 protein expression 24h after paclitaxel or 
vehicle control treatment following 48h of siCON or siCERT transfection. 
C) Graph of qPCR assessment of gene expression of LAMP2 and LAMP2A specifically 
following CERT silencing. 
D) Graph of relative expression levels of CERT (above) and LAMP2 (below) as 
measured using qPCR 48h post-treatment with paclitaxel or vehicle control following 
48h of siRNA transfection. 
A 
B 
C 
D 
E 
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E) Graph of relative cell number following transfection of siCON or individual siRNAs 
(siLAMP2 02 and siLAMP2 04) that make up the siLAMP2 siRNA pool and resulted in 
resistance to paclitaxel compared to siCON transfected cells. Data were normalised to 
cell number in siCON/vehicle control and siCON/paclitaxel for paclitaxel treated 
experiments. Error bars represent standard deviations across 6 replicates. 
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6.2.4 Ceramide treatment on the background of CERT silencing induces a 
specific transcriptional response 
Previously it has been shown that CERT depletion attenuates the transport of exogenous 
ceramide from the ER to the Golgi and promotes an increase in cellular ceramide levels 
with paclitaxel. I hypothesised that the rise in cellular ceramide, restricted to the ER 
compartment following CERT depletion, might contribute to cellular cytotoxicity 
coordinated with a CERT-specific transcriptional response.  
To investigate the impact of ceramide that is likely to be ER-restricted due to CERT 
silencing, on the cellular transcriptional response, I asked what gene sets were 
significantly altered in HCT116 cells treated with ceramide on a CERT depleted 
background, relative to ceramide treated siCON-transfected cells. The autophagy 
geneset (Figure 52A) was significantly altered following ceramide treatment of CERT 
depleted cells compared to ceramide treatment of HCT116 cells with proficient CERT 
transport (p=3.5E-05). CERT functions to transport ceramide from the ER to the Golgi, 
where it is subsequently converted to sphingomyelin. Silencing of CERT is therefore 
likely to restrict ceramide to the ER, and this accumulation of ceramide in the ER may 
explain the specific transcriptional autophagy response observed here. 
6.2.5 CERT depletion and paclitaxel exposure initiates an autophagy 
response 
Given the observations that 1) CERT depletion induces a rise in cellular ceramide in the 
presence of paclitaxel, 2) Ceramide treatment of CERT depleted cells results in an 
autophagic transcriptional response and 3) LAMP2, induced following CERT depletion, 
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can antagonise paclitaxel-cell death when silenced from cells, I addressed whether 
autophagy induction might occur following paclitaxel treatment of CERT depleted 
cells. Expression and lipidation of endogenous microtubule-associated protein light 
chain 3 (LC3) were studied in HCT116 cells following CERT silencing and paclitaxel 
exposure. LC3 is used as a marker of autophagy and is converted from LC3-I to LC3 
during the formation of autophagosomes. Changes in levels of both LC3 species may 
reflect changes in autophagic flux. Following transfection of siCON and paclitaxel 
treatment, there was minimal change in LC3-I (unlipidated LC3) or LC3-II (lipidated 
LC3) levels compared to vehicle control-treated HCT116 cells (Figure 53). Similarly, 
CERT silencing in the absence of drug treatment did not significantly alter LC3-I or 
LC3-II levels. However, the combination of CERT silencing and paclitaxel treatment 
resulted in a reduction of both LC3-I and LC3-II, suggestive of autophagy flux 
induction. Consistent with the degradation of LC3 by lysosomal proteases, addition of 
the lysosomal protease inhibitor, leupeptin, resulted in the reappearance of LC3-I and 
LC3-II in siCERT cells treated with paclitaxel (Figure 54). 
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Figure 52 siCERT and ceramide mediates an autophagy transcriptional response 
Heatmap of autophagy gene set (as defined using Metacore from GeneGo Inc.).  
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Figure 53 LC3I/II western blot analysis following CERT and LAMP2 silencing for 48h 
and 24h of paclitaxel exposure 
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Figure 54 LC3I/II western blot analysis following siCON or CERT silencing for 48h 
and 24h of paclitaxel exposure in the presence of leupeptin protease inhibitor 
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6.2.6 CERT-mediated paclitaxel sensitisation is LAMP2 dependent 
It has been proposed that the tethering of the autophagosome to the lysosomal 
membrane is a rate-limiting step that defines the life-span of autophagosomes (283). 
The expression of LAMP2, encoding a lysosomal membrane protein (282), is induced 
following CERT depletion and LAMP2 silencing antagonises paclitaxel sensitisation 
following CERT depletion. Given the reported role of the lysosome and lysosomal 
proteases in response to taxanes (153, 154), I speculated that the expression of LAMP2 
following CERT depletion may contribute to paclitaxel-sensitisation through autophagic 
cell death. Supporting the role of LAMP2 in siCERT/paclitaxel induced autophagy 
response and LC3 degradation, LAMP2 silencing attenuated LC3 degradation following 
CERT and LAMP2 co-depletion (Figure 52B). 
To investigate the timing of cell death relative to LC3 disappearance, cells were 
transfected with siCON or siCERT and treated with vehicle control or paclitaxel. Cells 
were assayed at 12h, 24h, 48h and 72h for apoptotic activity as measured by Caspase 
3/7 activity (Figure 55) and for LC3-I and LC3-II expression. Maximal reduction of 
LC3-I and LC3-II following siCERT and Paclitaxel was observed at 12h with 
reappearance of both moieties by 72h. In contrast, maximal apoptotic activity of 
siCERT and siCON transfected cells was observed 36 hours later, at 48h following 
paclitaxel treatment. Taken together, these data suggest that increased autophagic flux 
precedes caspase activity following paclitaxel exposure of CERT depleted cells.  
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Figure 55 Autophagy response precedes apoptotic activity following CERT silencing 
and paclitaxel treatment 
Graph showing corrected Caspase 3/7 activity of siCON/paclitaxel and 
siCERT/paclitaxel treated HCT116 cells normalised to siCON/vehicle control over 72h. 
Error bars represent standard deviations over 6 replicates per condition. Below the 
graph is a western blot analysis over the same time course showing LC3 expression 
following siCON or siCERT transfection with vehicle control or paclitaxel treatment.  
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6.2.7 CERT depletion induces localisation of LAMP2/LC3 and the 
accumulation of lysosomal structures in the presence of paclitaxel 
The localisation of endogenous LAMP2 expression was addressed following CERT 
depletion in GFP-LC3-HEK293 (transformed Human Embryonic Kidney) cells, cells 
which stably express GFP-LC3, by fixed cell immunofluorescence in the presence of 
the lysosomal acidification inhibitor Bafilomycin A to prevent GFP-LC3 degradation. 
Endogenous LAMP2 intensity was elevated in siCERT/paclitaxel treated relative to 
siCON/paclitaxel GFP-LC3-HEK293 cells, and there was marked co-localisation of 
GFP-LC3 with LAMP2 (Figure 56A). These results suggest that CERT depletion 
induces paclitaxel sensitisation through a LAMP2-dependent mechanism that is 
associated with LAMP2/LC3 co-localisation and LC3 degradation. Next, lysosomal 
mass was estimated by quantifying LAMP2 intensity per spot. Depletion of CERT 
resulted in a significant increase in LAMP2 spot intensity (Mann-Whitney U, p=0.015). 
Co-depletion of LAMP2 significantly decreased this intensity (Mann-Whitney U, 
p=0.0043) (Figure 56B). 
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Figure 56 CERT depletion results in increased LAMP2 spot intensity as measured using 
immunofluorescence microscopy 
A) Representative immunofluorescence microscopy images of siCON/paclitaxel and 
siCERT/paclitaxel cells in the presence of Bafilomycin A1. Blue corresponds to DAPI 
staining, green to GFP-LC3 and red to LAMP2.  
B) Scatter plot of LAMP2 intensity per spot following siCON, siCERT, siLAMP2 or 
siCERT+siLAMP2 silencing and treatment with 25nM paclitaxel. Each dot represents a 
replicate well. Horizontal lines signify mean and standard deviations. 
A 
B 
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I asked whether specific changes to the cellular ultrastructure could be identified by 
electron microscopy (EM) analysis of siCERT/paclitaxel and siCON/paclitaxel treated 
cells (Figure 57). EM analysis revealed an increase in the number of cells with electron 
dense structures that may correspond to lysosomal or autophagosomal structures in 
siCERT/paclitaxel treated cells in contrast to siCON/paclitaxel treated cells (Figure 58: 
percentage of cells with electron dense structures with siCERT/paclitaxel: 75% n=24 vs 
siCON/paclitaxel: 44%, n=27, p=0.045, Fisher’s Exact Test). In contrast, co-depletion 
of CERT and LAMP2 in the presence of paclitaxel significantly reduced the number of 
cells with these electron dense structures compared to siCERT/paclitaxel treated cells 
(siCERT/siLAMP2/Paclitaxel: 32% vs siCERT/Paclitaxel 75%, n=25 and n-24 
respectively, p=0.004, Fisher’s Exact Test). 
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Figure 57 Representative transmission electron micrographs (TEM) of siCON/paclitaxel 
and siCERT/paclitaxel cells 
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Figure 58 Electron dense structures appearing following CERT silencing were 
quantified 
 Graph of percentage of cells with electron dense structures following paclitaxel 
treatment and siCON, siCERT, siLAMP2 or siCERT and siLAMP2 transfection. 
Representative high magnification TEM images of siCON/paclitaxel and 
siCERT/paclitaxel cells, showing electron dense structures (arrow). N=nucleus, 
G=Golgi Apparatus, C=Centriole, M=Mitochondria. 
Quantification of Cells with Electron Dense Structures 
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6.2.8 Relationship of paclitaxel response with autophagy gene 
expression 
To further explore the relationship of autophagy with paclitaxel response, I addressed 
whether silencing other components of the autophagy pathway might influence 
paclitaxel sensitivity. Silencing the majority of these genes resulted in significant cell 
death independent of taxane exposure. However, silencing of ATG7 induced paclitaxel 
resistance, indicating that a proximal member of the autophagy pathway may influence 
paclitaxel response (Figure 59A). Phenocopying LAMP2 silencing, co-depletion of both 
ATG7 and CERT significantly attenuated CERT-mediate cell death (Mann Whitney-U, 
p=0.002) (Figure 59B). 
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Figure 59 Assessment of relationship of paclitaxel response with autophagy gene 
expression 
A) Graph of relative cell number following transfection of siCON or siRNAs targeting 
regulators of autophagy. Data were normalised to cell number in siCON/vehicle control 
or siCON/paclitaxel for paclitaxel treated experiments. Error bars represent standard 
deviations across six replicates per condition. 
B) Graph of relative cell number in paclitaxel treated compared to vehicle control 
following transfection of siCON, siCERT, siATG7 or siCERT+siATG7. 
Treated/control ratio for siCON was set to 1. Error bars represent standard deviations 
across six replicates per condition. 
A 
B 
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6.2.9 CERT depletion promotes mitotic catastrophe that is LAMP2 
dependent 
I sought to establish the cell cycle fate of individual cells following paclitaxel treatment 
and CERT silencing, through live cell microscopy imaging of H2B-GFP labelled 
HCT116 cells during 48 hours of paclitaxel exposure. Paclitaxel treatment of siCON 
transfected cells promoted cell death following mitosis or during interphase following 
exposure to anti-mitotic agents as previously reported (76). CERT depletion induced 
two-fold more death events over 48 hours compared to control transfected cells 
following paclitaxel treatment, consistent with the drug-sensitising effect of CERT 
depletion (Figure 60A and B). The majority of death events following paclitaxel 
treatment of CERT depleted cells occurred during a multinucleated interphase resulting 
from an aberrant mitosis. Next, I sought to identify the role of LAMP2 in this process. 
Consistent with my previous observations (Figure 51A), co-depletion of LAMP2 with 
CERT reversed paclitaxel-sensitisation following 48 hours of paclitaxel exposure. 
Paclitaxel induced cell death was still observed in interphase cells but LAMP2 depletion 
abrogated the majority of mitotic and post-mitotic cell death events, with the majority of 
multinucleated cells surviving to the end of the observation period. Taken together, 
these data suggest that CERT depletion promotes the elimination of multinucleated 
polyploid cells following paclitaxel exposure that is abrogated by LAMP2 co-silencing. 
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Figure 60 Live cell imaging and single cell fate analysis following CERT silencing and 
paclitaxel treatment 
A) Graph of single cell fate analysis during paclitaxel exposure following transfection 
with siCON, siCERT, or siCERT and siLAMP2. Cells were individually tracked for 
48h following paclitaxel treatment. Timing of entry into mitosis was scored from time 
from nuclear envelope breakdown (NEB) to reformation of nuclei.  
B) Example of a time-lapse sequence (t=time in minutes) of a CERT depleted cell 
treated with paclitaxel over 1200 minutes following mitotic entry. Cell undergoes 
nuclear envelope breakdown (NEB) followed by an aberrant mitosis resulting in a 
multinucleated interphase and subsequently cell death. 
A 
B 
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6.2.10 CERT is overexpressed in HER2+ primary breast cancer 
Work in this section has been contributed by Neil Jones, Nicolai Juul Birkbak, David 
Endesfelder, Jil Sander, Rebecca Roylance and Patricia Gorman. 
The expression of CERT in a panel of cancer cell lines was determined by qPCR to 
attempt to identify cancer subtypes in which CERT expression may play a role (Figure 
61A). Breast cancer cell lines appeared to have the broadest distribution of CERT 
expression. Analysis of four HER2+ and eight HER2- breast cancer cell lines revealed 
higher relative CERT expression in the HER2+ cell lines in comparison to HER2- 
cancer cell lines (p=0.006, t-test) (Figure 61A). 12 breast cancer datasets for which 
CERT expression was measured by microarray analysis were identified. CERT mRNA 
expression was significantly repressed in basal breast cancers (p=1.41e-51) relative to 
other intrinsic subtypes of breast cancer (Figure 61B). Next CERT protein expression 
was analysed in a Tissue Microarray (TMA) panel of 356 primary breast cancers of 
mixed ER/HER2 receptor subtype, tumour grade and nodal status (Table 7). CERT 
protein levels, determined by the quickscore (CERT protein intensity x percentage of 
cells positive) (173), appeared to be significantly elevated in HER2+ relative to HER2- 
primary breast cancers (Wilcoxon test p=0.0009) (Figure 62) (Representative images, 
Figure 63) with no significant difference between ER+ and ER2 subtypes (p=0.0889). 
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Figure 61 CERT mRNAis overexpressed in HER2+ primary breast cancer  
A) Graph of relative CERT cDNA expression in cell lines of various tissue origins. 
Horizontal lines signify median and interquartile range. 
B) Boxplot showing CERT expression in breast cancer divided into intrinsic subtypes in 
a meta-analysis across 12 datasets. The length of the whiskers was limited by maximal 
= 1.5 times the interquartile range. 
B 
A 
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Figure 62 CERT protein expression in TMA Cohort 
Graph demonstrates CERT protein intensity x percentage in a breast cancer TMA 
cohort of 356 primary breast cancers divided into various subtypes based on ER and 
HER2 receptor status. 
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 All Patients 
(n = 426) 
CERT low 
(n = 271) 
CERT high 
(n = 102) 
    
Median Age (range)  58 (27 - 92) 58 (30 - 90) 59 (27 - 92) 
     Unknown 2 2 0 
    
Median Size in mm (range) 20 (1 - 130) 19 (1 - 100) 20 (6 - 130) 
     Unknown 13 11 1 
    
Grade, N(%)    
     1 98 (23) 67 (25) 11 (11) 
     2 184 (43) 127 (47) 43 (42) 
     3 143 (34) 76 (28) 48 (47) 
     Unknown 1 1 0 
    
Lymph Node Status, N(%)    
     positive  215 (53) 125 (48) 63 (65) 
     negative 192 (47) 134 (52) 34 (35) 
     Unknown 19 12 5 
    
Stage, N(%)    
     T1: 0 – 2cm 246 (60) 163 (62) 54 (53) 
     T2: 2 – 5cm 149 (36) 90 (35) 39 (39) 
     T3: >5cm 18 (4) 7 (3) 8 (8) 
     Unknown 13 11 1 
    
ER Status, N(%)     
     positive 326 (78) 216 (80) 75 (74) 
     negative 92 (22) 54 (20) 27 (26) 
     Unknown 8 1 0 
    
HER2 Status, N(%)    
     positive 31 (7) 11 (4) 18 (18) 
     negative 393 (93) 258 (96) 84 (82) 
     Unknown 2 2 0 
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PR Status, N(%)    
     positive 300 (79) 198 (78) 79 (79) 
     negative 80 (21) 57 (22) 21 (21) 
     Unknown 46 16 2 
    
Chemotherapy, N(%)    
     yes 149 (49) 100 (48) 41(49) 
     no 157 (51) 107 (52) 43 (51) 
     Unknown 120 64 18 
Table 7 Demographic data of patients in breast cancer TMA cohort 
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Figure 63 Representative IHC images for CERT expression. 
(Above) Representative image showing a complete absence of CERT staining with 
benign breast tissue acting as internal control. 
(Below) Representative image of CERT expression with a quickscore of 3. 
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6.2.11 CERT depletion sensitises HER2+ breast cancer cell lines to 
cytotoxics and induces autophagic flux  
Given the observation that CERT was selectively over-expressed in HER2+ cell lines 
and HER2+ breast cancers, I assessed drug sensitivity in three HER2+ breast cancer cell 
lines, BT474, HCC1954 and SKBR3, following CERT silencing. CERT depletion 
resulted in multidrug sensitisation to clinically relevant cytotoxics, paclitaxel, 
doxorubicin and cisplatin (Figure 64). In order to establish whether CERT depletion and 
drug exposure was associated with enhanced autophagic flux, I analysed LC3-I/II 
expression in drug treated HCC1954 cells. CERT depletion in the HCC1954 cell line 
resulted in decreased levels of LC3-I and LC3-II following treatment with paclitaxel, 
cisplatin or doxorubicin when compared to siCON transfected cells (Figure 65A), 
suggesting that, concordant with the HCT116 analyses, increased autophagic flux 
occurs following CERT depletion and cytotoxic drug treatment in HER2+ breast cancer 
cells. 
Next, the HCC1954 cell line was transfected with siCON, siCERT, siLAMP2 or 
siCERT and siLAMP2 and treated with either paclitaxel or doxorubicin, drugs widely 
used in the management of high-risk breast cancer in the adjuvant setting (Figure 65B). 
In all conditions, LAMP2 co-silencing resulted in a significant attenuation of CERT 
depletion-induced drug sensitisation (Mann-Whitney U, paclitaxel 50nM, p=0.0087, 
paclitaxel 500nM, p=0.0043, doxorubicin 250nM, p=0.0087, doxorubicin 1000nM, 
p=0.015). Finally, I assessed the efficacy of Trastuzumab, a monoclonal antibody 
targeting the HER2 receptor used in the treatment of HER2+ breast cancer. The 
HCC1954 cell line has been shown to be more resistant to Trastuzumab compared to 
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other HER2+ cell lines (284). CERT depletion resulted in Trastuzumab sensitisation 
(Figure 65C, Mann-Whitney, p=0.0087). 
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Figure 64 CERT silencing sensitises HER2+ breast cancer cell lines to various drugs 
and induces autophagic flux changes. 
Graphs showing relative cell number compared to vehicle control of HER2+ breast 
cancer cell lines, BT474, HCC1954 and SKBR3 following either siCON or siCERT 
transfection and treatment with paclitaxel, cisplatin or doxorubicin. 
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Figure 65 CERT silencing induces changes in autophagic flux in HCC1954 cells and 
sensitisation that is LAMP2-dependent in response to drug treatment 
C 
B 
A 
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A) Western blot demonstrating LC3I and LC3-II expression in HCC1954 cells 
following 48h of CERT depletion followed by 24h of treatment with paclitaxel, 
cisplatin or doxorubicin. 
B) Scatter plot of cell number (as measured by fluorescence activity) in paclitaxel 
treated (50nM and 500nM) (left) and doxorubicin treated (250nM and 1000nM) (right) 
HCC1954 cells following transfection with siCON, siCERT, siLAMP2 or siCERT and 
siLAMP2. Each dot represents a replicate well. Horizontal lines signify mean and 
standard deviations. 
C) Scatter plot of cell number (as measured by fluorescence activity) in HCC1954 cells 
following transfection with siCON or siCERT and treatment with 100µg/ml 
Trastuzumab or vehicle control. Each dot represents a replicate well. Horizontal lines 
signify mean and standard deviations. 
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6.2.12 CERT expression is associated with survival outcome in patients 
with primary breast cancer treated with adjuvant chemotherapy. 
Survival analysis in this section has been contributed by David Endesfelder and Jil 
Sander. 
According to data from my laboratory, CERT silencing alone appears to have little 
impact on cancer cell viability, but sensitises cells to multiple clinically relevant 
cytotoxics in parallel with enhanced autophagic flux. Therefore, I wanted to address 
whether low CERT expression might be associated with improved clinical outcome, 
particularly in primary breast cancers treated with adjuvant chemotherapy. First, it was 
addressed whether CERT expression was associated with survival outcome (breast 
cancer specific survival (BCSS)) in the 356 primary breast cancer TMA cohort. A 
maximally selected rank statistic (174) was used to derive a threshold for separating 
tumours into cohorts of low and high CERT expression based on survival outcome. This 
method selects an optimal threshold for prediction, but avoids the erroneous reporting 
of overoptimistic low p-values by adjusting for the multiple test problem inherent in the 
selection of the threshold. A CERT quickscore threshold of <175 and >175 was 
obtained for separating tumours into low and high CERT expression respectively. 
Significantly poorer breast cancer outcome was observed across all patients with 
primary breast cancers with a CERT quick score >175 compared to patients with a 
CERT quick score <175 (HR 2.2 95% CI 1.3-3.6, p=0.003) (Figure 66A). A similar 
relationship was observed when the analysis was restricted to HER2+ breast cancer 
patients only (Figure 66B, p=0.035 HR 6.81). This association was confirmed for 
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relapse free survival in a meta-analysis of 1861 patients with primary breast cancer 
using the publicly available Kaplan-Meier meta-analysis tool (285) (Figure 66C) HR 
1.2 (1.1-1.4 p=0.027). 
CERT silencing alone has limited or no effect on cancer cell viability, but induces 
autophagy flux and enhanced cell death only in combination with multiple cytotoxics 
with different mechanisms of action. It was investigated whether the relationship of low 
CERT expression with significantly improved outcome was observed when patients 
were stratified by use of adjuvant chemotherapy. Consistent with a role for CERT in 
augmenting drug sensitivity when repressed, low CERT expression in the 356 patient 
TMA cohort was associated with significantly improved outcome in patients treated 
with adjuvant chemotherapy (Figure 66D, n=134 HR 2.2 1.2-5.5 p=0.014). In contrast, 
in a similarly powered analysis of 150 patients who did not receive adjuvant 
chemotherapy from within this cohort, there was no such significant association of low 
CERT expression with improved outcome (Figure 66E). Consistent with the drug 
sensitising phenotype associated with CERT silencing, these data suggest that CERT 
expression may predict outcome specifically in patients with primary breast cancer 
receiving chemotherapy. Finally, in a robust multivariate cox regression model using 
data from the TMA cohort of 356 patients with primary breast cancer, when known 
breast cancer histopathological prognostic markers are considered, the association of 
CERT expression with survival acts as a significant independent prognostic variable 
(Table 8). 
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Figure 66 CERT expression is associated with survival outcome in patients with 
primary breast cancer treated with adjuvant chemotherapy 
C 
B 
A D 
E 
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A) Kaplan-Meier analysis of high CERT expression compared to tumours with low 
CERT expression (Quickscore >175 vs <175). 
B) Kaplan-Meier analysis of high CERT expression compared to tumours with low 
CERT expression (Quickscore >175 vs <175) restricted to HER2+ breast cancer 
patients (n=29) within the same cohort of 356 patients. 
C) Kaplan-Meier analysis of high CERT expression compared to tumours with low 
CERT expression within 1861 patients with 10-year relapse-free survival data available 
using online kmplot.com tool that uses gene expression data and survival information of 
1908 patients downloaded from GEO (Affymetrix HGU133A and HGU133+2 
microarrays). 
D) Kaplan-Meier analysis of high CERT expression compared to tumours with low 
CERT expression (Quickscore >175 vs <175) restricted to patients treated with adjuvant 
chemotheraphy (n=134) within the same cohort of 356 patients. 
E) Kaplan-Meier analysis of high CERT expression compared to tumours with low 
CERT expression (Quickscore >175 vs <175) restricted to patients treated without 
adjuvant chemotheraphy (n=150) within the same cohort of 356 patients. 
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 log(HR) HR se(log(HR)) P Value 
Size in mm 0.02005 1.020 0.0084 0.017 
Grade 2 1.66957 5.310 1.0356 0.110 
Grade 3 2.87047 17.65 1.0224 0.005 
Node positive 0.49507 1.64 0.3477 0.150 
CERT  0.00365 1.004 0.0017 0.030 
Table 8 Multivariate analysis of prognostic predictors including CERT expression in 
breast cancer TMA cohort 
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6.3 Discussion 
It has been previously demonstrated that reduced CERT expression forms part of a 
functional metagene that is predictive of pathological complete response to 
paclitaxel/doxorubicin combination chemotherapy in breast cancer (286). In order to 
explore how CERT depletion might mediate its drug sensitisation effect, I investigated 
how CERT silencing results in paclitaxel sensitisation using transcriptomic and 
functional genomics based approaches. I find that CERT depletion and paclitaxel 
exposure accelerates autophagic flux in both colon and breast cancer models and results 
in LAMP2-dependent death of multinucleated cells following paclitaxel exposure, 
observed through single cell fate tracking experiments by live cell microscopy. 
Accumulating evidence supports the importance of autophagy in the response to 
cytotoxic drug or radiation therapy that may enhance death or augment cancer cell 
viability (287-290). Lysosomal activity has also been implicated in the paclitaxel 
response. The lysosomal enzymes GBA1 and GBA3 was previously identified by our 
laboratory as regulators of paclitaxel sensitivity and microtubule stabilising drugs 
initiate lysosomal cathepsin B activation and release, inhibition of which promotes 
resistance to this class of drug (153). 
Transcriptomic analysis identified that an autophagy gene module is significantly 
enriched following CERT silencing and ceramide treatment. This gene signature may 
reflect the accumulation of ceramide within the ER. Through this analysis I suggest an 
explanation for the synergistic activities of CERT depletion and paclitaxel exposure that 
provides a molecular basis for the elimination of multinucleated polyploid cells 
resulting from an aberrant mitosis. I speculate that expression of LAMP2 primes the cell 
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for completion of the autophagic process but on its own LAMP2 expression is 
insufficient to drive cell death. This process may depend on CERT depletion with drug 
exposure that promotes a greater rise in ER-restricted cellular ceramide resulting in the 
expression of an autophagy gene module, in agreement with previous reports of 
autophagy initiation by ceramide (291, 292) and autophagy regulation by transcriptional 
dependent mechanisms (293). Consistent with the requirement for both CERT depletion 
and drug treatment for the induction and completion of autophagy, I observed co-
localisation of LAMP2 and LC3 in the presence of lysosomal inhibitors in HEK293 
cells as well as a potent reduction of both LC3-I and LC3-II in CERT depleted cells 
treated with paclitaxel. The requirement for LAMP2 in the synergistic interaction 
between siCERT and drug sensitisation was demonstrated through abrogation of the 
siCERT sensitising phenotype following LAMP2 silencing in both paclitaxel and 
doxorubicin treated HER2+ HCC1954 cells.  
Studies suggest that multinucleation may be a precursor of mononucleate 
aneuploidy/polyploidy and CIN (98-100). Autophagic flux and the consequent cell 
death of multinucleated cells following paclitaxel exposure is dependent upon LAMP2 
induction following CERT depletion, suggesting a rational approach for limiting the 
development of CIN in cancer. Recently, Amon and colleagues demonstrated that 
aneuploid cells display an increased susceptibility to compounds that interfere with 
protein folding and trisomic MEFs displayed increased LC3 lipidation relative to wild-
type MEFs, that was further enhanced following treatment with the aneuploidy-specific 
agent, AICAR (129). These data are strikingly similar to our observations 
demonstrating that CERT depletion and paclitaxel treatment induces the unfolded 
protein response (12), autophagic flux and as demonstrated using live cell microscopy, 
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the specific death of cells that have undergone an aberrant mitosis or entered a 
multinucleated state.  
CERT was established to be relatively over-expressed in HER2+ breast cancer. I 
provide evidence for the ability of CERT silencing to sensitise HER2+ breast cancer 
cell lines to paclitaxel, doxorubicin, cisplatin and Trastuzumab and demonstrate that 
cytotoxic multidrug sensitisation is associated with accelerated autophagic flux. 
Consistent with a role for LAMP2 induction in the multidrug sensitisation phenotype, 
LAMP2 co-silencing attenuates doxorubicin sensitisation following CERT depletion in 
the HER2+ HCC1954 breast cancer cell line. As HER2 positivity is also associated with 
CIN (294), CERT targeting may provide a mechanisms to improve patient outcome in 
those with HER+ by allowing the targeting of aneuploid cells via a LAMP2-dependent 
pathway. 
Furthermore, CERT expression defines a population of patients with breast cancer with 
divergent survival outcomes in multivariate analysis. Additionally, consistent with the 
drug sensitising phenotype following CERT silencing, low expression of CERT appears 
to predict improved outcome in patients treated with adjuvant chemotherapy. 
Prospective validation of the potential role for CERT in predicting outcome following 
adjuvant chemotherapy in breast cancer is in progress. 
This chapter has focused mainly on the effect of CERT silencing on paclitaxel 
sensitisation. However, previous findings have shown that CERT silencing results in 
sensitisation to non-mitotic targeting drugs such as 5-FU, cisplatin and doxorubicin (12) 
and I observed that CERT silencing induces changes in autophagic flux following 
treatment with cisplatin and doxorubicin in HER2+ breast cancer cells. Taken together, 
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these findings suggest that changes in autophagic flux following CERT silencing and 
drug treatment may also play a role in sensitisation to these drugs. Further work is 
needed to investigate the role of LAMP2 in this process and to study the timing of cell 
death following exposure to these drugs. 
6.4 Conclusion 
Taken together, these results suggest that there may be therapeutic potential in the 
targeting of CERT to augment autophagy and the death of multinucleated cells in order 
to limit the initiation of chromosomal instability, intra-tumour heterogeneity and 
chemotherapy resistance. These studies also suggest that an increase in autophagic flux 
may act to selectively target cells that have undergone an aberrant mitosis or that 
undergo an increase in ploidy due to mitotic slippage into a multinucleated interphase 
state. Furthermore, these data also implies that cell death following mitotic catastrophe 
may be coupled to autophagy and lysosomal activity. Further understanding of the 
coupling of death following and aberrant mitosis and autophagic-lysosomal activity 
may provide further insight into the targeting of CIN+ cancer cells for death. 
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Chapter 7. Discussion 
The causes and consequences of aneuploidy and CIN have been an intriguing part of 
cancer research ever since von Hansemann reported abnormal mitotic figures in cancer 
cells and Boveri postulated that aneuploidy may promote cancer (295). It has been 
established for some time now that patients with CIN+ tumours have a worse prognosis 
(198, 200, 296) compared to those with diploid or near-diploid tumours. 
In 2000, it was proposed that aneuploid cells are able to acquire multidrug resistance at 
a high rate due to having a high chromosome reassortment rate that confers genetic 
variation and an evolutionary advantage in the face of selection pressure (11). More 
recently, our laboratory has shown that CIN+ cells are intrinsically taxane resistant (12, 
297). Further examining the link between CIN and intrinsic taxane resistance, my 
laboratory proposed that CIN+ cancer cells overexpress a set of genes termed the 
microtubule-stabilising (MTS) gene signature, genes that are repressed following MTS 
treatment (14), that enables them to survive down-regulation of these genes that occurs 
following MTS treatment. A similar link was not seen with the non-MTS-targeting 
cytotoxic, 5-FU. Together with work demonstrating that aneuploid tumours across 
different tissue types overexpress the CIN70 gene signature (59), this demonstrated that 
there exists stable gene expression changes in CIN+ cancer cells that enable these 
cancer cells to be intrinsically taxane resistant. As taxanes function by arresting cells in 
mitosis and inducing cell death by mitotic catastrophe, this may reflect the property of 
CIN+ cancer cells to escape proper mitotic surveillance. 
Work performed in aneuploid and polyploid yeast (93, 127) suggest that adaptations are 
required to tolerate abnormal numbers of chromosomes. It has also been proposed that 
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CIN cells acquire adaptations that enable them to tolerate chromosome missegregations 
(66). Taken together, it suggests that there indeed exist pathways that are required for 
survival in CIN+ cancer cells. Indeed, Roschke and colleagues (4, 123) defined several 
anticancer agents that had preferential activity in cancer cells with more structurally 
complex chromosomes. Recently, Tang and colleagues proposed that aneuploid cells 
are more sensitive to energy and protein stress induced by AICAR and 17-AAG 
treatment (129) and extended their results to a panel of 5 CIN+ and 5 CIN- cell lines. 
In my thesis, I set out to identify pathways that are required for the survival of CIN+ 
human cancer cells in an attempt to both further understand CIN and to provide means 
to limit the acquisition of CIN in human cancer. In chapter 3, I performed a kinase 
inhibitor and cytotoxic agent screen to identify compounds that may be selectively 
lethal in CIN+ cells. I used a large panel (18 CIN+ and 9 CIN-) of CRC cell lines in my 
studies to allow for the interrogation of a genetically diverse panel of CIN+ and CIN- 
cell lines with many compounds. Although I was unable to identify a single agent that 
was selectively lethal towards the CIN+ cancer cells, I demonstrated that CIN+ cancer 
cells were intrinsically resistant to these compounds of many different mechanisms of 
action, including 17-AAG and AICAR. Further examining the link between intrinsic 
multidrug resistance with CIN and polyploidy, I treated two isogenic models of CIN, 
HCT116 MAD2+/- and HCT116 PTTG1-/- cell lines, and HCT116 isogenic models of 
tetraploidy, with the kinase inhibitors and cytotoxic agents. Here, my work suggests that 
the intrinsic drug resistance phenotype is associated with increased CIN but not 
increased ploidy. The short time course of my experiments suggested that drug 
resistance phenotype that I observed was unlikely to be due to adaptive drug resistance. 
A possible explanation for my findings would be that even at low numbers of cells 
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(4000 non-clonally derived cells per cell line were plated prior to drug exposure) there 
may exist sufficient heterogeneity in the CIN+ cancer cell population to enable sub-
populations of the cancer cells to survive. An alternative hypothesis would be that cell 
lines that have acquired CIN also become intrinsically resistant to external stressors, 
and this may reflect survival adaptations to tolerate CIN, also known as a CIN survival 
state. 
In chapter 4, I discussed my efforts to identify CIN survival pathways using a functional 
genomics approach. Whole genome RNAi screens were performed in HCT116 diploid 
parental and HCT116 MAD2+/- cell lines. Candidate genes were identified that caused 
a reduction in cell viability in both cell lines but none appeared to consistently result in 
greater cell lethality in the CIN+ cancer cell line over the CIN- cell line. While I was 
unable to identify a CIN survival regulator that consistently targeted CIN+ cancer cells 
for death, statistical analysis revealed that the RNAi screens may have been sufficiently 
powered to identify candidate genes resulting in large difference in cell viability 
between the CIN+ and CIN- cancer cell lines (Power ≈ 75% to detect ≈ 60% difference 
in cell death). The failure to identify a CIN survival gene may be due to a number of 
reasons: 1) The isogenic cell lines are too genetically similar in order to enable the 
identification of a candidate gene that results in a great reduction in cell viability of one 
cell line but not the other. The lack of published whole genome siRNA screens for 
synthetic lethality using isogenic cell lines may support this argument. 2) There may not 
exist a single CIN survival pathway that results in a great reduction in cell viability 
when silenced in CIN+ cancer cells. This may reflect a dependency on multiple 
pathways for the survival of CIN+ cancer cells, therefore the disruption of just one 
pathway may be compensated for by the others. 
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Supporting the idea that the genome wide screens were not technically flawed, in 
chapter 5, using cell cycle profile data from the same HCT116 screen as performed in 
chapter 4, I identified both known and novel ploidy regulators that corresponded to 
regions of stable genomic loss in CIN+ cancer cell lines. Confirmation and evaluation 
of the phenotypic changes was performed using light cell microscopy. As it may be 
challenging to selectively target survival pathways of CIN+ cancer cells in order to 
induce lethality, an alternative approach to overcoming CIN in cancer may be to limit 
the acquisition of CIN by targeting ploidy regulators. The novel regulators of ploidy 
identified here may help achieve that aim although work is needed to further 
characterise the functions of the genes identified. 
Previously, my laboratory demonstrated that CERT when silenced mediates sensitivity 
to drugs with differing mechanisms of action (12), however the mechanisms of the drug 
sensitisation were not understood. Further investigation of this pathway was performed 
as 1) It is a drug sensitivity pathway that may be exploited to induce death in cancer 
cells including CIN+ cancer cells and 2) CERT depletion results in taxane sensitisation. 
As CIN+ cells are intrinsically resistant to taxanes, further understanding of the CERT 
pathway may allow us to understand cell death downstream of mitotic catastrophe and 
may provide insight into sensitising CIN+ cells to MTS agents. I showed that 
combination of CERT silencing and drug treatment resulted in changes to autophagic 
flux. While it has been previously shown that ceramide and ER-stress induction can 
result in an up-regulation of autophagy, I showed that CERT silencing induced the 
expression of the lysosomal membrane protein, LAMP2 (that mediates autophagosome-
lysosome fusion(298), that was required for the drug sensitisation phenotype following 
CERT silencing. LAMP2 was not up-regulated by ceramide nor was its expression 
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altered by the addition of paclitaxel to CERT silencing, suggesting that its change in 
expression was specific to CERT down-regulation and not due to changes in autophagic 
flux due to ceramide or ER-stress induced autophagy. I demonstrated that cell death 
following CERT silencing and paclitaxel treatment is often preceded by an abnormal 
mitosis and a multinucleated interphase state and by silencing LAMP2, multinucleated 
cell death was avoided. This may suggest that cells may be sensitive to changes in 
autophagic flux or lysosomal structure during a mitotic arrest, especially since 
transcription is halted during mitosis. Alternatively, cells in multinucleated interphase 
following mitotic slippage may be sensitive to CERT and LAMP2 expression. 
Interestingly this may link with work demonstrating that changes in lysosomal 
membrane activity synergise with taxane activity (299) further suggesting that cell 
death associated with mitotic arrest may be lysosomal dependent. 
In conclusion, my work has helped to demonstrate that CIN+ cancer cells are 
intrinsically more resistant to perturbations of many different pathways compared to 
CIN- cancer cells. Whilst it is conceivable that the survival and drug resistant properties 
of a CIN cancer cell population may be consequence of its genetic heterogeneity, an 
alternative and perhaps more compelling hypothesis is that in order to tolerate CIN a 
cell must evolve into a survival state that indirectly confers drug resistance. I was not 
able to identify a survival regulator of CIN+ using an isogenic whole genome RNAi 
screening model, however, my screen appeared to be sufficiently powered to detect 
large differences in cell viability. The negative result obtained may reflect the fact that 
there may not exist a dependency on just a single pathway for survival in CIN+ cancer.  
However, I have identified novel regulators of ploidy using a functional genomics 
approach. Finally, my work has helped to provide insight into the mechanisms 
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regulating drug sensitisation following CERT depletion and possibly indicates that 
increased autophagic flux or lysosomal activity may be lethal to cells arrested in mitosis 
or multinucleated cells. This may be exploited to specifically target polyploid cells. 
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